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Abstract 
Lymphocyte infiltration of the liver drives the progression of all inflammatory liver 
diseases.  Lymphocyte homing to the liver occurs within the hepatic sinusoids. The 
hepatic sinusoidal endothelial cells (HSEC) that line these channels have a unique 
phenotype and lack conventional adhesion molecules, making these cells a potential 
organ specific target for therapy.  I carried out a detailed analysis of the expression 
of CLEVER-1 in the human liver and show that it is expressed on sinusoidal 
endothelium in situ and in vitro and at other sites of lymphocyte recruitment in the 
inflamed liver including neovessels, portal associated lymphoid tissue and vessels 
supplying hepatocellular carcinomas.  The expression of CLEVER-1 on HSEC in 
vitro was upregulated by hepatocyte growth factor.  Flow based adhesion assays 
with HSEC demonstrated that CLEVER-1 mediated lymphocyte transmigration and 
that this activity was subset specific with preferential activity for B cells and T 
regulatory (Treg) cells.   Using confocal imaging I was able to show that CLEVER-1 
mediates Treg migration via the transcellular route through HSEC.  This is the first 
report of transcellular migration in the liver.   
This study identifies CLEVER-1 as a novel lymphocyte recruitment signal to the liver 
and a potential target for therapy in chronic liver diseases.          
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1.1 Background 
This thesis concerns the molecular mechanisms of lymphocyte recruitment to 
the human liver with emphasis on the role of the scavenger molecule 
CLEVER-1 and its potential as a therapeutic target.  I begin with emphasising 
the need for new medical therapies for liver disease.  This is followed by a 
description of the liver microvasculature and the changes that occur during 
liver injury that result in the establishment of a chronic hepatitis, the common 
pathway that links injury to scarring.  Hepatitis is characterised by lymphocyte 
recruitment into the liver from blood, liver injury and if unresolved eventually 
collagen deposition (fibrosis) and culminating in nodule formation (cirrhosis).  
I then review our current understanding of lymphocyte recruitment to the liver 
and conclude with a review of the scavenger molecule CLEVER-1 and its 
specific role in lymphocyte recruitment.    
1.2 The burden of liver disease 
Liver disease is a huge and increasing global problem reflected in the United 
Kingdom where rates of chronic liver disease have been increasing, 
especially since the 1990s, to levels that are now amongst the highest in 
Europe (Leon and McCambridge, 2006).  Unfortunately, despite this global 
burden, therapies for chronic liver disease remain limited and the main 
treatment strategies presently involve either removing the underlying trigger 
for the liver disease (Henderson and Iredale, 2007) or liver transplantation for 
end stage disease.  Liver transplantation can be highly effective but there are 
several drawbacks.  The major issue is the limited donor organ pool which 
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means a significant proportion of patients do not survive until an organ 
becomes available (El-Serag, 2001; Ubel and Caplan, 1998). Liver 
transplantation itself is a major operation and therefore co-existing medical 
and psychiatric issues can prevent patients from being considered for this 
procedure.  Liver transplantation also carries with it the requirement for 
lifelong immunosuppression and problems consequent upon that as well as 
the problems of graft rejection and disease recurrence which can take an 
accelerated form in certain situations (Prieto et al., 1999).  The current 
situation therefore requires further understanding of the mechanisms that 
underlie the progression of chronic liver disease so as to identify potential 
targets for treatment.   
Chronic liver disease can develop in response to several different injurious 
factors that include chronic alcohol abuse, chronic infection with hepatitis B 
and C viruses, non alcoholic fatty liver disease and immune-mediated liver 
conditions (eg primary biliary cirrhosis (PBC) and primary sclerosing 
cholangitis (PSC)).  Despite this variety of initiating injuries the progression of 
nearly all chronic  liver diseases follows a common pathway that leads to 
fibrosis and scarring, termed cirrhosis (Iredale, 2007).  Cirrhosis leads to 
further complications of liver failure, including portal hypertension and the 
development of hepatocellular carcinoma (Gines et al., 2004).  
1.3 Liver function and architecture 
The liver is the second largest organ of the body where it plays a critical 
metabolic and synthetic role.  Its anatomical location allows it to directly 
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receive nutrients and compounds from the intestinal lumen.  This close 
relationship to the intestinal tract allows the liver to process and redistribute 
fatty acids and glucose as well as modify and detoxify a range of compounds 
prior to release into the circulation.  The liver can either store or release 
nutrients in response to hormonal regulation from endocrine organs, as well 
as neuronal stimuli.  Glucose is an essential nutrient for the brain, 
erythrocytes and muscle and the supply of glucose is maintained by the 
ability of the liver to store glycogen and synthesise glucose (Pilkis and 
Granner, 1992).  The liver also plays a role in fatty acid metabolism by 
regulating synthesis and transport to other organs in association with 
lipoproteins (Dixon and Ginsberg, 1992).  
The liver is essential for the synthesis of a wide range of proteins.  These 
include the acute-phase reactants which are present in acute and chronic 
inflammation and are thought to play a role in host defence, as well as blood 
coagulation factors (factor II, VII, IX and X).  Another protein synthesised by 
the liver is albumin, which is the body’s main serum binding protein as well as 
providing serum oncotic pressure.   
Biotransformation of endogenous and exogenous compounds also occurs in 
the liver and is controlled by numerous transporter proteins which allow 
movement of these compounds into and out of the liver (Muller and Jansen, 
1997).  The excretion of these compounds can occur directly into the bile 
produced by the liver and thus to the intestine or into the blood for elimination 
by the kidney and lungs.  The efficient manner by which this diverse range of 
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functions is performed is partly explained by the liver’s vasculature and 
microarchitecture. 
1.3.1 The hepatic vasculature 
The liver has a unique dual blood supply which contributes to the liver’s 
metabolic functions and impacts on hepatic immune regulation.  Arterial 
blood from the hepatic artery comprises only 25% of the total blood supply, 
the rest coming from the portal vein which drains the gut and splanchnic 
organs.  The hepatic artery and the portal vein both drain into the hepatic 
sinusoids and blood then flows from the portal area into the hepatic venules 
at the centre of the hepatic lobule (Figure 1-1).  These venules connect to 
form the hepatic veins that drain into the inferior vena cava.  The endothelial 
cells that line the different vessels comprising the hepatic vasculature are not 
uniform (Aird, 2007b).  The portal venules and hepatic arterioles are lined by 
endothelium which is similar to vascular endothelium but there is still 
heterogeneity within these vessels.  The portal venules are lined by spindle 
shaped endothelium which is non-fenestrated but covered by short microvilli.  
At the transition from the portal venule to the hepatic sinusoid, the 
endothelium is smooth and large and contains many actin fibres.  This allows 
the endothelium to act as part of a sphincter which controls blood flow into 
the sinusoids.  The hepatic sinusoids form a unique capillary bed lined by 
discontinuous endothelium with fenestrae; open pores 100-200nm in 
diameter which make up 6-8% of the endothelial surface, and which lack a 
classical basement membrane (Braet and Wisse, 2002).  This unique 
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morphology has probably evolved in part as a consequence of the low flow 
sinusoidal environment, estimated to be 400-450mm/s compared with 500-
1000mm/s in other capillary beds.  This allows the sinusoidal endothelium to 
function as a sieve and the fenestrae to act as dynamic filters, for fluids, 
solutes and particles (Braet & Wisse, 2002).  
The normal liver microarchitecture can be divided into subunits which are 
termed lobules.  Each lobule consists of a terminal portal vein branch 
draining into terminal hepatic veins at the centre of the lobule with the gap 
between these vessels bridged by capillary-like sinusoidal channels.  The 
lobule is divided into zones, in part relating to the oxygen supply (Figure 1-1 
and Figure 1-2).  Zone 1 comprises the portal tract area consisting of the 
terminal portal vein, terminal branches of the hepatic artery and bile duct and 
is thus supplied with highly oxygenated blood. Zone 3 is located around the 
terminal hepatic veins where oxygenation is poor  and zone 2 represents the 
area between zone 1 and 3 (Saxena et al., 1999).  
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Figure 1-1 Structure of the hepatic lobule 
Schematic representation of the hepatic lobule with zones 1 to 3 and the 
microcirculatory subunit outlined.  The margins of each zone represent 
planes of equal blood pressure.  The tissue in zone 1 receives blood that is 
higher in oxygen concentration than the tissue in zone 3.   
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Figure 1-2 The hepatic microcirculatory subunit 
Diagram of the hepatic microcirculatory subunit which is the smallest 
functional subunit.  Blood from the portal venule drains into the proximal 
sinusoids (zone 1).  Some arterioles drain directly into the proximal sinusoids.  
Local control of the microcirculation depends on arteriole sphincters  and the 
state of contraction of the endothelial cells and stellate cells. 
 
 
 
 
 
9 
 
1.3.2 Cells of the Liver 
The main epithelial cells of the liver are the hepatocytes which are polarized 
and arranged in plates that are one cell in diameter surrounded by blood 
filled sinusoids.  The polarized nature of these cells is demonstrated by a 
canalicular region which consists of the lateral wall and numerous microvilli 
on the sinusoidal (basolateral) surface.  The canalicular region of each 
hepatocyte is bound to the adjacent hepatocyte surface by tight junctions 
thereby forming bile canaliculi which drain into bile ducts.  The sinusoidal 
surface is covered by the specialised hepatic endothelial bed which encloses 
the extracellular compartment called the Space of Disse.  Hepatocyte 
microvilli allow the interchange of nutrients between the blood within the 
sinusoids and the hepatocytes.   Liver resident macrophages, the Kupffer 
cells, are localised within the sinusoids where they have an important 
phagocytic role.  The other major non-parenchymal cell is the stellate cell, 
also known as fat storage cells or Ito cells which are identified by their high 
Vitamin A and lipid content; they are the major site for Vitamin A storage. 
They have an important role in regulating sinusoidal blood flow and play a 
central role in fibrogenesis.   
The healthy liver also contains a significant number of resident lymphocytes, 
estimated at 1010 (Racanelli and Rehermann, 2006).  The lymphocyte 
population is a mixture of conventional lymphocytes (B cells, CD4 and CD8 
cells) and unconventional cells (Natural Killer (NK) and Natural Killer T (NKT) 
cells).  These cells are discussed in more detail in the next section. 
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1.4 Lymphoid cells 
Lymphocytes are a vital arm of the human immune system and constitute 20-
40% of the body’s white blood cells.  They are produced in the bone marrow 
by the process of haematopoeisis and then circulate into the blood, 
lymphatics and lymphoid tissue.  They can be broadly divided into three 
groups, T cells, B cells and natural killer cells with each population having 
distinct functions and characterised by cell membrane components.  T and B 
cells are the central cells of the adaptive immune system.    
1.4.1 T cells 
T cells arise in the bone marrow but mature in the thymus.  They comprise of 
two well defined subpopulations defined by the nature of their TCR into alpha 
beta or gamma delta T cells.  The majority of T cells in the circulation are 
alpha beta T cells and they can be divided into T helper cells and T cytotoxic 
cells.  T helper cells are characterised by the presence of CD4 membrane 
glycoproteins and T cytotoxic cells are characterised by CD8 membrane 
glycoproteins.  A CD4 or CD8 T cell which has not interacted with an antigen 
is unprimed and termed a naive T cell.  If these naive T cells come across 
antigen they then differentiate into effector or memory cells, CD4 naive T 
cells differentiate into T helper cells and CD8 naive T cells into T cytotoxic 
cells.  T helper cells function predominantly by secreting cytokines that 
modulate the local microenvironment to support specific types of immune 
responses.   Cytokines are small proteins which are signalling molecules that 
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determine the immune response to antigens.   The release of cytokines by T 
helper cells influences the function of other immune cells. 
1.4.2 T helper subsets 
We now know that CD4 cells can differentiate into a variety of T helper 
subsets.  The type of T helper subset that develops will depend on signals 
received during antigen presentation including the nature of the cytokines 
present in the microenvironment, the strength of interaction of the antigen 
and T cell antigen receptor and the nature of the antigen presenting cell. 
(Boyton and Altmann, 2002).  The first T helper subsets to be described were 
the Th1 and Th2 subsets.  Th1 subsets are important for the control of 
cellular immunity against intracellular pathogens.  They are characterized by 
expression of the transcription factor Tbet which promotes  their production of 
interferon-γ.  The cytokine trigger for Th1 differentiation is IL-12 produced by 
innate immune cells and interferon-γ production by NK cells and other T 
cells.  Within the cell the differentiation requires activation of signal 
transducer and activator of transcription 4 (STAT4) and the transcription 
factor T-bet.  The Th2 subgroup has a key role in humoral immunity and the 
defense against extracellular pathogens by producing IL-4, IL-5 and IL-13.  
The differentiation into this group is driven by IL-4 and STAT6 with the 
transcription factor GATA-3 (Zhou et al., 2009).  More recently, a new group 
of effector cells have been identified termed Th17.  These are an IL-17A, IL-
17F and IL-22 producing subgroup which requires the transcription factor 
retinoid-related orphan receptor (ROR)γt  being induced by TGFβ, along with 
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IL-6, IL-21 and IL-23 which activate STAT3 (Chen et al., 2007).  The Th17 
subgroup plays important roles in host defense against bacteria and fungi 
(Korn et al., 2007).  Follicular T helper cells are a subset of T helper cells that 
have been shown to regulate the maturation of B cell responses and are 
dependent on the cytokine IL-21 (Breitfeld et al., 2000; Vogelzang et al., 
2008).   Further subsets including Th9 and Th22 cells have been proposed 
but whether these are truly distinct subsets remains to be determined.   
1.4.3 Regulatory T cells  
T helper cells are critical in mediating effector responses in antimicrobial 
immunity but the realisation that immune responses must also be controlled 
to prevent autoimmunity led to the search for cells capable of switching off or 
with suppressing immune responses.  Sakaguchi and colleagues 
demonstrated that if T cells were depleted of the CD25+ population and 
transferred into animals they caused multiorgan autoimmunity (Sakaguchi et 
al., 1995).  This CD25+ population was further identified as a CD4 subset 
and they were regulatory cells (T regs).  They are vital in maintaining 
homeostasis of T effector functions and preventing pathological 
consequences (Shevach, 2009).  This subset requires the transcription factor 
FOXP3 with induction by TGFβ, IL-2 and Retinoic acid (Josefowicz and 
Rudensky, 2009).  The regulatory T cell subset can be further subdivided into 
two groups.  The first group are natural occurring T regulatory cells that 
develop within the thymus during the fetal and neonatal stages of T cell 
maturation (Sakaguchi et al., 2001).  This population is long lived, specific for 
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self antigens and characterised by expression of high levels of CD25, 
cytotoxic T-lymphocyte antigen 4 (CTLA-4) and glucocorticoid-induced TNF 
receptor family-related protein (GITR)(Bluestone and Abbas, 2003; Salomon 
et al., 2000; Shimizu et al., 2002).  The second group are adaptive regulatory 
T cells which are generated from mature T cells by antigenic stimulation in 
certain conditions (Kingsley et al., 2002; Nakamura et al., 2001).  In the ex 
vivo setting this has been demonstrated by culturing mature CD4 T cells in 
the presence of IL-10 (Barrat et al., 2002).  The mechanism by which natural 
T regulatory cells suppress inflammation appears to be by direct contact with 
effector T cells or antigen presenting cells (Shevach, 2002).  Whereas 
adaptive T regulatory cells appear to suppress inflammation by secreting 
cytokines such as IL-10 and TGF-β (Kingsley et al., 2002; Nakamura et al., 
2001) 
It is quite clear that T regulatory cells have suppressor function but there is 
debate whether these cells are a distinct subset of T helper cells or have 
plasticity to develop into other subsets and become effector cells.  Recent in 
vivo studies have been able to track Foxp3 positive populations in 
physiological and inflammatory conditions (Rubtsov et al., 2010).   These 
experiments demonstrated that T regulatory cells were a stable population of 
CD4 cells in both physiological and inflammatory conditions. 
The subsets of  CD4 Tcells are summarised in Figure 1-3. 
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Figure 1-3 CD4 T helper subsets 
A summary of the T helper subgroups and an outline of the cytokines which 
lead to each subset generation as well as the cytokines produces by each 
subset.   
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1.4.4 Cytotoxic T lymphocytes 
Recognition of antigen-MHC complexes by a naive CD8 leads to a 
differentiation into an effector or memory cytotoxic T lymphocyte (CTL).  
CTLs recognise endogenous antigens that are processed and presented on 
MHC class I molecules.  They monitor cells and bind to and then kill any that 
display foreign antigen in the context of the correct MHC class I complex.  
This allows them to recognise and mount an immune response against 
intracellular pathogens and tumour cells (de Visser et al., 2006; Wong and 
Pamer, 2003).  Effector CTLs express cytokines such as tumour necrosis 
factor α (TNFα) and interferon γ as well as granzyme and perforin molecules 
which are cytolytic when released into apposing target cells. (Obar and 
Lefrancois, 2010).   
1.4.5 B lymphocytes 
B cells arise from the bone marrow and this is also the site of their 
maturation.  They can be distinguished from other lymphocytes by the fact 
that they express membrane bound immunoglobulin (antibody) molecules 
which act as receptors for antigen.  When a naive B cell encounters antigen 
that is recognised by its antibody it undergoes proliferation and differentiates 
into a memory cell and under the correct conditions long-lived plasma cells.   
Memory B cells are longer lived than naive B cells but express the same 
antibody as their parent B cell.  Plasma cells are end-stage B cells and they 
have the ability to produce antibody which is secreted.  Antibodies play 
important roles in complement activation, mediating opsonisation and 
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mucosal defences.   It is important to mention that effective antibody 
production by B cells is dependent on interactions with T helper cells.  B and 
T cells are present in peripheral lymphoid organs.  When these populations 
are activated by an antigen, they migrate towards each other within the 
peripheral lymphoid organ.  The B and T cell population interact and this 
leads to B cell proliferation and differentiation into antibody secreting cells.  
Subsequently the B cells migrate back into the follicles of the lymphoid tissue 
and proliferate rapidly to form germinal centres.  The B cells within the 
germinal centre can perform isotype switching, leading to the production of 
different classes of antibody.  B cells also undergo affinity maturation, where 
the antibodies generated have an increased capacity to bind antigens and 
therefore more efficiently bind to and neutralize foreign pathogens.   
1.4.6 Natural Killer cells and Natural Killer T cells 
Natural Killer cells (NK cells) are large, granular lymphocytes.  They are part 
of the innate immune system and do not have the T cell receptor or 
antibodies on their membrane.  They have cytotoxic activity against tumour 
cells and virally infected cells.  This is carried out by using NK cell receptors 
which have the ability to detect target cells by either the reduction in MHC 
class I expression or an altered range of surface antigens which can be 
characteristic of tumour cells or virally infected cells.  Natural Killer T cells 
(NKT cells) are a subtype of lymphocytes which share characteristics of NK 
cells and T cells.  NKT cells have T cell receptors but these receptors 
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recognise CD1 which is a MHC-like receptor.  They also express several 
surface markers seen on NK cells and like NK cells they can kill target cells.  
I have described the lymphoid cells of the liver, there is also a myeloid 
population of cells within the liver comprising of resident tissue macrophages.  
There is gathering evidence that the response to antigens within the liver is 
skewed towards tolerance, in other words there is a lack of an immune 
response.  The following section describes this in more detail and what 
happens if this tolerance is broken.  
1.5 The liver as a lymphoid organ  
The local population of lymphocytes in the liver are profoundly influenced by 
the hepatic microenvironment.  Due to its vascular supply the liver is 
continually exposed to products of digestion as well as microbial products 
that originate from bacteria in the intestines.  The hepatic immune system 
must strike a fine balance between tolerance of harmless antigens from the 
gastrointestinal system and the ability to rapidly respond to invading foreign 
pathogens.   
The initial response to antigens is dictated by the innate immune system 
which is comprised of pattern recognition receptors such as Toll-like 
receptors (TLRs), cytoplasmic nucleotide-binding oligomerization domain 
(NOD)-like receptors and RNA helicases, including retinoic acid inducible 
protein-I (RIG-I) (Thompson and Locarnini, 2007).  
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The continual exposure of certain antigens to pattern recognition receptors 
seems to lead to a state of active tolerance.  One of the best examples of this 
can be seen with lipopolysaccharide endotoxin (LPS).   LPS is a component 
of gram-negative bacterial cell walls and it is found at relatively high levels in 
portal blood, up to 1ng/ml (Lumsden et al., 1988) but in the circulation the 
levels are almost undetectable. The removal of LPS from the circulation has 
been attributed to the cells of hepatic sinusoid which express the LPS 
receptor (Catala et al., 1999) but unlike other innate cells of the body the 
detection of LPS does not lead to a strong activating signal.  This lack of 
activation by bacterial components is thought to be due to the continual 
exposure of these antigens to the liver.  Pattern recognition receptors within 
the liver bind to these antigens which leads to intracellular signalling but the 
outcome is the release of tolerogenic cytokines such as interleukin 10 (IL-10) 
rather than pro-inflammatory cytokines such as tumour necrosis factor alpha 
(TNFα) or interleukin-6 (IL-6) (Crispe, 2009).  In contrast, the presence of 
viral components which are not constitutively exposed to the liver leads to an 
alternative pathway which leads to the release of cytokines with strong anti-
viral properties such as Interferon α, and Inteferon β.   
In addition to pattern recognition receptors there are also innate lymphocyte 
populations of NK and NKT cells which are both found at higher frequencies 
compared to other tissues (Norris et al., 1998; Tu et al., 2007).   NK cells 
contribute to immunity against pathogens and increase in numbers during 
infection of the liver (McIntyre and Welsh, 1986). As seen with NK cells in 
other tissues they are activated by cytokine stimulation and triggered by 
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stronger signalling through activating receptors compared to inhibitory 
receptors, which leads to cytotoxicity and cytokine release (Lanier, 2008).  In 
addition NK cells have the ability to promote T cell recruitment to the liver.  
Models of viral liver infection in mice demonstrate accumulation of NK cells in 
response to the chemoattractant cytokine CCL3 (Salazar-Mather et al., 
1998).  The NK cells synthesise interferon γ which promotes the secretion of 
CXCL9, which is responsible for T cell accumulation (Itoh et al., 2001).  
Through this cascade NK cells recruit T cells to the liver and promotes T cell 
immunity rather than tolerance.   
NKT cells usually make up a small percentage of T cell populations in the 
body (<5%) but are enriched in the liver and have recently been shown to 
patrol the hepatic sinusoidal channels (Geissmann et al., 2005).  Like NK 
cells, there is evidence that NKT cells promote hepatic immunity.  This has 
been shown in the context of infections such as malaria and hepatitis B and 
tumour immunity (Gonzalez-Aseguinolaza et al., 2000; Kakimi et al., 2000; 
Toura et al., 1999). As described with NK cells above, NKT cells can also 
drive a cytokine/chemokine cascade to promote T cell homing to the liver.   In 
vivo murine models have shown that activation of NKT cells leads to 
interferon γ production which leads to the production of the chemokine 
CXCL10.  The induction of this chemokine by NKT cells was shown to 
promote the recruitment of a subset of T cells, specifically regulatory T cells 
(Santodomingo-Garzon et al., 2008).   
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The liver also has a large intravascular macrophage population, the Kupffer 
cells and contains liver dendritic cells.  Kupffer cells express MHC class I and 
II molecules and co-stimulatory molecules making them potential antigen 
presenting cells.  They have been shown to have tolerogenic properties by 
secreting IL-10 in response to LPS (Knolle et al., 1995).  In contrast, they can 
also demonstrate anti-viral properties by presenting antigen in the context of 
hepatitis C infection (Burgio et al., 1998).    The other myeloid group of cells 
are dendritic cells which have the most powerful antigen presentation 
properties (Nussenzweig and Steinman, 1980), both subgroups of 
plasmacytoid DCs (pDCs) and myeloids DCs (mDCs) are present within the 
liver. pDCs are known to produce high levels of IFN-α (Crispe, 2009), 
whereas the liver mDCs have been shown to produce IL-10 with an 
increased production of this cytokine in patients with chronic viral infections 
such as hepatitis C (Averill et al., 2007). 
The sinusoidal endothelial cells of the liver express several surface markers 
which are associated with antigen presentation (MHC II, CD40, CD86).  They 
can take up and process antigens and cross-present peptides on MHC class 
I to CD8 T cells.  However, the results of both CD4 and CD8 T cell activation 
by LSEC tends to be tolerance rather than effector cell expansion allowing 
these cells to maintain homeostasis in the face of a large quantity of dietary 
antigens in the portal blood (Knolle et al., 1998).  Antigen presentation has 
also been attributed to stellate cells and this is supported by their expression 
of MHC class I and II (Friedman, 2008).  Ex vivo experiments suggested that 
stellate cells have the potential to activate T cells but most of the data 
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suggest they are poor T cell activators that tend to induce tolerance or 
regulatory T cell expansion rather than effector responses (Winau et al., 
2007; Yu et al., 2004). 
1.5.1 The liver’s role in priming T cells and induction of tolerance. 
The microanatomy of the liver and the range of antigen presenting 
populations make the liver an ideal site for lymphocyte activation.  The 
priming and activation of lymphocytes are properties seen in lymphoid tissue 
and there is evidence that the liver shares these properties.  Priming of 
lymphocytes requires direct contact with APCs and lymphocytes circulating 
through hepatic sinusoids can make direct contact with underlying 
hepatocytes, stellate cells as well as with HSEC and Kupffer cells. This has 
been confirmed with electron microscopy (Warren et al., 2006).   Local 
activation and priming has been confirmed in the liver in murine models of 
chronic viral infections and liver transplants where bone-marrow APCs have 
been depleted (Ando et al., 1994; Klein and Crispe, 2006).  
Despite the overlapping ability of the liver and lymphoid organs to activate 
and prime lymphocytes, the initial site of lymphocyte activation leads to 
opposing outcomes. The liver apears to induce tolerance, this is partly 
explained by the fact that antigen presentation in the liver is associated with 
the production of tolerogenic cytokines such as IL-10 as outlined above.  In 
addition the liver also appears to have specific effects on the behaviour of 
CD8 and CD4 lymphocytes.  This was clearly shown with CD8 lymphocytes 
where initial antigen presentation within lymph nodes in transgenic mice led 
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to a significant hepatitis, whereas initial antigen presentation in the liver led to 
defective CD8 cytotoxic activity and no hepatocellular damage (Bowen et al., 
2004).  It has been shown that CD8 lymphocytes activated in the liver appear 
to undergo apoptosis preventing an immune response (Bertolino et al., 1998; 
Bertolino et al., 1999).  CD4 lymphocytes activated in the liver appear to 
undergo differentiation into a regulatory phenotype.  The sinusoidal 
endothelial cell appears to play a central role in this process.  CD8 T cells 
that are primed by sinusoidal endothelial cells do not differentiate into 
cytotoxic effector cells and CD4 T cells primed by these cells appear to 
differentiate into an anti-inflammatory/ regulatory phenotype where they 
secrete IL-4 and IL-10 (Knolle et al., 1999; Limmer et al., 2000). 
The local environment of the liver induces tolerance but this also impacts on 
systemic tolerance.  This was highlighted during the early experiments in 
organ transplantation where the transplantation of a liver with a kidney 
significantly improved the survival of the renal allograft (Calne et al., 1969).  
Tolerance of liver allografts has been suggested to be due to resident APCs 
of the transplanted liver inducing deletion of host T cells that have entered 
the graft.  This may also be the explanation for oral tolerance, where antigen 
administered to the stomach induces systemic tolerance.  When the venous 
drainage from the gut to the liver is diverted, oral tolerance is lost (Yang et 
al., 1994). The mechanism by which liver APCs could induce systemic 
tolerance is unclear but it is suggested that it could be due to peripheral 
deletion of CD8 cells or the induction of antigen specific Tregs (Crispe, 
2009). Support for the deletion of CD8 cells in tolerance induction comes 
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from an influenza model of infection, where the influenza pathogen is limited 
to the respiratory tract but CD8 cells specific for influenza are found in the 
liver, associated with Kupffer cells (John and Crispe, 2004). Support for T 
regulatory cells contributing to systemic tolerance comes from mouse liver 
transplantation, where T reg numbers increased significantly after grafting.  
Depletion of these cells with anti-CD25 antibodies led to rejection of the graft. 
(Li et al., 2006)  
It is quite clear that the liver is in a resting state of active tolerance, the 
mechanisms that switch the local microenviroment to promote an effector 
immune response are unclear.  Type I inteferons (α/β) are likely to be 
involved, they are induced in hepatic viral infections and they are implicated 
in the recruitment of T cells during these infections (Liu et al., 2000; Salazar-
Mather et al., 1998).  It has also been hypothesised that DCs and sinusoidal 
endothelial cells must switch from their induction of tolerance within the liver 
to priming of T cells to deliver effector functions (Crispe, 2003). 
1.6 Liver injury 
In viral infections with Hepatitis A or E infected hepatocytes are killed by 
innate immune cells and antigen-specific CD8 T cells resulting in liver injury, 
inflammation followed by resolution, regeneration and repair with the 
restitution of normal hepatic microarchitecture.  Chronic liver injury on the 
other hand takes a different pathway, here repeated insults lead to continuing 
liver injury, chronic inflammation that persists and an aberrant resolution 
phase characterised by chronic inflammation and scarring with collagen 
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deposition and fibrosis rather than regeneration.  If this process progresses it 
leads to permanent tissue loss which is termed parenchymal extinction and 
the liver scar forms to heal the wound (Wanless et al., 2000).  This is seen as 
fibrous septa which are flattened sheets of connective tissue containing 
remnants of damaged tissue, elements of healing and neovascularization.  
As the disease progresses these fibrous septa become more numerous and 
become confluent dividing the liver tissue into nodules that characterise 
established’ cirrhosis (Wanless et al., 2000).   
The development of cirrhosis leads to complications of portal hypertension 
due to distorted architecture, liver failure due to hepatocyte loss and 
carcinogenesis driven by the inflammatory and profibrotic environment.  Thus 
understanding how chronic liver injury leads to cirrhosis may identify 
important therapeutic targets.   
At the cellular level the response to injury by the liver leads the hepatic 
stellate cells to undergo a process of ‘activation’ and transdifferentiation 
which transforms them from quiescent cells to fibrogenic myofibroblasts 
(Friedman, 2000).  This occurs under the influence of cytokines and growth 
factors secreted by other cells within the hepatic sinusoids including Kupffer 
cells, hepatocytes and sinusoidal endothelial cells.  Hepatocytes and Kupffer 
cells are also a source of oxygen free radicals that have a paracrine effect on 
stellate cells (Maher, 1999) and endothelial cells activate stellate cells by 
depositing a splice variant of fibronectin and transforming the latent form of 
the cytokine transforming growth factor β1 (TGFβ1) into the fibrogenic form 
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(Friedman, 1999; Jarnagin et al., 1994).  TGFβ1 is the main stimulant to 
matrix deposition by stellate cells (Friedman, 1999) and although it is 
secreted from several cells autocrine secretion is the main stimulus for 
stellate cell activation (Gressner, 1995).  On activation stellate cells undergo 
proliferation and secrete matrix components and matrix modelling enzymes 
that result in ECM remodelling with replacement of the normal subendothelial 
ECM by fibril-forming collagen (Benyon et al., 1999; Theret et al., 1999).   
This is associated with profound morphological changes within the hepatic 
sinusoid.  Hepatocytes lose their microvilli, sinusoidal endothelial lose their 
fenestrae which are characteristic of their normal phenotype and Kupffer cells 
become activated (Friedman, 2000).  These morphological changes and 
deposition of scar within the sinusoids are responsible for the liver failure and 
portal hypertension seen in cirrhosis.  
1.6.1 The importance of inflammation in the pathogenesis of cirrhosis 
The inflammatory response is a vital part of the process by which the immune 
system deals with foreign organisms but if it persists and fails to resolve it 
can lead to continuing tissue injury and scarring and in the context of chronic 
liver disease this means progressive liver damage and cirrhosis (Iredale, 
2007).  There is evidence that the persistent inflammatory reaction that 
develops in response to recurrent liver injury and tissue death plays a central 
role in the development of fibrosis and progression to cirrhosis.  During the 
early stages of fibrosis in vivo it can be seen that sites of inflammation are 
closely linked to deposition of fibrous material (Iredale, 2007) in both human 
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studies and animal models  (Brunt, 2004; Constandinou et al., 2005; 
Sorensen et al., 1984; Tsukamoto et al., 1990).  Thus histological evidence of 
necroinflammatory activity in liver biopsies correlates strongly with the 
subsequent development of fibrosis and cirrhosis in several liver diseases 
including alcoholic liver disease, viral and autoimmune hepatitis.  The 
inflammatory process is characterised by activation of resident immune cells 
of the liver but also the recruitment of a lymphocyte-predominant infiltrate that 
constitutes chronic hepatitis (Lalor and Adams, 1999).  This drives the 
deposition of collagen and the development of fibrosis leading to cirrhosis 
(Figure 1-4).  The infiltrating lymphocytes are made up of various subsets 
which were discussed in section 1.4 and the following section summarises 
the evidence for their roles in liver disease.   
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Figure 1-4 The progression from liver injury to cirrhosis 
Inflammatory infiltration of immune cells in liver disease can occur around the 
portal tract or within the parenchyma.  Irrespective of the pattern of infiltration 
the progression of disease follows a common pathway of collagen 
deposition/fibrosis leading to bridging fibrosis and nodule formation 
(cirrhosis). 
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1.7 Evidence for the role of lymphoid cells in liver disease 
1.7.1 T cells 
T cell infiltration into the liver has been shown to drive hepatocellular injury in 
various animal models of liver injury and is a characteristic feature of most 
progressive liver diseases including autoimmune hepatitis, viral infection, 
alcoholic liver disease and allograft rejection (Bogdanos et al., 2000; Chedid 
et al., 1993; Heneghan and Mcfarlane, 2002; Kita et al., 2001; Rehermann 
and Chisari; Rosen, 2008).  A CD4 predominate T cell infiltrate is seen in 
autoimmune liver disease (Lohr et al., 1996) and in chronic viral hepatitis 
secondary to either hepatitis B or C, both CD4 and CD8 T cells have been 
implicated in liver injury (Chang et al.; Chisari, 1997; Napoli et al., 1996; 
Rosen et al., 2002).  Experimental models of T cell mediated liver injury in 
mice by concavalin-A have shown that this process is influenced  by STAT1 
and STAT-3, where IFNγ-activation of STAT1 has detrimental effects by 
activating CD4 T cells while IL-6 activation of STAT3 has a protective role by 
suppression of IFNγ signalling (Hong et al., 2002).  Concavalin A models 
have also demonstrated that IL-4 and TNFα play important roles in T cell 
mediated injury (Gantner et al., 1995; Jaruga et al., 2003).  However, how 
well such animals reflect the situation in human disease is unclear where 
chronic iterative injury and persistent inflammation acts over months and 
years to drive fibrogensis and cirrhosis.  There is also gathering evidence 
that the different functional T cell subsets may have important and distinct 
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roles in liver disease.  The Th17 subpopulation of CD4 T cells has been 
noted to be increased in chronic inflammatory liver diseases (Lan et al., 
2009; Lemmers et al., 2009), and both CD4 and CD8(Tc17) Il-17 secreting 
cells have been detected in chronic viral hepatitis  (Billerbeck et al., 2010) 
and chronic inflammatory liver disease.  These studies reported the presence 
in the liver of IL-22 secreting Th17 and Tc17 cells but the role of IL-22 is 
unclear because it can promote epithelial repair and regeneration through its 
effects on hepatocyte proliferation (Zenewicz et al., 2007). 
1.7.2 T regulatory cells 
Lymphocytes infiltrating liver tissue also contain populations of anti-
inflammatory or suppressor cells including regulatory T cells (Oo et al., 
2010).   There is evidence that this population can influence the inflammatory 
microenvironment and thereby impact on disease progression.  In viral 
hepatitis increased numbers of T regulatory cells within the liver may prevent 
an effective immune response allowing for viral persistence (Lan et al., 2006; 
Rushbrook et al., 2007).  In chronic hepatitis C it has been shown that T regs 
specific for the Hepatitis C virus (HCV) can directly suppress the actions of 
HCV specific CD8+ cells (Ebinuma et al., 2008).  T regulatory cells may also 
influence anti-tumour immunity.  The proportion of Tregs infiltrating primary 
liver tumours, hepatocellular carcinomas, has been found to be increased 
and the numbers of tumour-infiltrating Tregs correlates with disease 
progression and survival (Fu et al., 2007).   
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Whilst increased T reg infiltration of the liver may promote viral infection and 
tumour development, decreased numbers or defective function may have 
other consequences.  Autoimmune diseases develop because of a 
breakdown in immune tolerance to self-antigens.  Tregs play an important 
role in preventing this autoreactivity.  In autoimmune hepatitis it has been 
shown that circulating T regs are reduced in numbers and show functional 
impairment (Longhi et al., 2004; Longhi et al., 2005).  Decreased frequency 
of T regulatory cells has also been reported in other autoimmune liver 
diseases such as primary biliary cirrhosis (Lan et al., 2006).  It is possible 
that Tregs are defective in the face of severe inflammation or that they are 
overwhelmed by the effector response.  However, work from our own group 
shows that the proportion of Tregs within the hepatic infiltrate is greatest in 
patients with severe inflammation.  Indeed the highest levels were seen in 
seronegative fulminant hepatitis (Oo et al., 2010) .  This suggests that 
recruitment of Tregs is maintained and either that they are defective or more 
likely that they are suppressed by the inflammatory microenvironment or 
more simply that they are swamped by the vigour of the effector response.  
These findings suggest that the balance between effector/suppressor 
subsets can have important implications for disease development and 
progression.  
1.7.3 B cells 
Whilst T cell populations have been shown to contribute to several 
inflammatory liver diseases, there is also gathering interest in B cells.  The 
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majority of B cells are found within the spleen and secondary lymphoid tissue 
where interactions occur with T cells (Karrer et al., 1997).  They also produce 
antibody and differentiate into memory B cells and plasma cells that migrate 
to the gut and bone marrow and secrete high affinity antibodies. B cell 
populations can also be found in peripheral tissues as part of the chronic 
inflammatory infiltrate although at much lower frequencies than T cells.  In 
some forms of established chronic inflammation neolymphogenesis occurs 
leading to the development of tertiary lymphoid structures (Qin et al., 1998; 
Schroder et al., 1996). These tertiary lymphoid structures have been 
identified in inflammatory liver diseases (Grant et al., 2002; Murakami et al., 
1999) and contain B cell rich areas arranged into lose aggregates that 
resemble the B cell follicles seen in secondary lymph nodes.  Whether such 
structures are sites of local antibody production is less clear.  
B cells have also been directly implicated in the progression of liver injury in 
murine models of liver diseases including autoimmune cholangitis and 
primary biliary cirrhosis.  Experimental data has shown an important role for 
these cells in murine models of primary biliary cirrhosis (Moritoki et al., 
2009a; Moritoki et al., 2009b).  In a model of autoimmune cholangitis and 
colitis the depletion of B cells with anti CD20 antibodies led to an 
amelioration of liver disease but a worsening of gut inflammation. More 
recent studies in a murine model of primary biliary cirrhosis reported that B 
cell depletion led to a worsening of disease (Dhirapong et al., 2011).  B cells 
have also been directly implicated in the development of liver fibrosis 
(Novobrantseva et al., 2005).  These murine experiments demonstrated that 
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B cells isolated from the bone marrow homed to the liver and contributed to 
the progression of fibrosis in an antibody-independent manner.  B cells are 
able to produce large amounts of cytokines and it may be that they promote a 
profibrogenic environment by cytokine secretion. In the context of hepatitis C 
infection, B cells have been shown to internalise a strain of the HCV virus 
and efficiently transmit it to hepatoma cells (Stamataki et al., 2008) 
suggesting that B cells could transmit HCV infection on homing to the liver.  
These diverse results suggest that the role of B cells in liver disease is 
complex but emphasise how the underlying mechanisms are poorly 
understood.   
1.7.4 NK and NKT cells 
NK cells are present at higher frequencies in the liver compared to other 
tissues (Norris et al., 1998; Tu et al., 2007).  The human liver is also enriched 
for NKT cells, the numbers of these cells is highly variable ranging from 5% 
to 25% of the total lymphocyte population within the liver (Doherty and 
O'Farrelly, 2000).  Both these cell types have been implicated in the 
pathogenesis of several chronic liver diseases including chronic viral 
hepatitis, alcoholic liver disease and non-alcoholic fatty liver disease 
(NAFLD).  Both NK and NKT cells have the ability to kill virally infected cells 
and studies have shown that depleted numbers of these cells are associated 
with progression of chronic hepatitis C infection (Golden-Mason et al., 2007; 
Yamagiwa et al., 2008).  NK cells are particularly important in mediating 
hepatocyte killing in hepatitis B infection (Dunn et al., 2007).  However, the 
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role played by these cells is more complex and both cell types can have 
protective regulatory functions under certain circumstances.  Studies in mice 
demonstrate that NKT cells are protective in some models of NAFLD and in 
con A hepatitis where they promote the recruitment of regulatory T cells (Li et 
al., 2005; Santodomingo-Garzon et al., 2008).  The complexity is well-
demonstrated by the situation in alcoholic liver disease where reduced 
numbers of NKT cells appear to be protective whereas activation of these 
cells exacerbates alcoholic liver injury (Minagawa et al., 2004).  In primary 
biliary cirrhosis both cell types have been implicated in driving the liver injury 
associated with this condition (Chuang et al., 2006; Chuang et al., 2007).   
All the lymphocyte subsets discussed above need to be recruited from the 
peripheral circulation to their site of action.  The recruitment of these 
lymphocyte subsets into tissue is complex but understanding the molecular 
mechanisms that mediate this cell subtype specific process within the liver 
could identify both organ-specific and subset specific targets which are anti-
inflammatory to halt progression to fibrosis and cirrhosis.  The following 
section reviews the current understanding of lymphocyte recruitment, with 
emphasis on the liver. 
. 
1.8 Lymphocyte trafficking 
The immune system is able to respond to foreign antigen in a rapid and 
specific way.  A major part of this process involves the trafficking of 
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lymphocytes from blood into various tissues and then into lymph and back to 
blood.  The continual recirculation of lymphocytes involves migration into 
tissues where antigen is found since they are only activated by direct contact 
with antigens (von Andrian and Mackay, 2000).  T cells that have not 
encountered antigen are termed naive T cells and they are programmed to 
migrate into secondary lymphoid organs (eg peripheral lymph nodes, Peyers 
patches, tonsils and spleen) where they encounter dendritic cells which 
present antigen that they have taken up in the periphery (Banchereau and 
Steinman, 1998).  If the T cell recognises the antigen presented by the 
dendritic cell it becomes either an effector capable of migrating to the site of 
inflammation or it is programmed to migrate into B cell rich follicles to provide 
help to B cells (Morita et al., 2011).  Once the antigen is cleared most of 
these activated cells die but subsets of primed, memory cells continue to 
patrol the peripheral tissue or remain in lymphoid tissue (Sallusto et al., 
1999).  These memory cells are then able to respond rapidly to repeated 
challenges by the same antigen thereby providing the basis of immunological 
memory.   
To enter tissues from blood lymphocytes must first bind to and then cross the 
endothelial cells lining the vessel wall  (Springer, 1995).  Lymphocyte 
recirculation is not a random process, the endothelium plays an important 
role in controlling the access of lymphocyte subsets to particular tissues and 
this has an important effect on the local immune responses (Butcher and 
Picker, 1996; Kunkel and Butcher, 2002).  The process is controlled by 
adhesion molecules on the surfaces of lymphocytes and endothelial cells and 
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the binding of chemoattractant cytokines, chemokines, to chemokine 
receptors on the surface of lymphocytes.  The process involves a sequence 
of combinatorial interactions termed the ‘adhesion cascade’. 
1.9 The adhesion cascade 
 The first interactions between flowing lymphocytes and endothelium under 
conditions of blood flow are tethering interactions which lead to rolling on the 
vessel wall followed by arrest, intravascular crawling and transendothelial 
migration into tissue. In the initial step the lymphocytes are captured by 
selectins (Tedder et al., 1995) or members of the immunoglobulin 
superfamily (Alon et al., 1995; Berlin et al., 1995; Lalor et al., 1997) This 
capture serves to slow the cell down allowing it to roll on the vessel wall and 
interact via G-protein coupled receptors (GPCRs) on the  lymphocyte surface  
with chemokines sequestered in endothelial glycocalyx (Adams and Lloyd, 
1997; Campbell et al., 1996).  Activation of these receptors leads to an 
intracellular signalling cascade which culminates in integrin receptors on the 
lymphocyte surface clustering at sites of contact and altering their 
confirmation to a ‘high affinity’ state allowing binding to the immunoglobulin 
family receptors on the endothelium which leads to arrest and firm adhesion 
to the vessel wall (Campbell et al., 1998; Tanaka et al., 1993).  The activation 
of integrins involves an unfolding and extension of the integrin and an 
opening of the binding domain to promote interactions with counter-receptors 
(Shamri et al., 2005).  The cell then undergoes intravascular crawling in 
which it migrates on the endothelial surface in search of sites where it can 
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undergo transendothelial migration into tissue.  This last step is complex and 
poorly understood process and involves multiple adhesion molecules and 
chemokines(Imhof and urrand-Lions, 2004).  Table 1-1 summarises the 
major adhesion molecules that play a role in the adhesion cascade and the 
individual stages in the ‘typical process’ are discussed below. 
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Molecule Expression Role in Adhesion Cascade 
L selectin Leucocytes Rolling 
P selectin Endothelial cells and 
Platelets 
 
Rolling 
E selectin Endothelial cells 
 
Rolling 
Selectin Ligands 
Sialyl Lewisx
 
 
 
PSGL-1 
 
PNAd 
CLA 
 
Various cells regulated by 
fucosyl transferase VII 
 
Leucocytes 
 
High endothelial venules 
Skin homing leucocytes 
 
Ligand for all selectins which 
is presented on the following 
molecules : 
Main ligand for P-selectin but 
binds all selectins 
Ligand for L-selectin  
Ligand for E-selectin 
ß2 Integrins 
αL ß2          
αM ß2 
 
Leucocytes 
Myeloid cells 
 
Firm adhesion and 
transmigration 
α4 Integrins 
α4 ß1 
 
α4 ß7 
 
Leucocytes except 
neutrophils 
Gut homing leucocytes 
 
Rolling and Firm Adhesion 
 
Rolling and Firm Adhesion 
Immunoglobulin 
Superfamily 
ICAM-1 
 
ICAM-2 
 
VCAM-1 
 
 
MAdCAM-1 
 
Increased expression on 
endothelial cells with 
cytokines 
Constitutive on 
endothelium 
Induced expression on 
endothelial cells with 
cytokines 
High endothelial venules 
on gut associated 
lymphoid tissue 
 
Ligand for ß2 Integrins: firm 
adhesion and transmigration 
 
Ligand for β2 integrins: firm 
adhesion and transmigration 
Ligand for α4 Integrins: 
rolling and firm adhesion 
 
Ligand for L-selectin and  α4 
ß7: 
rolling and firm adhesion 
PECAM-1 Endothelial cells and 
leucocytes 
Transmigration 
JAM A,B,C Endothelial cells Transmigration 
Table 1-1 Summary of the molecular determinants of the adhesion 
cascade 
PSGL-1, P-selectin glycoprotein ligand 1; PNAd, Peripheral-node addressin; CLA, 
Cutaneous lymphocyte antigen; ICAM-1, Intercellular adhesion molecule 1; ICAM-2, 
Intercellular adhesion molecule 2; VCAM-1, Vascular cell adhesion molecule 1; MAdCAM-1, 
Mucosal vascular addressin  cell adhesion molecule 1; PECAM-1, Platelet-endothelial cell 
adhesion molecule 1; JAM, Junctional adhesion molecule.  
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1.9.1 Rolling 
Capture and rolling is classically mediated by molecules called selectins (L-
selectin, P-selectin and E-selectin), which bind to glycosylated ligands 
((McEver and Cummings, 1997).  L-selectin is expressed on most 
lymphocytes, whereas E and P-selectin are predominantly expressed on 
endothelial cells.  The selectin-ligand interaction involves a ‘catch-bond’ 
phenomenon in which each bond is strengthened with increasing shear 
stress (Marshall et al., 2003).  In addition a transport phenomenon between 
selectin ligands and selectins allows the rolling motion of the cell to generate 
new bonds before old bonds are broken (Yago et al., 2007).  There are 
situations where integrins can mediate rolling particularly α4 integrins and 
their ligands vascular cell adhesion molecule- 1 (VCAM-1) and mucosal 
vascular addressin cell adhesion molecule-1(MAdCAM-1) (Berlin et al., 1995; 
Lalor et al., 1997; Sigal et al., 2000) 
1.9.2 Activation and Arrest 
 Following the rolling step, lymphocytes undergo activation by chemokines or 
other chemoattractants.  This leads to integrins binding to immunoglobulin 
superfamily members such as intercellular adhesion molecule-1 (ICAM-1) or 
VCAM-1 on endothelial cells leading to arrest and firm adhesion (Campbell et 
al., 1996; Campbell et al., 1998).  During inflammation, endothelial cells are 
activated by cytokines to express adhesion molecules and synthesise 
chemokines that are presented on their luminal surface via binding to 
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glycosoaminoglycans (GAGs) in the endothelial glycocalyx (Johnson et al., 
2005). The binding of chemokines to GPCRs  leads to a conformational 
change in the integrins from a bent low affinity state to an extended 
conformation which opens up the ligand binding pocket (Arnaout et al., 
2005).  This process is not completely understood but there appear to be 
three stages involving phospholipase C (PLC), activation of small GTPases 
and finally transitional integrin conformational changes through association 
with actin-binding proteins such as Talin-1(Ley et al., 2007). 
1.9.3 Transmigration 
 Once leucocytes undergo firm adhesion they can migrate through the 
endothelial layer.  The first step is crawling on the vessel wall which is 
integrin and ICAM-1 dependent (Phillipson et al., 2006; Schenkel et al., 
2004).  The initiation of transmigration may involve several mechanisms 
including chemoattractants acting under conditions of shear stress and 
interactions between integrins and endothelial cell ligands which stimulate 
endothelial cells to promote migration.  The interaction between leucocytes 
and endothelial cells has been shown to involve the formation of ‘docking 
sites’ or’ transmigratory cups’ which are rich in ICAM-1 and VCAM-1(Barreiro 
et al., 2002; Carman and Springer, 2004a).  Transmigration then occurs 
through the endothelial layer and this has been to shown to occur via a 
paracellular route or a transcellular route.  In the paracellular route, ligation of 
adhesion molecules leads to weakening of intra-endothelial contacts. This 
has been shown for ICAM-1 ligation which leads to the release of intracellular 
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calcium and activation of p38 mitogen activated protein kinase and Ras 
homologue (RHO) GTPase which results in opening up of the endothelial 
junctions (Huang et al., 1993; Millan and Ridley, 2005).  In addition 
endothelial junctional molecules which bind leucocytes such as 
platelet/endothelial cell adhesion molecule 1 (PECAM-1) and junctional 
adhesion molecule A (JAM A) are mobilized to junctions and thereby create a 
haptotactic gradient which guides leucocytes to the junctional zone (Muller, 
2003a).  The molecules directly implicated in migration include 
immunoglobulin superfamily members- PECAM-1, ICAM-1, ICAM-2, JAM A,B 
and C and endothelial cell-selective adhesion molecule (ESAM), as well as 
the non-immunoglobulin molecule CD99 (Ley et al., 2007).  Other molecules 
implicated include poliovirus receptor (CD155) and several ectoenzymes, 
vascular adhesion protein-1 (VAP-1), CD157 and leucocyte specific protein 
1(LSP 1) (Liu et al., 2005; Reymond et al., 2004; Salmi and Jalkanen, 2005).  
Transmigration involves several molecular interactions occurring in sequence 
as demonstrated by the fact that blockade of CD99 and PECAM-1 exerts an 
additive effect on leucocyte transmigration (Lou et al., 2007; Schenkel et al., 
2002).   
An alternative path for transmigration is the transcellular route.  This route of 
leucocyte migration was described in several early in vivo studies (Azzali et 
al., 1990; Chamberlain and Lichtman, 1978; Feng et al., 1998; Lossinsky et 
al., 1989) but the inability to reproduce these findings in vitro led to 
controversy regarding the importance of transcellular migration (Luscinskas 
et al., 2002; Muller, 2003b).  More recently with improved imaging techniques 
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the transcellular route has been confirmed in both in vivo and in vitro settings 
(Carman and Springer, 2004b; Cinamon et al., 2004; Engelhardt and 
Wolburg, 2004; Millan et al., 2006).  The mechanism involves translocation of 
apical ICAM-1 to caveolae and F-actin rich regions and the transport of 
caveolin-1 to the basal membrane resulting in a channel through which the 
leucocyte can migrate (Cinamon and Alon, 2004; Millan et al., 2006).  The 
proportion of paracellular versus transcellular migration appears to differ 
between endothelium in different tissues.  Studies with human umbilical vein 
endothelial cells (HUVEC) have shown that transcellular migration occurs in 
only a small proportion of leucocytes (5-10%) (Carman & Springer, 2004b; 
Cinamon et al., 2004).  A much larger proportion of leucocytes undergo 
transcellular migration across microvascular endothelium such as human 
dermal (HDMEC) and human lung (HLMVEC) microvascular endothelial cells 
and human lymphatic endothelial cells (HLyECs) (30-40%)(Carman et al., 
2007; Millan et al., 2006).  In vivo studies have demonstrated that 100% of 
lymphocytes that cross the blood-brain barrier underwent transcellular 
migration in a murine model of multiple sclerosis.  Figure 1-5 summarises the 
two routes of leucocyte transmigration.   To our knowledge the transcellular 
route of transmigration has never been reported in hepatic sinusoidal 
endothelium.  The lack of tight junctions and a classical basement membrane 
in hepatic sinusoidal endothelium suggest that different mechanisms may 
apply in this bed. 
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The adhesion cascade that has been described above is the generally 
accepted paradigm for lymphocyte interactions with endothelium but it is 
clear that there are tissue-specific differences.  Increasing evidence over the 
last 15 years has confirmed that specific molecular determinants regulate 
lymphocyte homing to specific tissues.  This has been demonstrated by the 
molecular regulation of lymphocyte homing to the skin and the intestines 
which has been described in recent years (Butcher & Picker, 1996; Robert 
and Kupper, 1999).  Tissue-specific signals may also play a role in 
lymphocyte trafficking to the liver but a true liver-specific adhesion receptor 
has yet to be found (Lalor et al., 2002b).   
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Figure 1-5 Leucocyte transendothelial migration 
A schematic summary of the two possible routes that can be taken by 
transmigrating leucocytes. The paracellular route involves leucocytes binding 
to junctional molecules such as JAM-A and CD31 as well as the dissociation 
of tight junction molecules such as VE-Cadherin.  Transcellular migration 
appears to be triggered by the binding of β2 integrins to ICAM-1 which leads 
to the formation of a transcellular channel comprising of VVOs and 
reorganisation of the actin cytoskeleton. JAM-A: Junctional adhesion 
molecule A, ICAM-1: Intracellular adhesion molecule- 1, VVO: Vesiculo-
vacuolar organelle.   
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1.10 Lymphocyte recruitment to the liver 
As mentioned in section 1.6.1, during the development of inflammatory liver 
diseases lymphocyte recruitment increases markedly and the intrahepatic 
localization of these infiltrating lymphocytes determines the nature and 
severity of disease.  Parenchymal infiltrates lead to a lobular hepatitis as 
seen in viral infections, whereas portal infiltrates are seen in biliary diseases 
such as primary biliary cirrhosis and primary sclerosing cholangitis (Lalor et 
al., 2002b).   
1.10.1 A unique environment for lymphocyte recruitment 
Lymphocyte interactions with the hepatic microvasculature do not conform 
with the classical pathway of leucocyte adhesion described earlier (Lee and 
Kubes, 2008).  Intravital experiments have shown that lymphocytes are 
capable of adhesion to different regions of the hepatic microvasculature but 
the majority adhere to the hepatic sinusoids (Wong et al., 1997).  This is in 
contrast to most other organs where leucocyte extravasation takes place in 
the post-capillary venules.  The hepatic sinusoids have several functions 
which set them apart from other vascular beds.  They are the primary site for 
filtration in the liver and also display highly efficient scavenging function 
implicating the hepatic endothelium in the removal of soluble waste 
molecules and colloids from the circulation (Smedsrod, 2004).  Thirdly they 
have an important role in antigen presentation being able to process and 
present antigens to CD4 and CD8 T cells and to tolerize immune responses 
to CD8 cells (Knolle and Limmer, 2001).  In addition hepatic sinusoidal 
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endothelial cells (HSEC) display differences in adhesion molecule expression 
when compared to other endothelial cells.  A fundamental example is the lack 
of expression of P-selectin under most circumstances in vitro or in vivo and a 
markedly reduced E-selectin expression (Adams et al., 1996).  Furthermore 
there is no upregulation of these receptors on HSEC in diseases such as 
PBC (Steinhoff et al., 1993).   
1.10.2  Classical endothelial adhesion molecules involved in 
lymphocyte recruitment to the liver.   
Intravital experiments confirmed that lymphocyte recruitment within the 
hepatic sinusoids was selectin independent (Wong et al., 1997).  In view of 
these findings, lymphocyte recruitment was initially thought to be due to 
‘physical trapping’ but subsequent studies have demonstrated that 
lymphocytes do interact with sinusoidal endothelium via adhesion molecules.  
ICAM-1 is constitutively expressed on post-capillary venules and only 
minimally on true capillaries, in keeping with the fact that leucocyte 
recruitment occurs in the post-capillary venules (Iigo et al., 1997) but in the 
liver the density of ICAM-1 in the hepatic sinusoids is comparable to the 
central venules (Iigo et al., 1997).  VCAM-1 is not expressed in normal liver 
tissue but it is markedly upregulated in inflammatory liver diseases (Volpes et 
al., 1992).  Multiple strands of evidence implicate ICAM-1 and VCAM-1 in 
lymphocyte adhesion to the hepatic sinusoids.  ICAM-1 deficient mice 
demonstrate reduced leucocyte adhesion to hepatic sinusoids (Wong et al., 
1997) and VCAM-1 has been shown to mediate lymphocyte capture and 
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adhesion via α4 integrins.  In vitro studies with human HSEC show reduced 
lymphocyte adhesion to hepatic sinusoids when VCAM-1 and ICAM-1 are 
blocked (Edwards et al., 2005; Lalor et al., 2002a).   
1.10.3 Non-classical adhesion molecules involved in lymphocyte 
recruitment to the liver 
ICAM-1 and VCAM-1 play a role in adhesion of leucocytes to endothelium, 
but the liver sinusoids also express another adhesion receptor known as 
vascular adhesion protein-1 (VAP-1) which appears to play a more specific 
role for lymphocyte recruitment to the liver.  VAP-1 is a 170kDa homodimeric 
glycoprotein that has monoamine oxidase activity.  It is expressed 
constitutively within hepatic sinusoids but is absent from other non-inflamed 
vessels in extralymphoid organs (Jalkanen and Salmi, 2001).  In vitro VAP-1 
mediates lymphocyte adhesion to human HSEC (Lalor et al., 2002a) and in 
vivo experiments on mice using intravital microscopy have suggested that 
VAP-1 has preferential activity for particular T cell subsets (Bonder et al., 
2005).  VAP-1 has also been implicated in lymphocyte recruitment to rodent 
liver transplants (Martelius et al., 2004).  The precise role of VAP-1 is 
unclear.  With regard to lymphocyte interaction with HSEC, VAP-1 mediates 
lymphocyte transmigration and intriguingly this transmigration can be 
inhibited with either blocking antibodies or enzyme inhibitors (Lalor et al., 
2002a).  How the enzyme activity of VAP-1 modulates recruitment is unclear.  
Provision of substrate to the amine oxidase of VAP-1 modulates the 
expression and function of ICAM-1 and VCAM-1 and MADCAM-1.  Provision 
47 
 
of substrate to VAP-1 on monolayers of HSEC results in NFkB-dependent 
upregulation of ICAM-1 and VCAM-1 which results in increased lymphocyte 
adhesion from flow (Lalor et al., 2007).   Some of these effects may be 
dependent on H2O2 generated by the catalytic activity of VAP-1 (Liaskou et 
al., 2011) 
CD44 is another adhesion molecule which is widely expressed but appears 
to play a particular role in the liver.  It has been shown to mediate 
sequestration of neutrophils in hepatic sinusoids during sepsis (McDonald et 
al., 2008) and is one of the receptors along with α4 integrins and VAP-1 
which can mediate selectin-independent tethering in the liver sinusoids under 
flow.  A recent study on neutrophil adhesion to hepatic sinusoids using 
intravital microscopy suggests that hyaluronan, a ligand of CD44, is 
increased on sinusoids in sepsis where it can support CD44-mediated 
adhesion.  Moreover CD44 alone was sufficient and necessary for reversible 
neutrophil adhesion to hepatic sinusoids in vivo (McDonald et al., 2008).   
MadCAM-1 is an adhesion molecule which is normally confined to mucosal 
endothelium in the bowel but can be induced on hepatic endothelium in some 
inflammatory situations (Grant et al., 2001).  It plays a critical role in the 
compartmentalization of lymphocyte trafficking by recruiting gut specific 
mucosal lymphocytes.  MadCAM-1 seems to be induced within the liver by as 
yet unknown factors, with the result that mucosal T cells are recruited to the 
liver where they drive immune-mediated liver disease (Adams and Eksteen, 
2006).   
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1.10.4 The involvement of chemokines in liver disease  
As described previously, chemokines play a critical role in several steps of 
the adhesion cascade involving triggering of integrin-mediated adhesion and 
migration responses (Rot and von Andrian, 2004).  They also play a crucial 
role in the liver and chemokines secreted by liver cells contribute to the 
intrahepatic compartmentalization of lymphocyte recruitment. The CCR5 
ligands CCL3-5 are strongly expressed on vascular endothelium within the 
portal tracts where they mediate lymphocyte recruitment in a range of 
inflammatory diseases including graft versus host diseases, immune 
mediated liver diseases and graft rejection (Goddard et al., 2001; Murai et al., 
1999).  Lymphocyte recruitment into the parenchyma via inflamed hepatic 
sinusoids is a feature of progressive liver injury in chronic viral infection and 
autoimmune disease and is associated with strong expression of the CXCR3 
ligands CXCL9-11 on sinusoidal endothelium (Harvey et al., 2003; Shields et 
al., 1999).  These chemokines are not only secreted by endothelium but by 
cholangiocytes, hepatocytes and stellate cells in the inflamed liver, but 
regardless of their source they can be presented on sinusoidal endothelium.  
For example the process of transcytosis (Middleton et al., 1997) allows 
chemokines secreted by hepatocytes or stellate cells to be transported to the 
luminal surface of the endothelial cell or chemokines secreted by 
cholangiocytes can be captured by retention in the proteoglycan-rich 
endothelial glycocalyx (Curbishley et al., 2005).  In vitro experiments show 
that activation of CXCR3 on lymphocytes by its ligands promotes lymphocyte 
adhesion and transmigration across HSEC (Curbishley et al., 2005).  In vivo 
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experiments suggest that CXCR3 and its ligands play a significant role in 
recruitment of virus specific CD8+ T cells to the murine liver (Hokeness et al., 
2007).   
Liver infiltrating lymphocytes also express the chemokine receptor CXCR6.  
This receptor is seen on CD4, CD8 and NKT cells (Boisvert et al., 2003). The 
CXCR6 ligand is a transmembrane chemokine, CXCL16 expressed by 
cholangiocytes in the inflamed liver and sinusoidal endothelium in the normal 
liver (Heydtmann et al., 2005).  CXCR6 has been shown to mediate 
trafficking of NKT cells in murine sinusoids (Geissmann et al., 2005).  The 
increased expression of CXCL16 on epithelial cells suggests that it may act 
to localize and retain effector lymphocytes at epithelial sites and biliary 
epithelium during viral hepatitis (Heydtmann et al., 2005).  It has also been 
demonstrated that the chemokine CCL28 is present on inflamed 
endothelium, cholangicytes and hepatocytes.  A high proportion of liver 
infiltrating T cells which expressed the receptor for CCL28 ,CCR10, were 
phenotypically and functionally T regulatory cells (Eksteen et al., 2006) which 
suggested that regulatory T cells were retained at bile ducts by the secretion 
of CCL28.   
Aberrant expression of the gut chemokine CCL25 in the liver can promote the 
recruitment of mucosal T cells to the liver resulting in inflammatory disease in 
primary sclerosing cholangitis (PSC) (Eksteen et al., 2004).  It promotes the 
homing of lymphocytes bearing the receptor CCR9 and suggests that 
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aberrant homing of mucosal T cells to the liver underlies the pathogenesis of 
PSC ((Adams & Eksteen, 2006).   
1.10.5 Transendothelial migration across the hepatic sinusoids 
The process of transmigration of lymphocytes across HSEC has several 
features which differ from that observed in other vascular beds.  The tight 
junctions of vascular endothelium express PECAM/CD31 which has been 
shown to mediate leucocyte transmigration (Ley et al., 2007).  Liver 
sinusoidal cells lack tight junctions, express lower levels of CD31 than 
vascular endothelium and blocking CD31 has no effect on neutrophil 
extravasation in the murine liver (Chosay et al., 1998).  Additional 
experiments have demonstrated that junctional adhesion molecule-A (JAM-
A) mediates neutrophil but not T cell extravasation into the liver (Khandoga et 
al., 2005) all of which suggests that novel mechanisms may apply. The 
precise molecular basis of lymphocyte transmigration across sinusoidal 
endothelium is not yet known.  ICAM-1 and LFA-1 and VAP-1 have all been 
implicated in transmigration of lymphocytes and monocytes by our group 
using flow based adhesion assays and human HSEC (Aspinall et al., 2009) 
(Lalor et al., 2002a). VAP-1 is constitutively expressed and is not regulated 
by the same proinflammatory signals as ICAM-1 and VCAM-1.  It is not yet 
clear how VAP-1 mediates adhesion and transmigration and nature of its 
ligand is not known.  Interestingly, the enzymatic activity of VAP-1 can 
mediate NFk-B dependent activation of human HSEC leading to expression 
of adhesion molecules and secretion of chemokines (Lalor et al., 2007).  The 
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fact that some of the VAP-1 substrates such as methylamine are constituents 
of food, wine and cigarette smoke suggest intriguing links between the gut 
and liver inflammation(Liaskou et al., 2011).  Figure 1-6 summarises the 
major molecular determinants of lymphocyte recruitment within the hepatic 
sinusoids. 
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Figure 1-6 Molecular determinants of lymphocyte recruitment within the 
hepatic sinusoids 
A schematic representation of lymphocyte recruitment via the hepatic 
sinusoids.  Lymphocytes enter the hepatic sinusoids under conditions of flow.  
Following a brief tethering step they are exposed to chemokines on the 
endothelial surface.  If they express the appropriate chemokine receptor they 
undergo activation which leads to firm adhesion and transmigration.  The 
receptors involved each step are outlined on the bottom row. 
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1.10.6 The route taken by trafficking lymphocytes 
Although, as discussed above, there has been a great deal of study into the 
molecular determinants of lymphocyte interactions with hepatic endothelium 
that promote homing to the liver, the precise anatomical route of lymphocytes 
trafficking through the liver is poorly understood.  Recent in vivo studies have 
shed important light on this.   
The trafficking of lymphocytes through the lymphatic system has been 
studied in detail, and in this situation naive lymphocytes continuously home 
to T cell areas via high endothelial vessels allowing them to interact with 
dendritic cells which have entered the lymph node via afferent lymphatic 
vessels.  If lymphocytes are activated they are imprinted with receptors that 
allow them to migrate via blood to peripheral tissues whereas lymphocytes 
which do not recognise antigen leave the lymph node via the efferent vessels 
into the thoracic duct (von Andrian and Mempel, 2003).  The liver has a large 
population of resident lymphocytes, which are continually patrolling from 
blood into the liver and back to hepatic lymph nodes via hepatic lymphatics 
(Xu et al., 2008).  This is in keeping with the large antigen load that the liver 
receives from the gut and periphery.  Recent studies in a rat model provide 
further insight into the route taken by lymphocytes within the liver (Xu et al., 
2008).  Using a model where the hepatic lymph nodes were either removed 
or ligated the authors showed that the transit time within the liver was 
approximately 3-4 hours, but lymphocytes appeared within the portal area 
within 30 minutes.  Their studies suggest that most lymphocytes enter via the 
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sinusoids in the periportal regions with the subsequent route taken 
determined by the hepatic microenvironment.  Lymphocytes may then exit 
the liver via lymphatic vessels located in the hepatic portal area to hepatic 
lymph nodes or be retained in the liver to carry out immune surveillance in 
the non-inflamed liver or as effector cells in the context of inflammatory 
disease.   
The signals which mediate lymphocyte retention are unclear but there is 
evidence that other liver cell populations such as epithelial cells, stromal cells 
and kupffer cells play important roles.  Kupffer cells, the resident liver 
macrophages, patrol the hepatic sinusoids ready to phagocytose foreign 
material.  Interaction between Kupffer cells and other liver cell types 
profoundly effects their behaviour and secretion of cytokines (Alabraba et al., 
2008).  Stellate cells are fibroblasts situated in the Space of Disse and are 
central mediators of matrix formation during liver injury and fibrosis 
(Friedman, 2008).  Our group has shown that stellate cells and activated liver 
myofibroblasts can support lymphocyte adhesion and promote migration 
suggesting to us that they may be critical regulators of post-endothelial 
migration and positioning of cells within the liver parenchyma (Holt et al., 
2009).  Hepatocytes have also been shown to directly influence the 
expression of adhesion molecules on sinusoidal endothelium in in vitro 
coculture models (Edwards et al., 2005).  The levels of lymphocyte adhesion 
in these models were equivalent to those seen with stimulation by 
inflammatory cytokines. Once the lymphocytes have entered the liver, the 
mechanisms underlying their retention are still to be fully characterized.  As 
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discussed above this may be as a result of interactions with epithelial cells or 
stromal cells but additional structures develop during some forms of chronic 
hepatic inflammation that may act as portals for ongoing recruitment and 
retention.  Neovessels are formed in the portal tracts which are similar to 
HEVs seen in lymphoid tissue (Garcia-Monzon et al., 1995) and in both 
animals and humans they can become organized into ‘portal tract associated 
lymphoid tissue’ (PALT), (Grant et al., 2002; Yoneyama et al., 2001) tertiary 
lymphoid follicles within the portal tract which include discrete T and B cell 
areas and which contain dendritic cells and stromal cells.  The development 
of this tissue provides an ideal environment for recruitment and retention of 
lymphocytes within the liver.  This formation of tertiary lymphoid tissue 
appears to be partly explained by the presence of CCL19 and CCL21 which 
are expressed in lymphoid follicles in chronic inflammatory liver disease.  In 
secondary lymphoid tissues CCL19 and CCL21 lead to the recruitment and 
organization of naïve T-cells and dendritic cells and they have been 
implicated in the formation of tertiary lymphoid tissues in chronic 
inflammation as part of the process of lymphoidneogenesis (Grant et al., 
2002). 
1.11 Novel aspects of hepatic endothelial function which may 
provide additional mechanisms for leucocyte recruitment 
Despite this body of work there is still a requirement for further studies to 
elucidate the molecular determinants of lymphocyte recruitment to the 
hepatic microvasculature.  In previous sections I have discussed the 
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importance of lymphocyte interactions within the unique sinusoidal vascular 
bed and the receptors which have been shown to be important.  However, 
the unusual nature of the hepatic sinusoidal endothelium provides 
alternatives which may have functional significance.  The sinusoidal 
endothelial layer is discontinuous, lacks a basement membrane and the cells 
themselves have fenestrae (Braet & Wisse, 2002).  Within these cells there 
are numerous endocytic vesicles and lysosome-like vacuoles in comparison 
to other endothelial cells (Aird, 2007b).  These morphological properties are 
associated with the unique functional properties of HSEC.  The fenestrae 
allow HSEC to acts as a communication route between the sinusoidal lumen 
and the Space of Disse.  They are organised in groups of structures known 
as ‘sieve plates’ and the filtration they permit is dynamic allowing passage of 
fluids, solutes and particles in a bidirectional manner (Braet & Wisse, 2002).  
Along with this filtration capacity, HSEC also have the ability to take up waste 
molecules from blood via endocytic vesicles.  Many cells have the ability to 
perform endocytosis but HSEC are unique in that they can endocytose a 
large number of different ligands in a highly efficient manner (Smedsrod, 
2004).  It is important to make a distinction between the uptake of particles by 
HSEC and Kupffer cells, especially since they are in such close proximity.  
Kupffer cells perform phagocytosis which involves the uptake of particles 
from the blood above a certain size (approximately 1 µm or greater), whereas 
HSEC perform receptor mediated endocytosis of colloids and soluble 
macromolecules (Smedsrod, 2004).  These physiological functions of HSEC 
are essential for the maintenance of homeostasis in terms of degradation of 
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macromolecules and as well as allowing hepatocytes to interact with the 
peripheral circulation.  The ability to perform such efficient endocytosis and 
scavenge a diverse array of ligands is partly explained by the C-type lectins 
that  are expressed on these cells.   
1.11.1 C-Type Lectins 
The C-type lectin-like receptors (LLRs) comprises a diverse family of 
proteins.  They are related by a structural motif which was originally identified 
in the carbohydrate–recognition domain of the mannose-binding lectin.  
Whilst many proteins in this family bind specific sugar structures that mediate 
biological events such as cell-cell adhesion and innate immune responses in 
a calcium dependent manner, the motif in question  has subsequently been 
identified in proteins which do not demonstrate calcium binding or 
carbohydrate specificity (Robinson et al., 2006).  The groups within this 
family are listed in Table 1-2. 
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Table 1-2 C Type Lectin Groups 
Group I Proteoglycans 
Group II Type 2 receptors-eg Dendritic cell-
specific intercellular adhesion molecule 
3-grabbing non-integrin (DC-SIGN) and 
Liver/Lymph node-specific intercellular 
adhesion molecule 3- grabbing non-
integrin (L-SIGN) 
Group III Collectins eg Mannose binding Proteins 
Group IV Selectins 
Group V NK- cell receptors group- NK cell 
receptors and dectin-1, C-type lectin-like 
receptors (CLEC)-1 and -2).   
Group VI Mannose receptor family-eg DEC205 
and mannose receptor 
Group VII Free CTLD 
Group VIII Simple type 1 receptors eg Layilin 
Group IX Tetranectin family 
Group X Polycystin 
Group XI Attractin family 
Group XII CTLD with acidic neck/ Eosinophil major 
basic protein 
Group XIII Integral membrane protein 
Group XIV Endosialin family 
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They are expressed on a variety of cell-types but predominantly on myeloid 
cells (dendritic cells and macrophages), the receptors in group V are 
specifically found on NK cells.  Consistent with this expression profile, they 
play important roles within the immune-system, especially with regard to 
inflammation and immunity towards tumour and virally-infected cells.  They 
have the ability to bind exogenous ligands and like toll-like receptors (TLRs) 
can recognise pathogen-associated molecular patterns.  Their expression 
also extends to specialised vascular beds including lymphatic endothelium 
and the hepatic sinusoidal endothelium, where they have been associated 
with a homeostatic role.  Importantly, unlike TLRs, these receptors do not 
discriminate between self and non-self and readily bind endogenous ligands 
(Cambi and Figdor, 2003).   
Receptor mediated endocytosis by HSEC utilises several members of the 
LLR family. These receptors include the collagen-alpha chain receptor 
(COLLA-R) which binds free alpha chains and therefore allows HSEC to take 
up collagen waste molecules (Ostgaard et al., 1995) as well as the  Fc-
gamma receptors (FcgRs) which bind the Fc domain of Immunoglobulin G 
(Johansson et al., 1996; Skogh et al., 1985).  One of the most extensively 
studied C-type lectins on HSEC is the mannose receptor (MR). It has been 
shown to bind several ligands, many of which are endogenous waste 
molecules, including lysosomal hydrolases, denatured collagen and c-
terminal procollagen peptides.   (Malovic et al., 2007; Martinez-Pomares et 
al., 2001; Smedsrod et al., 1990).   
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Two more recently discovered LLRs are stabilin-1 and stabilin 2 which are 
both expressed on sinusoidal endothelium (Politz et al., 2002).  These 
receptors are homologues consisting of multi domain proteins and a C-type 
lectin-like hyaluronan-binding link domain.  The presence of this link domain 
suggests that these receptors should bind hyaluronan (HA), this is indeed 
true of Stabilin 2 which has been shown to be the major HA binding receptor 
of HSEC (McCourt et al., 1999).  Stabilin-1, on the other hand, does not 
appear to bind HA but has also been separately identified as FEEL-1 
(fasciclin, EGF-like, laminin-type EGF-like, and link domain-containing 
scavenger receptor-1) and CLEVER-1 (common lymphatic endothelium and 
vascular endothelium receptor-1) and unlike stabilin-2 it is expressed on 
macrophages (Martens et al., 2006).  As well as binding HA, stabilin-2 is also 
the receptor for several other blood borne scavenger ligands (McCourt et al., 
2004).  These include amino-terminal propeptides of types I and III collagen 
(McCourt et al., 1999; Melkko et al., 1994) and advanced glycation end 
products (AGEs) (Hansen et al., 2002) all of which are endocytosed by 
stabilin-2 in studies of rat liver sinusoidal cells. 
Other LLRs which are expressed on HSEC come from the type-2 receptor 
subclass and are called dendritic cell-specific intercellular adhesion molecule 
3-grabbing non-integrin (DC-SIGN) and liver/lymph node-specific intercellular 
adhesion molecule 3- grabbing non-integrin (L-SIGN) (Bashirova et al., 2001; 
Lai et al., 2006). LLRs in the type 2 group have a single C-terminal C-type 
lectin domain which is separated from the transmembrane domain by a neck 
region.  The members of this group are involved in varied functions from cell-
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cell interaction to uptake of serum glycoproteins.  DC-SIGN was originally 
identified on dendritic cells and has been shown to internalize antigen and 
promote antigen presentation as well as cell-cell interaction via ICAM-3 
(Engering et al.).  There is now increasing evidence that DC-SIGN and L-
SIGN may also play a role in the uptake of blood-borne viruses into the liver.  
Both these receptors have been shown to capture the human 
immunodeficiency virus (HIV) by binding to envelope glycoprotein gp120 
(Bashirova et al., 2001). They have been implicated in the capture of 
Hepatitis C via interaction with the hepatitis C virus glycoprotein E2 (Lai et 
al., 2006).  A third lectin with a similar structure to DC-SIGN and L-SIGN has 
been identified and designated the liver and lymph node sinusoidal 
endothelial cell C-type lectin (LSECtin) (Liu et al., 2004).  This lectin has 
been shown to be co-expressed with L-SIGN and is encoded in the same 
cluster of lectin encoding genes as DC-SIGN and L-SIGN (Liu et al., 2004).  
Whereas DC-SIGN and L-SIGN have an almost identical ligand binding 
specificity, LSECtin exhibits important differences despite expression and 
structural similarities.  LSECtin has been shown to interact with proteins from 
the Ebola virus and the SARS coronavirus but, unlike DC-SIGN and L-SIGN, 
does not interact with HIV or Hepatitis C glyocproteins (Gramberg et al., 
2005).   
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1.12 A role for C-type lectins in lymphocyte adhesion and 
recruitment. 
More recently, there has been interest in the ability of scavenger receptors to 
act as cell adhesion molecules.  The selectins which are classed as group IV 
LLRs are well known for their role in mediating lymphocyte adhesion and 
homing to lymph nodes (Ley et al., 2007), but other LLRs have also been 
shown to have leucocyte binding properties.   An example of this is the 
oxidised low-density lipoprotein receptor-1 (LOX-1) which is a type II 
membrane glycoprotein with a C-type lectin like structure in the extracellular 
domain.  It is an endocytosis receptor for atherogenic oxidized low-density 
lipoprotein (LDL) (Sawamura et al., 1997).  LOX-1 has been shown to 
support rolling and adhesion of mononuclear leucocytes in static and flow 
conditions and to promote leucocyte recruitment in an in vivo model of 
endotoxin induced inflammation (Honjo et al., 2003).  In this model blockade 
of LOX-1 led to an amelioration of endotoxin induced uveitis.   
Whilst LOX-1 is a scavenger receptor expressed on vascular endothelium, 
scavenger receptors expressed preferentially on lymphatic endothelium have 
also been implicated in lymphocyte recruitment.  The mannose receptor has 
been shown to play an important role in lymphocyte binding to lymphatic 
endothelium and its ligand in this process has been identified as L-selectin 
(Irjala et al., 2001).  Lymphatic endothelium expresses several LLRs that are 
found on HSEC including the mannose receptor, CLEVER-1 and stabilin-2 
(Martens et al., 2006).  Stabilin-2 has been reported to mediate the firm 
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adhesion of lymphocytes to HSEC via interaction with the integrin αMβ2 
(Jung et al., 2007).  Aside from binding lymphocytes stabilins have also been 
implicated in other cell adhesion processes.  Stabilin-2 is present in the 
sinusoidal endothelial cells of the bone marrow where it plays a scavenging 
role but also mediates adhesion of stem and progenitor cells by a hyaluronan 
dependent mechanism (Qian et al., 2009). 
As discussed earlier, stabilin-2 has a clear scavenging function in endothelial 
cells but the role of its close homologue stabilin-1 (also known as CLEVER-1 
or FEEL-1) in endothelial cells is less well understood.  The following section 
summarises the current understanding of this receptor’s function and 
regulation.    
1.13 Common Lymphatic Endothelial and Vascular 
Endothelial Receptor-1 (CLEVER-1) 
CLEVER-1 was originally identified as the MS-1 antigen  which was shown to 
be a marker of sinusoidal endothelium of the spleen, lymph node, liver and 
adrenal cortex (Goerdt et al., 1991).  Ultrastructural analysis of splenic 
sinusoidal endothelial cells by electron microscopy demonstrated the antigen 
in these cells as small clusters of cytoplasmic reactivity deposited at zones of 
contact between sinusoidal endothelial cells (Goerdt et al., 1991).  Further 
studies of skin lesions demonstrated that MS-1 antigen can be identified on 
endothelial cells of continuous origin in certain pathological conditions such 
as psoriasis, T cell lymphomas and melanoma metastasis (Goerdt et al., 
1993).  These studies also identified the presence of MS-1 antigen on 
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dendritic cells and macrophages in vivo and in vitro.  Interleukin 4 and 
dexamethasone were shown to strongly induce the expression of MS-1 on 
cultured monocytes (Goerdt et al., 1993).   
1.13.1 Structure and function of CLEVER-1 
The antigen recognised by MS-1 antibody was subsequently identified as a 
280kDa type 1 transmembrane protein with multiple epidermal growth factor-
like repeats, seven fasciculin domains and  a single Link domain and a short 
cytoplasmic tail (Politz et al., 2002) (Figure 1-7).  The protein was named 
stabilin-1 and a homologous protein was also cloned in parallel named 
stabilin-2 which, as mentioned before, is the hyaluronan receptor on hepatic 
sinusoidal endothelium (McCourt et al., 1999; Politz et al., 2002).  Further 
analysis of  stabilin-1 localised it to chromosome 3 and scanning for sorting 
signals identified a a tyrosine-based motif and a dileucine motif involved in 
protein kinase C/ kinase CK2-dependent sorting into the endosomal 
compartment (Politz et al., 2002).  The authors suggested that these three 
sorting signals indicated that stabilin-1 shuttled between the plasma 
membrane and endosomal compartments.  Further studies of alternatively 
activated macrophages have demonstrated that stabilin-1 is involved in two 
intracellular trafficking pathways and in early endosomes and the trans Golgi 
network (Kzhyshkowska et al., 2004).   
The upregulation of stabilin-1 in alternatively activated macrophages has led 
several groups to try and understand its role in this subset of macrophages.  
Classical activation of macrophages is mainly induced by LPS or TH1-related 
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cytokines whereas alternative activation is mediated by glucocorticoids or 
TH2-related cytokines such as IL-4, IL-10, IL-13.  Macrophages are generally 
known to orchestrate immune responses to pathogens but they also play an 
important role in tissue homeostasis and wound healing (Hume, 2006).  The 
homestatic functions of macrophages are performed by the alternatively 
activated subset and involve clearance of exogenous components in the 
extracellular environment. These macrophages are characterised by the 
expression of molecules that lead to tolerance and the resolution of 
inflammation and have a high phagocytic capacity (Gratchev et al., 2005).  It 
has been suggested that stabillin-1 contributes to this process by mediating 
the uptake of certain breakdown products as well as separate intracellular 
sorting of other molecules.  Subsequent functional studies have shown that 
stabilin-1 performs endocytosis of substances such as acetylated LDL and 
secreted protein acidic and rich in cysteine (SPARC) as well as the 
intracellular sorting of a novel chitinase-like protein (Kzhyshkowska et al., 
2005; Kzhyshkowska et al., 2006b; Kzhyshkowska et al., 2006c). It has also 
been shown implicated in endocytosis of placental lactogen by alternatively 
activated macrophages (Kzhyshkowska et al., 2008).  These homeostatic 
functions may be coupled with the ability of stabilin-1 to prevent excess 
tissue damage during inflammation or autoimmune responses.  This is 
highlighted by a recent study which demonstrated that stabilin-1 functions as 
a receptor on macrophages for the removal of cell corpses (Park et al., 
2009).  Here Stabilin-1 was shown to bind to phosophatidlyserine (PS) 
presented on the surface of these cell corpses.  
66 
 
The sequences corresponding to stabilin-1 were cloned separately by 
another group who, in view of its structure named it FEEL-1 (fasciculin, EGF-
like, laminin-type EGF-like link domain- containing scavenger receptor-1) 
(Adachi and Tsujimoto, 2002).  FEEL-1 was shown to bind acetylated LDL 
and AGEs as well as gram negative and gram positive bacteria (Adachi & 
Tsujimoto, 2002; Tamura et al., 2003).  These binding studies were 
performed in CHO cells transfected with FEEL-1.  A monoclonal antibody to 
FEEL-1 also influenced the vascular remodelling of human umbilical vein 
endothelial cells suggesting that FEEL-1 played a role in angiogenesis 
(Adachi & Tsujimoto, 2002).  Subsequent studies broadened the repertoire of 
FEEL-1 by demonstrating that it also binds heat shock protein 70 (HSP70) 
(Theriault et al., 2006).  HSP70 is an intracellular chaperone that can be 
released from tumour cells and therefore may have a role in anti-tumour 
immunity (Calderwood et al., 2005). 
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Figure 1-7 The structure of CLEVER-1 
Schematic outline of the structure  of the Common Lymphatic and Vascular 
Endothelial Receptor-1 (CLEVER-1) also known as Stabilin-1 and FEEL-1. 
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1.13.2 The intracellular trafficking of CLEVER-1 
Functional studies of CLEVER-1/stabilin-1 identified its involvement in two 
intracellular pathways 1) as a classical endocytic receptor undergoing 
endocytosis and recycling and 2) as an intracellular sorting receptor shuttling 
between the endosomal compartment and the trans-Golgi network (Error! 
eference source not found.).  The role of CLEVER-1/Stabilin-1 in these two 
pathways is regulated by different factors.   
A model utilising transfected CHO cells demonstrated that CLEVER-
1/stabilin-1 internalised extracellular ligands and then translocated them from 
early endosomes to late endosomes.  Treatment with wortmannin led to a 
block of receptor trafficking to the late endosomal compartment 
(Kzhyshkowska et al., 2005).  Wortmannin is a specific inhibitor of 
phosphatidylinositide-3 (PI3K) and therefore the trafficking of CLEVER-
1/stabilin-1 from early to late endosomal compartment is PI3K dependent.  
More recently, sorting nexins (SNXs) have been implicated in regulating the 
intracellular trafficking of CLEVER-1/stabilin-1.  SNXs are a family of proteins 
which are involved in intracellular membrane trafficking (Carlton et al., 2005). 
Specifically, SNX17 directly interacts with the cytoplasmic domain of 
CLEVER-1/stabilin-1 and is an important regulator of CLEVER-1/stabilin-1 
shuttling between the plasma membrane and early endosomes.   Knockdown 
of SNX17 led to decreased surface expression of CLEVER-1/stabilin-1 and 
increased degradation (Adachi and Tsujimoto, 2010).  
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In contrast, the intracellular sorting pathway of CLEVER-1/stabilin-1 appears 
to be mediated by Golgi-localized, γ-ear-containing Arf (ADP-ribosylation 
factor)-binding proteins (GGAs).  GGAs are monomeric clathrin receptors 
that mediate the intracellular sorting of several receptors (Ghosh et al., 2003; 
He et al., 2005)  The CLEVER-1/stabilin-1 cytoplasmic tail contains distinct 
binding sites for GGAs and this interaction appears to be specific for 
intracellular sorting. Deletion of these binding sites on CLEVER-1/Stabilin-1 
led to the abrogation of intracellular sorting by this receptor but had no effect 
on receptor mediated endocytosis (Zhang et al., 2009).  
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1-8 CLEVER-1 Trafficking Pathways 
Schematic representation of the current understanding of CLEVER-1 
trafficking.  CLEVER-1 can bind endocytic ligand and as shown transports 
this to early and late endosomes before dissociation which leads to ligand 
degradation.  Ligand free receptor can recycle back to the plasma 
membrane.  CLEVER-1 can also shuttle between the transgolgi network 
(TGN) and late endosomes.It has been suggested that the ligands bound in 
this pathway are destined for secretion via the lysosomal pathway.  
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These CLEVER-1/Stabilin-1 functional and regulation studies have 
concentrated on alternatively activated macrophages or transfected cell lines, 
parallel studies in endothelial cells have given less conclusive results.  
Studies in pig and rat endothelial cells showed that CLEVER-1/stabilin-1 was 
mainly found within the early endosomes but was also on the cell surface 
(Hansen et al., 2005a).  CLEVER-1/Stabilin-1 did not recognise classical 
scavenger ligands such as advanced glycation end products (AGEs) and 
collagen N-terminal propeptides, whilst its homologue, stabilin-2, had a clear 
scavenger profile, (Hansen et al., 2005a).  Studies in human lymphatic 
endothelium demonstrated that stabilin-1 underwent rapid cycling between 
the plasma membrane and early endosomes and confirmed that the stabilin-
1 Link-domain did not bind hyaluronan (Prevo et al., 2004).   
1.13.3 The role of CLEVER-1 in lymphocyte recruitment 
An antibody against CLEVER-1, 3-372, was initially shown to clearly stain 
lymphatic endothelium both in afferent and efferent lymphatics (Irjala et al., 
2003b).  The antibody was developed from a programme that raised 
monoclonal antibodies against isolated efferent lymphatic vessels of human 
lymph nodes.  The molecule identified by 3-372 was also present on vascular 
endothelium in high endothelial venules (HEVs), hence it was named the 
common lymphatic endothelial and vascular endothelial receptor (CLEVER-
1).  Static adhesion assays on lymph node sections demonstrated that 3-372 
blocked lymphocyte adhesion to HEVs and lymphatic endothelium.  3-372 
also cross reacted with rabbit CLEVER-1 allowing in vivo studies to be 
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carried out.  In these studies rabbits were challenged with keyhole limpet 
hemocyanin injected into the footpad which led to an immune response and 
enlargement of draining lymph nodes.  The animals given anti-CLEVER-1 
antibody had significantly smaller draining lymph nodes and lymphatic 
sections showed significantly fewer lymphocytes in comparison to control 
animals (Irjala et al., 2003b).   
Further analysis by immunoblotting demonstrated that CLEVER-1 was a 
molecule of approximately 270-300 kDa with several isoforms.  Affinity 
chromatography allowed purification of the protein and after cleavage with 
trypsin and mass spectrometry the sequences identified were identical to 
stabilin-1 (Irjala et al., 2003b).  Tissue lysate analysis for CLEVER-1 protein 
showed that there were three different isoforms seen in lymph node, tonsil 
and synovium.  These isoforms varied in intensity suggesting the existence of 
splice variants or different glycoforms (Irjala et al., 2003b). 
Expression of CLEVER-1 in vivo was studied in normal and diseased states 
by analysing normal skin samples and inflamed samples from psoriatic 
lesions.  This demonstrated that CLEVER-1 was present on lymphatic 
vessels in the normal state but in the context of inflammation CLEVER-1 was 
also seen on chronically inflamed HEV- like neo blood vessels (Salmi et al., 
2004).  It was clear from these findings that CLEVER-1 was regulated 
differently on lymphatic and vascular endothelium.   
Although CLEVER-1 supported lymphocyte adhesion in static assays and in 
vivo blockade of CLEVER-1 resulted in a reduced inflammatory response in 
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lymph nodes (Irjala et al., 2003b), the exact role of CLEVER-1 was not 
known.  This led to studies of lymphocyte interactions with human lymphatic 
endothelial monolayers under the conditions of physiological flow which 
revealed that CLEVER-1 contributes to the rolling and transmigration steps of 
lymphocyte recruitment to lymphatic endothelium (Salmi et al., 2004).  
Expression studies on human tissue demonstrated that CLEVER-1 was 
expressed on lymphatic endothelium constitutively and only on vascular 
endothelium when it was inflamed.  Thus it was proposed that CLEVER-1 
may play a dual role: 1) in the diapedesis of lymphocytes into non-lymphoid 
tissue during inflammation and 2) the egress of lymphocytes from secondary 
lymphoid organs via efferent lymphatic endothelium (Irjala et al., 2003b; 
Salmi et al., 2004).  
Recent studies have provided more in vivo evidence for the role of CLEVER-
1 in lymphocyte homing.  Blocking antibodies to CLEVER-1 efficiently 
prevented migration of lymphocytes into draining lymph nodes in both murine 
and rabbit models.  The role of CLEVER-1 on inflamed vascular endothelium 
was also investigated using a mouse model of peritonitis.  In these 
experiments, treatment with a blocking antibody to murine CLEVER-1 led to 
significant reduction of lymphocyte trafficking at the site of inflammation 
(Karikoski et al., 2009a).   
In conclusion, CLEVER-1 is a lectin-like receptor which has been identified in 
alternatively activated macrophages and the specialised vascular beds of 
lymph nodes and the liver.  In macrophages there is evidence that CLEVER-
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1 contributes to tissue homeostasis and scavenging.  In lymphatic 
endothelium there is in vitro and in vivo evidence that CLEVER-1 plays a role 
in lymphocyte recruitment, specifically contributing to transmigration.   
This thesis tested the hypothesis that CLEVER-1 is involved in the 
recruitment of lymphocytes via human hepatic sinusoidal endothelium. 
Specific Aims 
1. Document the expression of CLEVER-1 in normal and diseased 
human liver tissue. 
2. Determine the factors responsible for the expression at these sites. 
3. Determine the contribution of CLEVER-1 to lymphocyte adhesion to 
HSEC and assess if CLEVER-1 had preferentially activity for particular 
lymphocyte subsets. 
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CHAPTER 2  
              MATERIAL AND METHODS 
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2.1 Human liver tissue 
We obtained normal liver tissue from margins of hepatic resections carried 
out for hepatocellular cancer and donor tissue that was not used or excess to 
requirement for transplantation.  Diseased liver tissue from explanted livers 
was obtained from transplantation explants as part of the Birmingham liver 
transplant programme.  All tissue was obtained with prior consent and 
ethically approved. 
2.2 Cell culture and isolation of Human Sinusoidal 
Endothelial Cells (HSEC) 
2.2.1 Plastics used for cell culture  
Sterile pipettes, 25 cm2 and 75cm2 flasks, sterile 15ml and 50 ml tubes and 
sterile cryovials were all purchased from Corning CoStar Incorporated, 
Bucks.  Sterile 96 well plates were purchased from Becton Dickinson 
Labware.  20ml plastic tubes and 5ml bijous were purchased from Ramboldi .   
2.2.2 Cell culture work 
All tissue culture was performed in class II microflow safety cabinet.  At all 
times aseptic technique was followed and cabinets were sprayed with 
industrial methylated spirit (IMS;Adams Healthcare, Leeds UK) before and 
after use.  
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2.2.3 HSEC isolation 
I used a protocol established in our laboratory to isolate HSEC (Lalor et al., 
2002a). Approximately 50g of liver tissue was taken from diseased explanted 
livers or normal resections, mechanically chopped using sterile scalpels, 
enzymatically digested with 0.2% collagenase Type 1A  (Sigma, UK) filtered 
and further purified by density gradient centrifugation over PercollTM 
(Amersham Biosciences, Bucks UK).  HSEC were isolated using negative 
magnetic selection with HEA-125 antibody (50µg/ml, 1:10 Progen Biotec, 
GMBH, Germany) to deplete biliary epithelial cells, followed by positive 
selection with CD31 antibody (10µg/ml, DAKO, UK).and dynalbeads 
conjugated with goat anti-mouse mAbs (Dynal,UK.) The cells were 
maintained in human endothelial basal medium (Invitrogen, Paisley, UK) 
supplemented with 2mM L-glutamine, 100U/ml penicillin and 100µg/ml 
streptomycin (Sigma, UK)  10% Human serum, 10ng/ml of vascular 
epidermal growth factor (VEGF Peprotech UK) and 10ng/ml of hepatocyte 
growth factor (HGF Peprotech UK). The cells were transferred to a rat tail 
collagen (Sigma, UK) 25cm2 flask and cultured at 370C.  Once the cells were 
confluent they were passaged to a 75cm2 flask.   
2.2.4 Cell culture and passage 
Cells were cultured in standard tissue culture plastic flasks in complete media 
(as detailed above) and maintained at 370C in a humidified 5% CO2 
incubator.  Cell growth was assessed using an inverted phase contrast 
microscope (Olympus IX50).  Adherent cells formed projections when 
78 
 
attached to the plastic surface and cells in suspension remained rounded, 
phase-bright and symmetrical.  The cultures were monitored daily for normal 
cell morphology, media colour and cell density.  Where appropriate, cells 
were passaged using proteolytic enzymes (TrypLE™ Express (x1) stable 
trypsin like enzyme with Phenol red :Invitrogen, UK).  Initially, the media in 
the flasks was discarded and cells were washed in PBS.  An appropriate 
volume of TrypLE was added and the cells were agitated gently until they 
detached.  PBS was then added to the cells and the suspension was 
centrifuged at 550g for 5 minutes.  The pelletted cells were then resuspended 
in media and transferred to new culture flasks.   
2.2.5 Freezing and storing Cells 
For long term storage cells were preserved in liquid nitrogen.  After 
detachment and pelleting the cells were resuspended in freezing media 
consisting of 95% FCS+5% DMSO (Sigma, UK).  Cells were transferred to 
cryovials and placed in a MrFrosty™ freezing container (Wessington 
Cryogenics, UK) which was transferred to -800C to permit gradual cooling to 
prevent crystal formation within the cell cytoplasm.  Once cells had been 
stored at -800C overnight they were transferred to liquid nitrogen for long-
term storage.  When required cells were taken out of liquid nitrogen, thawed 
and washed in PBS and centrifuged to remove cellular debris.  Cells were 
counted and viability was assessed using trypan blue followed by 
resuspension and culture in appropriate media. 
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2.3 Isolation of peripheral blood lymphocytes and 
lymphocyte subsets. 
2.3.1 Isolation of peripheral blood lymphocytes 
Venous blood was collected from healthy volunteers or patients undergoing 
venesection for haemochromatosis, at the Queen Elizabeth Hospital 
Birmingham, Liver Outpatients Clinic.  The mononuclear fraction was purified 
by density gradient centrifugation over lympholyte (Lympholyte-H, VH Bio, 
UK) at 550g for 25 minutes.  Cells were then incubated on plastic for 1 hour 
to allow adherence of monocytes before aspiration of the lymphocyte-
enriched supernatant.  Lymphocytes were then resuspended to a known cell 
count in media appropriate for the desired application. 
2.3.2 Isolation of CD4 and CD8 lymphocyte subsets  
Peripheral blood mononuclear cells were purified as described above in 
section 2.3.1. The cell fraction was washed, pelleted and viability was 
confirmed following which 5x 107 cells were suspended in 500µl of isolation 
buffer (PBS containing 0.1% (v/v) BSA and 2 mM EDTA) with 100µl of heat 
inactivated FCS and 100 µl of Antibody mix from either the human CD8 T cell 
isolation kit (Dynabeads® Untouched™ Human CD8  Tcells, Invitrogen, UK) 
or CD4 T cell isolation kit (Dynabeads® Untouched™ Human CD4 Tcells, 
Invitrogen, UK) depending on which population was being isolated.  This was 
followed by an incubation step for 20 minutes at 40C on a mixer which 
provided tilting and rotation.  The cells were then washed and centrifuged at 
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350g for 8 minutes.  The cells were resuspended in 500µl of isolation buffer 
followed by addition of 500µl of magnetic beads supplied with the isolation 
kits (pre-washed as per manufacturer’s instructions). The cells were 
incubated with the beads for 15 minutes at room temperature with gentle 
tilting and rotation.  Following this the cells were vigorously pipetted followed 
by addition of 5mls of isolation buffer and placed in a magnet for 2 minutes.  
The supernatant containing the untouched T cell population was transferred 
to another tube. The negatively isolated cells were washed at 350g for 8 
minutes and then resuspended in RPMI with 10% (v/v) FCS.   
2.3.3 Isolation of CD4 effector and CD4 regulatory T cell subsets 
Peripheral blood mononuclear cells were freshly prepared as described 
above and viability was confirmed following which 2x108 mononuclear cells 
were resuspended in 1 ml of cold isolation buffer (PBS containing 0.1% (v/v) 
BSA and 2 mM EDTA) with 400 µl FCS and 400µl of antibody mix from the 
CD4+CD25+ T cell isolation kit (Dynabeads® Regulatory CD4+CD25+ T cell 
Kit, Invitrogen, UK).  The cells were incubated for 20 minutes at 40C on a 
mixer with tilting and rolling followed by a wash and centrifugation for 8 
minutes at 350g.  The cells were resuspended in 4 ml of cold isolation buffer 
with the addition of 2 ml of depletion magnetic Dynabeads® from the 
isolation kit and incubated for 15 minutes at room temperature on a mixer 
with rolling and tilting.  The bead bound cells were vigorously pipetted, added 
to 6 mls of isolation buffer and placed in a magnet for 3 minutes.  The 
supernatant, containing the bead-free CD4 T cell fraction, was removed, 
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washed and centrifuged at 350g for 8 minutes.  The cell pellet was 
resuspended at a concentration of 1.5 x107 cells ml-1.  400µl of Dynabeads® 
CD25, supplied with the isolation kit, were added to 2 ml of CD4 cell 
suspension and incubated for 25 minutes at 40C on a mixer which provided 
tilting and rotation.  The cell suspension was then placed in a magnet for 1 
minute and the supernatant was removed.  This supernatant contained the 
CD4+CD25- T cell fraction which was washed pelletted and resuspended in 
RPMI 10% v/v FCS.  The bead bound cells were resuspended in 1 ml of 
RPMI 1% v/v FCS and incubated with 160 µl of DETACHaBEAD®, supplied 
with isolation kit, for 45 minutes at room temperature with gentle tilting and 
rotation.  The cell suspension was placed in a magnet for 1 minute and the 
supernatant containing the CD4+CD25+ population was removed, washed 
and centrifuged at 350g for 8 minutes followed by resuspension in RPMI 10% 
v/v FCS.  The CD25- fraction generated was used as the effector population 
and the CD25+ fraction was used as the regulatory population. 
2.3.4  Isolation of B cells 
Mononuclear cells were freshly prepared from venous blood as above and 
were resuspended to 2.5 x107cells ml-1 in isolation buffer (PBS containing 
0.1% v/v BSA 2 mM EDTA).  100µl of pre-washed Dynabeads (as per 
manufacturer’s instructions) from the B cell isolation kit (Dynabeads® CD19 
pan B, Invitrogen, UK) were added to 4 mls of cell suspension.  Cells were 
incubated for 20 minutes at 40C with gentle tilting and rolling.  The cell 
suspension was then placed in a magnet for two minutes and the 
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supernatant discarded.  The bead bound cells were washed four times, on 
each occasion 4 ml of buffer was added to the cells and the solution was 
placed in a magnet for 1 minute following which the supernatant was 
removed.  The cells were then resuspended in 1ml of RPMI 1%v/v FCS and 
incubated with 40µl of bead detachment solution (DETACHaBEAD® CD19, 
Invitrogen, UK) for 45 minutes with gentle tilting and rotation at room 
temperature.  Following this the cell solution was pipetted vigorously and 
placed in a magnet for 1 minute.  The supernatant containing the cells was 
removed, washed in RPMI 1%v/v FCS, centrifuged for 6 minutes at 400g and 
resuspended in RPMI 10% v/v FCS. 
2.3.5 Assessment of cell purity using flow cytometry 
The purity of HSEC isolates and lymphocyte subsets isolations was 
confirmed by flow cytometry.  HSEC were grown to confluence in a T25 flask 
and then trypsinised followed by washing in ice cold PBS and centrifugation.  
The cell pellet was resuspended in ice cold wash buffer (PBS containing 10% 
(v/v) FCS) at 1x106 cells/ml.  100µl of cell suspension was incubated with 
mouse anti-human CD31 (R and D systems) at 5µg/ml for 30 minutes at 40C 
in the dark.  Control samples were labelled with an isotype matched control 
IgG1 antibody (DAKO, UK) at 5µg/ml. The cell suspensions were washed 
and incubated with a goat anti mouse FITC conjugated secondary antibody 
(Cambridge Biosciences,UK) 1 in 50 dilution of stock for 30 minutes at 40C in 
the dark followed by a further wash and resuspension in wash buffer prior to 
83 
 
flow cytometry.  Samples were run on a Cyan flow cytometer and results 
were analysed using a Summit Software (Dako Cytomation, UK). 
Purity of CD4, CD8 and B cell isolations was assessed by resuspending 
lymphocyte samples in ice-cold wash buffer at 1x106 cells ml-1.  100µl of cell 
suspension was incubated with appropriate fluorochrome-labeled antibody 
for 30 minutes at 4oC.  Control samples were labeled with a fluorochrome-
labeled isotype matched controls.  The cell suspension was washed and 
resuspended in wash buffer prior to flow cytometry.   
Purity of T regulatory cell isolations was assessed by surface and 
intracellular staining.  Lymphocytes were resuspended in ice-cold wash 
buffer at 1x106 cells ml-1.  100 µl of cell suspension was incubated with 
conjugated antibodies against CD4, CD25 and CD127 for 30 minutes at 40 C.  
Intracellular staining was performed by incubating lymphocytes in 100µl of 
FoxP3 fixation solution (eBioscience, UK) for 20 minutes at room 
temperature in the dark.  The cells were then washed twice in 
permeabilisation buffer (eBioscience, UK) followed by incubation in 100µl of 
permeabilisation buffer and appropriate amount of fluorochrome labeled 
antibody against FoxP3 or isotype matched control for 20 minutes in the dark 
at room temperature.  Samples were then washed in permeabilisation buffer.  
Finally, the cell suspension was washed and resuspended in wash buffer 
prior to flow cytometry.   
Antibodies and the concentrations they were used at for flow cytometry are 
summarized in Table 2-1.   
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Table 2-1 Antibodies used for Flow cytometry 
Conjugated 
Monoclonal 
Antibodies 
Clone Source Final 
Concentration 
Pacific Blue Mouse 
anti Human CD4 
RPA-T4 BD Bioscience 1 in 20 dilution of 
stock 
Pacific Blue Mouse  
IgG1 control 
MOPC-21 BD Bioscience 1 in 20 dilution of 
stock 
FITC Mouse anti 
Human CD8 
RPA-T8 BD Bioscience 1 in 10 dilution of 
stock 
FITC Mouse anti 
Human IgG1 
control 
MOPC-21 BD Bioscience 1 in 10 dilution of 
stock 
APC Mouse anti 
Human CD19 
HIB 19 BD Bioscience 1 in 10 dilution of 
stock 
APC Mouse anti 
Human IgG1 
MOPC-21 BD Bioscience 1 in 10 dilution of 
stock 
PECy5 Mouse anti 
Human CD25 
IM2646 Beckman Coulter 1 in 10 dilution of 
stock 
PECy5 Mouse 
IgG2a control 
A09148 Beckman Coulter 1 in 10 dilution 
Alexa 488 Mouse 
anti Human CD127 
HCD127 Biolegend 1 in 20 dilution 
Alexa 488 Mouse 
IgG1 control 
MOPC 21 Biolegend 1 in 20 dilution 
PE Rat anti Human 
FoxP3 
PCH101 eBioscience 1 in 5 dilution 
PE Rat IgG2a 
control 
Ebr2A eBioscience 1 in 5 dilution 
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2.4 Immunohistochemistry and Immunofluorescence 
CLEVER-1 expression in human liver tissue was visualized by 
immunohistochemistry and immunofluorescence (Crosby et al., 2009).  Fresh 
liver was cut into 1cm2 cubes, snap frozen in liquid nitrogen and stored at -
700C.  Livers were embedded in OCT TissueTek mount and sections 5 
microns thick were cut using a cryostat (Bright OTF) and mounted on glass 
microscope slides (BDH UK) coated in 0.01% Poly-L-Lysine (stock 0.1% w/v 
from Sigma UK).  Once mounted, sections were fixed in acetone (NHS 
supplies), wrapped in foil and stored at -200C before use.  
2.4.1 Immunohistochemical staining. 
Liver sections were obtained from four representative samples of normal 
liver, or tissue from patients with alcoholic liver disease, primary biliary 
cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis.  All 
monoclonal antibodies used for immunohistochemical staining are 
summarized in Table 2-2. Tissue sections were initially re-fixed in acetone for 
5 minutes, and endogenous peroxide activity was then quenched by placing 
sections in 0.3% H2O2 in methanol for 30 minutes followed by washing in 
water.  This was followed by a blocking step with 2% casein for 20 minutes. 
Tissue sections were incubated with 100µl of mouse anti human primary 
mAbs (monoclonal antibodies) directed against the molecule of interest for 1 
hour.  Mouse IgG antibody was used as a negative control antibody at 
equivalent concentrations.  Samples were incubated at room temperature in 
a humidified chamber and placed on a rocker to ensure complete coverage 
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of samples in the antibody solution. The sections were then washed in tris 
buffered saline/0.1% Tween (TBS/Tween) for 5 minutes, followed by 
incubation with ImmPRESSTM Universal anti-mouse/rabbit IgG reagent 
(Vector Labs, Burlingame CA) at room temperature for 30 minutes.  This was 
followed by a further washing step in TBS/Tween for 5 minutes.  The sections 
were then incubated with a Vector® VIP substrate kit for 5 minutes.  Sections 
were finally rinsed in tap water and counterstained with haematoxylin. 
Images were analysed on a Zeiss Axioscope microscope in conjunction with 
Axiovision software (Carl Zeiss, UK).   
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Table 2-2 Primary and secondary monoclonal antibodies used for 
immunohistochemical staining 
Monoclonal 
Antibodies 
Clone Source Final 
Concentration 
Mouse IgG1 control DAK G01 DAKO 10µg/ml 
Mouse anti Human 
CLEVER-1 
3-372 Gift from S 
Jalkanen Turku 
Finland 
10µg/ml 
Anti mouse/rabbit 
secondary 
Immpress 
Universal kit 
- Vector Labs Use stock solution 
 
2.4.2 Immunofluorescence 
Prior to staining, all samples were removed from -200C to equilibriate  to 
room temperature before being re-fixed  in acetone for 5 minutes.  After air 
drying, samples were labeled, a wax pen was used to draw a well around the 
sections to retain antibody solutions, and each section was pre-wetted with 
staining buffer (PBS/10%FCS/0.1% sodium azide).  All monoclonal 
antibodies used for immunofluorescent staining are summarized in Table 2-3. 
If the antibodies used were biotinylated then the sections were preincubated 
using an avidin/biotin blocking kit (Vector Laboratories, UK) as per 
manufacturer’s instructions. The tissue sections were then incubated with 
100µl of mouse anti-human primary mAbs for 1 hour in a dark humidified box 
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for 1 hour.  This was followed by a washing step with PBS for 30 minutes.  
The sections were then stained with the appropriate fluorescent secondary 
antibodies for 30 minutes with a final washing step in PBS for 1 hour.  The 
sections were then mounted with Fluorescent Immunomount (DAKO,UK).  
Throughout these steps the sections were protected from light. 
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Table 2-3 Primary and secondary monoclonal antibodies used in 
immunofluorescent studies in liver tissue 
Monoclonal 
Antibodies 
Clone Source Final 
Concentration 
Mouse IgG1 
negative  control 
DAK GO1 DAKO 10µg/ml 
Mouse IgG2b 
negative control 
73009 R and D Systems 5µg/ml 
Mouse IgG1 biotin 
negative control 
- AbD Serotec 2.5µg/ml 
Mouse anti Human 
CLEVER-1 
3-372 Gift from S 
Jalkanen, Turku, 
Finland 
10µg/ml 
Mouse anti Human 
L-SIGN 
120604 R and D Systems 5µg/ml 
Mouse anti Human 
CD68 
Y1/82A BD Biosciences 5µg/ml 
Mouse anti Human 
CD34 Biotinylated 
QBEND/10 AbD Serotec 2.5µg/ml 
 Streptavidin- 
Alexafluor 488 
- Invitrogen 25µg/ml 
Goat anti Mouse 
IgG1 Texas Red 
- Cambridge 
Biosciences 
1/50 Manufacturers 
stock 
Goat anti Mouse 
IgG2b FITC 
- Cambridge 
Biosciences 
1/50 Manufacturers 
stock 
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For fluorescent staining of HSEC, cells were grown on RTC coated 
coverslips (Biosciences, University of Birmingham, UK) and when confluent 
they were fixed in 4% paraformaldehyde for 15 minutes. The cells were then 
permeabilised in 0.3% Triton for 15 minutes and then blocked with 10% goat 
serum (Sigma Aldrich, UK) for 20 minutes.  This was followed by incubation 
with mouse anti-human monoclonal antibodies for 60 minutes at room 
temperature. Summary of antibodies used in these studies are listed in Table 
2-4.  The cells were then washed in PBS and incubated with appropriate 
isotype and species specific secondary antibody for 30 minutes at room 
temperature protected from light.  Following this the cells were washed with 
PBS and mounted with fluorescent mounting media (DAKO,UK).   
In other experiments cells were incubated with anti CLEVER-1 antibody (3-
372) or an isotype matched control for 15 minutes or 30 minutes prior to 
fixation.  This was followed by fixation and permeabilisation as described 
above and stained with an appropriate isotype and species specific 
secondary antibody for 30 minutes at room temperature protected from light.  
Cells were then washed and mounted as described above. 
All staining was assessed using Axiovision software as before (section2.4.1) 
or imaged by confocal microscopy on an LSM 510 microscope equipped with 
63x1.32 objective.  Images were acquired and analysed by LSM software. 
LSM software was also used to create profiles of fluorescent intensity of each 
molecule which enabled graphical demonstration of overlapping fluorescent 
signals to confirm colocalisation.   
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Table 2-4 Monoclonal antibodies used for immunofluorescent studies in 
HSEC 
Monoclonal 
Antibodies 
Clone Source Final 
Concentration 
Mouse IgG1 
negative  control 
DAK GO1 DAKO 10µg/ml 
Mouse IgG2b 
negative control 
73009 R and D 5µg/ml 
Mouse anti Human 
CLEVER-1 
3-372 Gift from Sirpa 
Jalkanen 
10µg/ml 
Mouse anti Human 
LYVE-1 
264725 R and D 5µg/ml 
Goat anti Mouse 
IgG2b fluorescein 
isothiocyanate 
- Cambridge 
Biosciences 
1/50 dilution of 
stock 
Goat anti Mouse 
IgG1 fluorescein 
isothiocyanate 
- Cambridge 
Biosciences 
1/50 dilution of 
stock 
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2.5 Western Blotting of Liver Tissue 
Whole liver tissue blocks were weighed and homogenized in CellLytic™ MT 
buffer (Sigma, UK) with protease inhibitor and DNase-I (5U(Sigma, UK) 
according to manufacturer’s instructions.  Mechanical homogenization was 
performed with a scalpel followed by a hand-held homogenisor.  The 
samples were then placed on a Vibraplatform at 40C overnight, centrifuged at 
13,000 RPM for ten minutes and the supernatant was transferred to a 
separate tube.  The protein concentration of each sample was calculated 
using a Sigma® Total Protein Kit (Micro Lowry, Onishi & Barr modification) 
according to the manufacturer’s instructions.  Bovine Serum Albumin (Sigma, 
UK) was used as a protein concentration standard.  Samples were stored at -
200C prior to use. 
The protein samples were separated by SDS polyacrylamide gel 
electrophoresis using standard protocols.  Briefly, stacking and resolving gels 
were prepared as described in Table 2-7 and then poured between two glass 
plates and left to set.  The protein samples (20 µg) were diluted in 5xSDS-
PAGE loading buffer, with or without β-mercaptoethanol and boiled for ten 
minutes at 1000C, depending on the antibody used.  The gel apparatus was 
assembled and gel tank was set up by pouring in 1x running electrophoresis 
buffer to cover the electrodes.  25 µl of each sample was loaded onto the 
stacking gel along with 10µl of a molecular weight marker (Colorburst 
Marker; Sigma,UK).  Electrophoresis was performed at 200V for 30 minutes 
ensuring that the dye front reached the bottom of the gel.   
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2.5.1 Western blot transfer 
The proteins were then transferred from the gel to a nitrocellulose membrane 
(Amersham Biosciences,UK).  The nitrocellulose membrane, sponges and 
filter paper were pre-wetted by immersion in transfer buffer.  A ‘sandwich’ 
was then formed with the membrane and gel between the filter paper and 
sponges which were placed in a transfer block.  The transfer blocks with an 
ice pack were then placed in an electrophoresis tank filled with transfer 
buffer.  The blot was then run at 100V for 1 hour.  The transfer of protein was 
checked by adding Ponceau Red (0.1% ponceau in 5% acetic acid; Sigma) 
to the membrane for 5 minutes before washing off with water.    
2.5.2 Western blot development 
The protein-coated membranes were blocked with 5% non-fat milk (Marvel) 
in PBS/0.02% Tween for 1 hour at room temperature with continuous 
agitation, and then probed with primary antibodies diluted in 5% non-fat milk 
overnight at 40C on a rocker.  antibodies used for western Blotting are 
summarized in  
Table 2-8.  The membrane was washed three times with PBS-0.02% Tween 
for five minutes, followed by incubation with a peroxidase-conjugated 
secondary antibody in 5% non-fat milk for 1 hour at room temperature on a 
rocker.  The membrane was then washed for thirty minutes with PBS-
0.02%Tween. Chemiluminescence reagent (ECL plus: Amersham 
Pharmacia, Biotech, UK) was added to the membrane as per manufacturer’s 
instructions, and the membrane was then exposed with enhanced 
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chemiluminescence detection film (Amersham,UK) and developed using a 
Kodak X–Omat 1000 processor (University of Birmingham).  For reprobing,, 
the membrane was stripped by incubation with stripping buffer for 45 minutes 
at 500C followed by several washes with distilled water.  The membrane was 
then blocked with 5% non-fat milk and re-probed with anti β-actin antibody as 
described earlier.   
Table 2-5 Source and Molecular weights of reagents used for Western 
Buffers 
Reagent Molecular Weight (FW) Source 
Trisma Base 121.14 Sigma 
Glycine 75.07 Sigma 
Sodium dodecyl sulfate 
(SDS) 
288.38 Sigma 
Glycerol 92.09 Sigma 
Methanol 32.04 Fisher Scientific 
Tween 20 -  
β-mercaptoethanol 78.13 Sigma 
Non-fat milk - Marvel 
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Table 2-6 Buffers used in SDS PAGE 
Buffers Constituents 
10 x Electrophoresis Buffer Per litre- 30.3g Trisma base, 144g 
glycine, 10g SDS 
Transfer Buffer Per 2 litres- 28.8g glycine, 6g Trisma 
base, 400ml methanol, 1g SDS 
Resolving gel Buffer 1.5M Trisma Base pH8.8 (pH adjusted 
with HCl) 
Stacking gel Buffer 0.5M Trisma Base pH6.8 (pH adjusted 
with HCl) 
5XSDS-PAGE Sample buffer 200mM Trisma Base pH 6.8, 
20%glycerol, 10% SDS 0.05% 
bromophenol blue, 10mM β-
mercaptoethanol 
Stripping Buffer Per 100ml:20.0ml 10% SDS, 12.5ml 
0.5M Trisma base pH6.8, 67.5 dH20, 
0.8ml β-mercaptoethanol 
Blocking Buffer PBS +0.02% Tween-20, 5% non-fat milk 
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Table 2-7 Components of SDS PAGE gels 
 Stacking Gel (4%) Resolving Gel (6%) 
ddH20 6.1ml 5.4ml 
30% Degassed 
Acrylamide/Bis (BioRad) 
1.3ml 2ml 
Stacking Gel buffer 2.5ml - 
Resolving Gel buffer - 2.5ml 
10% w/v SDS (Sigma) 0.1ml 0.1ml 
10% w/v ammonium 
persulfate (APS) Sigma 
60µl 60µl 
N,N,NI,NI-
tetramethylethylenediamine 
60µl 60µl 
  
Table 2-8 Antibodies used for Western Blotting 
Antibody Clone concentration Source 
CLEVER-1 3-372 1µg/ml Gift from S 
Jalkanen, Turku, 
Finland 
β-actin Clone AC-15 1µg/ml Sigma 
Goat anti Mouse 
HRP 
- 1:2500 DAKO 
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2.6  PCR 
2.6.1 Conventional PCR 
CLEVER-1 and LYVE-1 gene expression by HSEC were analysed by RT-
PCR.  HSEC were grown to confluence before trypsinisation and pelletting.  
Total RNA was purified using the RNeasy kit (Qiagen, UK) as recommended 
by the manufacturer.  The concentration of RNA was measured using a 
NanoDrop spectrometer (ThermoFisher scientific,UK). An OD 260/280 of 
greater than 2 was taken as acceptable purity. One microgram of total RNA 
reverse transcribed to generate cDNA with Supersript II (Invitrogen,UK) 
according to manufacturers instructions.  All samples were treated with 
DNase I (Sigma, UK) prior to cDNA synthesis.  The concentration of cDNA 
was measured using a NanoDrop spectrometer. An OD 260/280 of greater 
than 1.8 was taken as acceptable cDNA purity. This method of RNA 
purification and cDNA generation was also performed for cells in quantitative 
PCR studies (see section2.6.1) and were pre-treated as described in 
sections 2.7.3,  2.7.4, 2.7.5 prior to trypsination and pelleting.   
Primer sequences for CLEVER-1 and LYVE-1 were designed based upon 
Genbank sequence information and GAPDH was used as an endogenous 
control. 
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Table 2-9 CLEVER-1 Primers for  Conventional PCR 
Forward Primer 5’-ACTCTGTCCTGGACAGCG-3’ 
Reverse Primer 5’-CAGCCGCTCATGGACACC-3’ 
Amplicon size 289 bp 
 
Table 2-10 LYVE-1 Primers for Conventional PCR 
Forward Primer 5’-GCCTGTAGGCTGCTGGGACTAAG-3’ 
Reverse Primer 5’-CCCAGCAGCTTCATTCTTGAATG-3’ 
Amplicon size 518 bp 
 
Table 2-11 GAPDH Primers for Conventional PCR 
Forward Primer 5’-AGAAGGCTGGGGCTCATTTG-3’ 
Reverse Primer 5’-AGGGGCCATCCACAGTCTTC-3’ 
Amplicon size 259 bp 
 
For CLEVER-1 PCR, the initial PCR reaction was set at thirty five cycles 
under the following conditions 95˚C for 1min, 50˚C for 1min, 72˚C for 2min 
and a final extension at 72˚C for 5min.  The PCR reaction was further 
optimized by developing a touchdown protocol which was run under the 
following conditions : thirty five cycles under the following conditions 95˚C for 
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1min, followed by an annealing step for 1 minute with a temperature range 
from 55˚C to 48˚C, 72˚C for 2min and a final extension at 72˚C for 5min.  
For the LYVE-1 reaction, thirty five PCR cycles were run under the following 
conditions: 95˚C for 1 min, 61˚C for 1min, 72˚C for 2min and a final extension 
at 72˚C for 5min, and for GAPDH primers thirty five cycles were run under 
the following conditions: 94˚C for 30 seconds, 55˚C for 30 seconds, 72˚C for 
45 seconds and a final extension at 72˚C for 10 minutes.  All amplified 
products were analysed on 2% agarose gel containing ethidium bromide 
(Sigma) diluted in 1 x TAE. The PCR products were identified by their 
respective sizes.  Further details of the components and concentrations of 
reagents used for PCR are described in Table 2-12  and Table 2-13.   
 
Table 2-12 10xTAE Electrophoresis Buffer 
Reagents Molecular Weight Final 
Concentration 
Source 
Trisma Base 121.14 40mM Sigma 
Acetic acid 60.05 20mM Sigma 
Na2EDTA2H20 372.24 1mM Sigma 
ddH20  Fill up to 1 litre  
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Table 2-13 PCR reaction components 
5x Green GoTaq®Flexi 
Buffer 
1x Promega, Southampton 
MgCl2 (25mM) 1.5mM Promega, Southampton 
Forward Primers 0.4uM Altabiosciences 
Reverse Primers 0.4uM Altabiosciences 
dNTPs 0.2mM (total) Invitrogen 
GoTaq®DNA polymerase 1.25u Promega, Southampton 
cDNA 10µg/ml Primary human hepatic 
sinusoidal endpthelial cells 
Nuclease free Water Make up to 50µl Sigma 
 
2.6.2 Quantitative PCR 
Quantitative analysis of relative mRNA expression of CLEVER-1 in HSEC 
was performed by Taqman® Gene expression assays with FAM labeled 
probes for CLEVER-1(alternate gene name stabilin-1: 
Hs01109068_m1,Applied Biosystems,UK).  GAPDH was used as the 
housekeeping gene (FAM labeled probe :Hs99999915_m1, Applied 
Biosystems,UK).  Assays were run in a MicroAmp® Optimal 96 well reaction 
plate-0.1ml (Applied Biosystems,UK) on an ABI prism 7900 sequence 
detector (University of Birmingham). The cycle threshold value (Ct) for 
CLEVER-1 was normalized against the housekeeping gene.  The relative 
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expression was calculated by the 2-∆∆Ct method.  Components of the PCR 
reaction are described in.Table 2-14. 
Table 2-14 Components of quantitative PCR reaction 
Component Final Concentration 
Taqman 2x master mix (Applied 
Biosystems) 
1x 
20x Assay mix(Applied Biosystems) 0.5x 
cDNA 100ug/ml 
RNAse free water Upto 10µl 
 
2.7 Stimulation of primary HSEC cultures. 
2.7.1 Cytokine Stimulation of Cell Monolayers 
All stimulations were performed in appropriate complete culture media.  Cells 
were cultured to confluence as described previously in RTC-coated 96-well 
plates (Becton Dickinson, Oxford, UK).  For test samples all culture medium 
was removed and replaced with unstimulated media (control) or stimulation 
media either alone or concominant with interferon-gamma (IFN-γ) (Table 
2-15). Cytokine concentrations used were previously determined optimal 
concentrations used by our group.  All stimulations were for 24 hours at 370C 
in a humidified incubator with a 5% CO2  atmosphere. 
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Table 2-15 Agents used for stimulation of cultured monolayers 
Cell Stimulant Final Concentration Source 
TNF-α 10ng/ml Pepro Tech 
IFN-γ 10ng/ml Pepro Tech 
TGF-β 10ng/ml Pepro Tech 
LPS 1µg/ml Sigma Aldrich 
IL-4 10ng/ml Pepro Tech 
IL-10 10ng ml-1 Pepro tech 
 
2.7.2 Measurement of adhesion molecule expression by primary cell 
cultures 
Expression of adhesion molecules on primary cell cultures was investigated 
by ELISA (Enzyme-linked Immunosorbent assay). Cells were cultured and 
stimulated as described before being fixed in 100% methanol (BDH, US) for 
5min and washed in buffer (PBS/0.1% gelofusin).  Cells were incubated with 
normal goat serum (Sigma, UK) for 60 min at 37oC to reduce non-specific 
secondary antibody binding before being washed twice with PBS prior to 
addition of primary antibodies in triplicate wells (60 min incubation at 37oC).  
Following two further washes, cells were incubated with a relevant secondary 
antibody conjugated to horseradish peroxidase for 45min at 37oC.  Cells 
were then washed a further three times before development of the 
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peroxidase enzyme label using an OPD-based substrate (1,2-
phenylenediamine dihydrochloride in tablet form; DAKO, UK) in accordance 
with manufacturer’s instructions.  Colour development was allowed to 
continue for 3-5 min before being stopped by the addition of 0.5M sulphuric 
acid (H2SO4; Fisher Scientific).  Absorbance at 490nm was measured on an 
automated plate reader (Dynax laboratories, MRX). Background absorbance 
was corrected by subtracting absorbance values of an isotype-matched 
control antibody (DAKO,UK) and mean absorbance values were calculated 
from triplicate tests.  All antibodies used are detailed in Table 2-16 . 
Table 2-16 Antibodies used for ELISA studies 
Monoclonal 
Antibodies 
Source Final Concentrations 
Mouse anti Human 
CLEVER-1 (3-372) 
Gift from Sirpa Jalkanen 10 µg/ml 
Mouse IgG1 control R and D 10 µg/ml 
Goat anti Mouse-HRP DAKO 1:5000 
 
2.7.3 Cytokine and growth factor stimulation of cultured HSEC. 
All stimulations were performed in appropriate complete culture media.  Cells 
were grown to confluence in 75cm2 flasks as described previously in section 
2.2.1.  For test samples all culture medium was removed and replaced with 
unstimulated media (control) or stimulation media containing cytokine of 
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choice (Table 2-17).  Stimulations were performed for either 4 or 24 hours at 
370C in a humidified incubator with a 5% CO2 atmosphere. To study the 
effect of vascular epidermal growth factor  (VEGF) and hepatocyte growth 
factor (HGF) all culture medium was removed from and replaced with media 
without growth factor supplementation (control) or media with either VEGF or 
HGF supplementation or a combination of both growth factors summarized in 
Table 2-17.  Studies were performed for 24 hours at 370C in a humidified 
incubator with a 5% CO2 atmosphere.   
Table 2-17 Cytokines and growth factors used to stimulate cultured 
HSEC for qPCR 
Cell Stimulant Final Concentration Source 
TNF-α 10ng/ml Pepro Tech 
IFN-γ 10ng/ml Pepro Tech 
LPS 1µg/ml  Sigma Aldrich 
IL-4 10ng/ml Pepro Tech 
IL-10 10ng/ml Pepro Tech 
Vascular Epidermal 
Growth Factor 
10ng/ml Pepro Tech 
Hepatocyte Growth 
factor 
10ng/ml Pepro Tech 
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2.7.4 Stimulation of HSEC with Bile. 
Bile was collected from resected gall bladders at the time of liver 
transplantation. HSEC was cultured to confluence in 75cm2 culture flasks.  
For test samples all culture medium was removed and replaced with 
unstimulated media (control) or media containing bile at a dilution of 1 in 100.  
Studies were performed for 24 hours at 370C in a humidified incubator with a 
5% CO2 atmosphere.    
2.7.5 Exposing HSEC to hypoxic conditions 
HSEC were grown to confluence in 75cm2 and test samples were maintained 
in either normoxia or incubated in hypoxic conditions for 24 hours.  Hypoxia 
was achieved by placing cells in an airtight incubator (RS Mini Galaxy A 
incubator, Wolf Laboratories, UK) which was flushed with 5% CO2 and 95% 
Nitrogen until oxygen content within the chamber reached 0.1%.  The level of 
oxygenation was checked by a dissolved oxygen monitor (DOH-247-KIT, 
Omega Engineering, UK).  To ensure culture media was appropriately 
oxygenated it was pre-incubated in a sterile container, which allowed gas 
exchange for 8 hours prior to study.  Oxygenation of the media was checked 
by the dissolved oxygen monitor.   
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2.8 Bafilomycin treatment of primary HSEC 
Trafficking of CLEVER-1 was assessed by inhibiting the vacuolar type H+-
ATPase with Bafilomycin A1 (Sigma UK) (Yoshimori et al., 1991).  HSEC 
grown on RTC-coated coverslips were treated with Bafilomycin A1 at a 
concentration of 10nM for 24 hours.  The cells were fixed and fluorescently 
stained as described in section 2.4.2.  Details of the antibodies used are in  
 
 
 
 
 
 
 
 
 
 
 
107 
 
Table 2-18. 
 
 
 
 
 
 
 
 
 
 
 
Table 2-18 Primary and secondary antibodies used for intracellular 
trafficking studies 
Monoclonal Abs Clone Source Final 
Concentration 
Mouse IgG1 
control 
DAK GO1 DAKO 10 µg/ml 
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Mouse IG2b 
control 
73009 Rand D Systems 5 µg/ml 
Rabbit IgG control - DAKO 5 µg/ml 
Mouse anti Human 
CLEVER-1 
3-372 Gift from S 
Jalkanen, 
Turku,Finland 
10 µg/ml 
Mouse anti Human 
Lamp-1 
25 BD Biosciences 5 µg/ml 
Mouse anti Human  
Rab5 
1/Rab5 BD Biosciences 5 µg/ml 
Rabbit  anti Human 
Trans-Golgi 
network protein 
- Sigma 5 µg/ml 
Goat anti Mouse 
IgG1 Alexa fluor 
546 
- Invitrogen 10 µg/ml 
Goat anti Mouse 
IgG2b FITC 
- Cambridge 
Biosciences 
1/50 dilution of 
stock 
Goat anti Rabbit 
IgG Alexa fluor 488 
- Invitrogen 1/500 dilution of 
stock 
Lectin GS-II from 
Griffonia 
simplicifolia, Alexa 
fluor 488 
- Invitrogen 10 µg/ml 
2.9 Static adhesion assays 
Static adhesion assays were performed on frozen liver sections with 
peripheral blood lymphocytes in order to screen for effects of function-
blocking antibodies on adhesion to intact tissue.  
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2.9.1 Static adhesion assay 
I used an established method (McNab et al., 1996) of adhesion assay.  
Frozen sections from different diseased liver specimens were obtained as 
previously mentioned, although sections were cut at 10 micron thickness.  
Where appropriate, tissue sections were incubated with 100µl of optimally 
diluted mouse anti human function-blocking antibody directed against the 
molecule of interest for 1 hour on a rocker in a humidified chamber. Isotype- 
matched mouse immunoglobulins were used as controls. The slides were 
then washed with PBS for 5 minutes, prior to addition of 100µl of peripheral 
blood lymphocytes resuspended in RPMI-1640/10%(v/v) FCS (Invitrogen,UK) 
at 1x106/ml for 30 minutes and allowed to bind in static conditions at room 
temperature.  The slides were then gently washed with PBS and then fixed in 
acetone for 5 minutes.  This was followed by two 5 minute washes in PBS.  
The slides were then stained with haematoxylin and mounted with glass 
coverslips and immunomount solution (Thermoscientific UK).  Slides were 
analysed by manual counting of adherent lymphocytes to sinusoids in 10 
representative high power fields.  Assays were counted blind. 
 
 
Table 2-19 Blocking antibodies used in static adhesion assays 
Monoclonal Abs Clone Source Final 
Concentration 
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Mouse IgG1 
control 
DAK GO1 DAKO 20 µg/ml 
Mouse anti Human 
CLEVER-1 
3-372 Gift from S. 
Jalkananen, Turku, 
Finland 
20 µg/ml 
 
2.10 Flow based adhesion assay 
In order to determine the physiological significance of CLEVER-1 expression 
on HSEC under physiological levels of flow I carried out flow-based adhesion 
using a method established in our laboratory (Lalor et al., 2002a). Assays 
used freshly isolated lymphocyte subsets and measured interactions with 
HSEC grown in glass capillary tubes (microslides) or IBIDI chambers as 
discussed below. 
 
 
 
 
2.10.1 Preparation of microslides 
Microslides are flattened glass capillary tubes, 5cm in length with a 
rectangular cross-section of 0.3 x 0.03 cm (Figure 2.2B). The microslides 
were initially acid-washed overnight (70% v/v nitric acid;Sigma,UK) before 
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being rinsed in excess of water with a final wash in distilled water and 
dehydration in anhydrous acetone.  Microslides were then coated for 10 mins 
at room temperature with a 4% (v/v) solution of 3-aminopropyltriethoxysilane 
(APES; Sigma UK) prepared in anhydrous acetone.  After a final wash in 
anhydrous acetone, microslides were rinsed in distilled water to remove any 
residual acetone before being blotted and dried in a glass oven overnight at 
600C.  To allow connection of microslides to a custom designed multi-port 
culture dish (Glassblower, School of Chemistry, University of Birmingham, 
UK) 1cm long sections of silicone tubing (3mm bore and 1mm wall thickness; 
Portex Ltd., Kent, UK) were attached at one end and the slides were 
autoclaved at 1210C prior to use. 
2.10.2 Culture of endothelial cells in microslides 
Sterile microslides were coated with RTC for 2 hours at 370C and washed 
thoroughly with PBS. HSEC were cultured (as described in 2.3) in a T75 flask 
until confluent before being dissociated in trypsin-EDTA, washed in PBS and 
resuspended at 0.5 x106/ 100µl in complete medium.  Microslides were then 
attached to a 1ml pipette and 50µl of the cell suspension was aspirated into 
each slide before being incubated at 370C for 1 hour to allow the cells to 
settle and adhere to the internal lower surface.  Individual microslides were 
then attached to each of the six ports within the culture dish via the 
previously attached silicone tubing and covered in approximately 40ml of 
complete medium.  The culture dish was placed in a humidified incubator at 
370C with a 5% CO2 atmosphere and attached via silicone tubing to an 
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external pump, timed to replace spent media in the microslides at 2 hourly 
intervals.  The endothelial monolayers in microslides were treated with 
cytokines (TNFα at 10ng/ml and IFN γ at 10ng/ml) for 24 hours prior to 
adhesion assay. 
2.10.3 Culture of endothelial cells in ibidi slides 
Whilst the microslide system is effective for use in flow assays, it is 
technically challenging to perform. Thus during the course of my studies we 
also used an alternative, commercially available multi channel culture system 
in the form of IBIDI chambers. Here, endothelial cells were grown in Ibidi ® µ-
Slide VI 0.4 channel slides (Thistle Scientific, UK).  These slides were 
precoated with RTC by injecting 30 µl of liquid into each channel and 
incubating for 2 hours at 370C and followed by washing thoroughly with PBS.  
HSEC were cultured (as described in section 2.2.4) in a  T75 flask until 
confluent before being dissociated in trypsin-EDTA, washed in PBS and 
resuspended at 3 x106 ml-1  in complete medium.  30 µl of cell suspension 
was injected directly into each channel.  The cells were left to adhere to the 
slides for one hour at 370C following which complete medium was added to 
fill the ports on either side of the channel.  The cells were grown to 
confluence in a humidified incubator at 370C with a 5% CO2 atmosphere and 
by placing the slides on a Ibidi ® µ-Slide rack (Thistle Scientific,UK) to allow 
gas exchange between the medium within the slide and the incubator 
atmosphere.  Once cells were confluent they could be stimulated with 
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cytokines as described in 2.10.2 by directly injecting cytokine solution into the 
slides.  
 
2.10.4 Flow based adhesion assays 
All manipulations of microslides and IBIDI chambers were at room 
temperature immediately prior to assay.  For microslides containing a 
confluent HSEC monolayer, the slides were fixed to a glass microscope slide 
using cyanoacrylate glue and the two ends of the microslide were coated in 
double-sided adhesive tape (Scotch TM pressure sensitive tape; 3M, 
Bracknell, Berks, UK) to allow an airtight seal.  One end of the microslide was 
then attached via a silicone tubing to Harvard syringe pump (Harvard 
Apparatus, South Natic, MA, USA) and the other to an electronic solenoid 
valve (Lee Products Ltd., Gerrards Cross, Bucks, UK) which permitted the 
alternation between a cell free wash buffer (Endothelial medium/0.1% (v/v) 
BSA) and a lymphocyte suspension (typically 1 x 106/ml in endothelial 
media/0.1% (v/v) BSA). The withdrawal rate of the syringe pump was altered 
such that the flow rate within the microslide maintained a shear stress of 0.5 
dyne/cm2 (0.05Pa).  In the case of Ibidi®  microslides the attachment to the 
silicone tubing was made using adaptors from the Ibidi ® µ-Slide VI 0.4 flow 
kit (Thistle Scientific).  Here the withdrawal rate of the syringe pump was 
altered according to the Ibidi ® instructions to maintain a shear stress of 0.5 
dyne/cm2 (0.05Pa).    
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Once attached to the flow system, chambers were enclosed in a 
thermostatically controlled transparent chamber maintained at 370C.  
Cultured endothelial cells were perfused with a 5 min bolus of lymphocytes at 
a constant wall shear stress of 0.05Pa, which approximates to the shear 
stress observed in the post-capillary venules in vivo. Some experiments 
involved HSEC monolayers or lymphocytes being pre-treated with function 
blocking antibodies or an isotype matched control.  Here antibodies were 
prepared in endothelial media/0.1% (v/v) BSA and 50 µl was aspirated into 
the relevant microslide or lymphocyte suspensions were resuspended in an 
appropriate dilution of antibody for 30mins prior to assay (Table 2-20).  All 
incubations were at 370C, and lymphocytes were resuspended in endothelial 
medium/0.1% (v/v) BSA to a final concentration of 1 x106ml-1 prior to flow 
adhesion assay. To investigate the effect of blocking chemokine activity via 
G-protein coupled receptors, lymphocytes were incubated with 200ng ml-1 of 
Pertussis Toxin (a Giα protein inhibitor, PTX; Sigma UK) for 30 minutes at 
370C.  Lymphocytes captured from flow were visualized by phase-contrast 
microscopy using an Olympus IX50 inverted microscope (Olympus (UK)Ltd., 
Southall Middlesex,UK) and video microscope recordings were made along 
the length of the microslide.  Offline analysis of videos allowed the pattern of 
adhesion to be assessed. Lymphocytes adherent to the upper surface of the 
HSEC monolayer appeared phase-bright whilst those that had migrated 
through the monolayer appeared phase dark.  Adherent cells were classified 
as exhibiting ‘static adhesion’ (non-migrated), ‘shape changed’/activated 
morphology or as ‘migrated’ and individual categories were expressed as 
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percentage of total adhesion.  Total adhesion was normalized for adhesive 
surface area and number of lymphocytes perfused i.e. adherent 
cells/mm2/106 perfused.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 2-20 Blocking antibodies used in flow adhesion  assays 
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Monoclonal 
Antibodies 
CLONE Source Final Concentration 
Mouse anti 
Human CLEVER-
1 
3-372 Gift from S. 
Jalkanen, Turku, 
Finland 
20µg/ml 
Mouse anti 
Human ICAM-1 
BBIG-I1 
R and D 10µg/ml 
Mouse anti 
Human VCAM-1 
BBIG-V1 
R and D 10µg/ml 
Mouse anti 
Human VAP-1 
TK-814 
Biotie, Finland 10µg/ml 
Mouse  anti 
Human 
IgG1 
11711 
R and D 20 µg/ml 
Mouse  anti 
Human 
IgG2a 
20102 
R and D 10µg/ml 
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Figure 2-1 Microslides and flow assay set-up 
HSEC were cultured in microslides (panel A) with silicone tubing attachments 
(Panel B) in microdishes before being used in flow assays.  Alternatively 
HSEC were cultured in Ibidi chamberslides (lateral view in panel C and view 
from above panel D). These microslides were then attached to flow assay 
tubing and lymphocytes perfused over HSEC.  Interactions were recorded 
using a phase contrast microscope and analysed offline (Panel E).   
 
A B 
C 
D 
E 
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2.11 Manual Tracking of Lymphocytes under conditions of 
flow 
To investigate the motility of lymphocytes on endothelial monolayers, flow 
adhesion assays were carried as described in section 2.10.4.  The assay 
involved timelapse video recordings of a randomly selected single field of 
view (10x objective) for a period of five minutes under conditions of flow.   
Offline analysis of the video recordings was carried out using Image J 
software and a manual tracking plug-in (version 1.42q, NIH, Bethesda, USA), 
allowing the position of each lymphocyte to be tracked throughout the period 
of recording.  The data was then analysed using the Ibidi Chemotaxis plug-in 
for Image J (http://www.ibidi.de/applications/ap_chemo.html) which facilitated 
the measurement of lymphocyte migration over the course of each recording 
and represented the data graphically for ease of interpretation.   These 
analyses were performed with B cell populations which were then compared 
to a mixed T cell population, comprising both CD4- and CD8-positive T cells.   
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2.12 Confocal imaging of lymphocytes undergoing 
transendothelial migration 
Flow based adhesion assays were performed followed by immunofluorescent 
staining and confocal microscopy to capture lymphocytes transmigrating 
across HSEC.   
 Initially, HSEC were seeded and cultured in ibidi ® µ-Slide VI 0.4 channel 
slides (Thistle Scientific, UK) as described in 2.10.3.  Cells were then 
stimulated for 24 hours with TNFα and IFNγ (both 10ng/ml) for 24 hours.   
Prior to flow assay HSEC were incubated with cell tracker green 
(Invitrogen,UK) diluted in serum free endothelial basal media as per 
manufacturer’s instructions for 30 minutes at 370C followed by a washing 
step with endothelium basal medium containing 10% human serum.  
Depending on which subset was being studied, CD4 lymphocyte purification 
or T regulatory cell purification was performed from whole blood as described 
in sections 2.3.2 and 2.3.3.  The lymphocyte subsets were diluted to 1x106 
cells/ml and prepared as described in 2.10.4.  If live cell imaging was being 
performed lymphocytes were stained with cell tracker violet  for 30 minutes 
followed by a washing step and then resuspended in endothelial 
medium/0.1% (v/v) BSA prior to flow assay. 
Flow adhesion assays were then performed as described in section 2.10.4.  
Initially cultured endothelial cells were perfused for 5 min with a bolus of CD4 
lymphocyte fractions at a constant wall shear stress of 0.05Pa.  To perform 
live cell imaging, ibidi slides were removed from flow assay chamber and  
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gently flushed with PBS followed by staining with cell mask orange 
(Invitrogen) for 15 minutes at 370C.    
In other experiments, CD4 or T regulatory cell fractions were perfused for 10 
minutes over HSEC and then fixed in 4% paraformaldehyde for 15 minutes 
followed by permeabilisation with 0.1% Triton for ten minutes.  FoxP3 
fixation/permeabilisation kit (eBioscience,UK) was used in experiments with T 
regulatory cells.  A blocking step was performed with 10% goat serum 
(Sigma,UK) for twenty minutes. Cells within the ibidi slides were then 
incubated with mouse anti-human or rat anti-human monoclonal antibodies 
for 60 minutes at room temperature.  The cells were then washed in PBS and 
incubated with appropriate isotype and species specific secondary antibody 
for 30 minutes at room temperature protected from light.  A further washing 
step was performed before staining with DAPI (Invitrogen,UK), washing with 
PBS and mounting with fluorescent mounting media (DAKO,UK). 
In all experiments lymphocyte/ endothelial interactions were imaged by 
confocal microscopy on an LSM 510 microscope equipped with 63x1.32 
objective.  Images were acquired and analysed by LSM software. LSM 
software was also used to create Z-stack profiles of images. 
 
 
 
121 
 
Table 2-21 Antibodies and cellular stains for cells in Ibidi microslides 
Monoclonal 
Antibodies 
CLONE Source Final Concentration 
Mouse anti Human 
CLEVER-1 
3-372 Gift from S. 
Jalkanen, Turku 
Finland 
10µg/ml 
Mouse IgG1 control DAK G01 DAKO 10µg/ml 
Mouse anti Human 
ICAM-1 
BBIG-I1 
R and D 10µg/ml 
Rat anti Human 
FoxP3 
PCH101 eBioscience 5µg/ml 
Rat IgG2a control - eBioscience 5µg/ml 
Goat α Mouse IgG1 
Alexa fluor 546 
- Invitrogen 10 µg/ml 
Goat α Rat IgG 
Alexa fluor 633 
- Invitrogen 5 µg/ml 
DAPI nucleic acid 
stain 
- Invitrogen 1 in 2000 of stock 
solution 
Cell 
Tracker™Green 
CMFDA 
- Invitrogen 1 in 1000 of stock 
solution 
CellMask™ Orange 
plasma membrane 
stain 
- Invitrogen 5µg/ml 
Cell Tracker™ 
violet BMQC dye 
- Invitrogen 1 in 1000 of stock 
dilution 
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2.13  Statistical Analysis 
Calculated means of data are given together with standard error of mean 
SEM.  Data means were compared using paired sample T-tests or the 
independent sample T-tests as appropriate.  A value of p≤ 0.05 (two tailed) 
was considered statistically significant.  Statistics were performed using the 
software package GraphPad Prism 5.  Where possible, statistics used the 
raw data rather than the calculated data.  For example, actual numbers of 
cells per high power field were used in adhesion assays to calculate 
statistical significance rather than percentage of maximal adhesion.   
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CHAPTER 3  
THE EXPRESSION OF CLEVER-1 IN HUMAN 
HEPATIC TISSUE 
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3.1 Introduction: The expression of CLEVER-1 in normal and 
diseased human liver tissue by immunohistochemistry 
CLEVER-1 is known to be expressed by tissue macrophages (Kzhyshkowska 
et al., 2006a) and on the sinusoidal endothelium (non-continuous 
endothelium) of spleen, lymph node and adrenal cortex (Goerdt et al., 1991).  
The presence of CLEVER-1 is thus restricted to sinusoidal endothelium in 
health but in certain disease states it is upregulated on continuous 
endothelium.  This has been shown in malignant conditions such as T-cell 
lymphomas, melanoma metastasis and also in psoriasis, a chronic 
inflammatory condition of the skin, and on a background of wound healing 
(Goerdt et al., 1993; Salmi et al., 2004).  The presence of CLEVER-1 in 
macrophages was initially demonstrated within placental tissue and 
subsequently found in tissue macrophages of the colon, stomach, skin and 
lymph node ((Goerdt et al., 1991; Martens et al., 2006; Prevo et al., 2004).   
These studies used various antibodies which include MS-1 (a mouse mAB 
against human spleen) (Goerdt et al., 1991), F4 (a rabbit polyclonal Ab 
against the recombinant cytoplasmic tails of human CLEVER-1) (Politz et al., 
2002), and 1.26 (mouse Mab against N-terminal fragment of CLEVER-1) 
(Schledzewski et al., 2006).    Previous studies in the normal human liver 
using the MS-1 antibody confirmed that CLEVER-1 was restricted to the 
sinusoidal regions in liver sections.  The staining did not outline the entire 
channel but appeared to stain the perinuclear region (Goerdt et al., 1991).  
Double immunohistochemical staining with CD11b and CD45 was used to 
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demonstrate that Kupffer cells were negative for CLEVER-1 but a sinusoidal 
specific marker was not used to confirm presence on sinusoidal endothelium.  
A further study using the MS-1 antibody and the F4 antibody demonstrated 
that, whilst CLEVER-1 was present on both the lymph node endothelial cells 
and a lymph node macrophage population, it was restricted to the sinusoidal 
endothelium in the human liver (Martens et al., 2006).  There have been no 
reported studies of the expression of CLEVER-1 within diseased human liver 
tissue or in the context of malignant liver disease such as hepatocellular 
carcinoma.   
Therefore the aims of our tissue expression studies were to   
1. Identify the cell-specific expression of CLEVER-1 within the normal 
human liver in vivo. 
2. Identify differences in CLEVER-1 expression between normal and 
diseased liver and any differences between specific aetiologies ie 
parenchymal diseases vs biliary diseases. 
3. Study the expression of CLEVER-1 in hepatocellular carcinomas 
(HCC). 
 Immunohistochemistry was performed with an ImmPRESSTM Universal anti-
mouse/rabbit IgG reagent (Vector Labs, Burlingame CA) and a Vector VIP 
substrate kit method to detect the localisation of CLEVER-1 in liver tissue.  At 
least four cases of normal liver and tissue from chronically inflamed 
parenchymal diseases (alcoholic liver disease and autoimmune liver disease) 
and biliary diseases (primary sclerosing cholangitis and primary biliary 
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cirrhosis) were studied. CLEVER-1 expression in malignant liver disease was 
studied in sections from hepatocellular carcinomas.     
3.1.1 Expression of CLEVER-1 in normal liver 
In normal liver tissue CLEVER-1 expression was localised within the 
sinusoidal channels (Figure 3-1). The staining was uniform across the 
hepatic lobule but confined to the sinusoids, other hepatic structures 
including hepatocytes, bile ducts, portal vessels and central veins were 
negative.  Examination of the normal tissue at increased magnification 
demonstrated that the staining did not outline the entire channel but was 
more prominent in the perinuclear region of positive staining cells (Figure 
3-2).  With this technique it was not possible to determine whether the 
positive staining was within Kupffer cells or HSEC.  Staining with isotype 
matched control was negative in all tissues. 
3.1.2 CLEVER-1 expression in diseased liver tissue. 
Analysis of CLEVER-1 staining in tissue from patients with alcoholic liver 
disease or autoimmune hepatitis demonstrated CLEVER-1 staining within the 
hepatic sinusoids but the expression was patchy compared to that seen in 
normal sections.  Sinusoids that were CLEVER-1 positive demonstrated 
increased intensity of staining in comparison to normal liver tissue (Figure 
3-3).  Similar findings were also seen in sections from biliary diseases (Figure 
3-4).  Higher magnification of the sections demonstrated that more of the 
outline of the sinusoidal channel was stained with CLEVER-1 suggesting that 
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there was a change in the localisation of CLEVER-1 expression to the 
membrane of the cells (Figure 3-5).  CLEVER-1 expression was also present 
in other structures apart from the sinusoids in diseased tissue.  Strong 
staining was seen within the fibrous septa and on the luminal aspect of 
neovessels within the septa (Figure 3-6A).  CLEVER-1 was also detected on 
endothelium within portal associated lymphoid follicles.  More specifically, 
positive CLEVER-1 staining was seen in the vessels supplying these follicles, 
which are characterised by their high endothelial venule-like structure (Figure 
3-6C, E).   
3.1.3 CLEVER-1 expression in malignant disease. 
CLEVER-1 was detected within tumour sinusoids in tissue taken from HCC 
arising on the background of different types of chronic liver disease.  The 
staining of CLEVER-1 in some tumours was similar in pattern to that found 
within normal liver sinusoids whereas in other tumours the staining was more 
continuous within the sinusoids (Figure 3-7 A, C).  Interestingly, in contrast to 
normal livers, CLEVER-1 staining was detected in the walls of vessels within 
the tumour (Figure 3-7 E).    
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Figure 3-1 Expression of CLEVER-1 in normal human liver 
Representative images from sinusoidal fields in normal liver samples which 
were stained with an antibody raised against CLEVER-1 (A) or isotype 
matched control antibody (B) Fields were captured by 20x objectives. 
CLEVER-1 staining (purple) can be seen within the sinusoids. 
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Figure 3-2 Expression of CLEVER-1 in normal hepatic sinusoids 
Representative images from sinusoidal fields in normal liver samples which 
were stained with an antibody raised against CLEVER-1 (A) or isotype 
matched control (B  Fields were captured by 40x objectives.  Arrows denote 
areas of prominent perinuclear staining of CLEVER-1 positive cells within the 
sinusoids. 
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Figure 3-3 Expression of CLEVER-1 in chronic parenchymal liver 
disease 
Representative images from samples of explanted livers from patients with 
chronic parenchymal liver disease which were stained with an antibody 
raised against CLEVER-1 (A and B) or isotype matched control (C and D). 
Fields were captured by 20x objectives. ALD (alcoholic liver disease), AIH 
(autoimmune hepatitis)  
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Figure 3-4 Expression of CLEVER-1 in chronic biliary liver disease 
Representative images from samples of explanted livers from patients with 
chronic biliary liver disease which were stained with an antibody raised 
against CLEVER-1 (A and B) or isotype matched control (C and D). Fields 
were captured by 20x objectives.  PBC (primary biliary cirrhosis), PSC 
(primary sclerosing cholangitis) 
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Figure 3-5 Expression of CLEVER-1 within diseased hepatic sinusoids 
Representative images from sinusoidal fields in diseased liver samples which 
were stained with an antibody raised against CLEVER-1 (A) or isotype 
matched control (B).  Arrows denote areas of CLEVER-1 staining where it 
outlines the sinusoidal channels. Fields were captured with a 40x objectives. 
The sample is from a patient with ALD. 
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Figure 3-6 Expression of CLEVER-1 within fibrous septum and portal 
associated lymphoid tissue 
Representative images of fibrous septa (A,B) and portal associated lymphoid 
tissue in chronically inflamed liver tissue (C-F) which were stained  with an 
antibody raised against CLEVER-1  (A and C), or isotype matched control (B 
and D).  E is inset of panel C and F is inset of panel D.    Arrows highlight 
vessels staining positive for CLEVER-1 and asterisk denotes a germinal 
centre.   Fields were captured with a 20x objective, apart from Panels E,F 
which were captured with 40x objective. Liver tissue from patients with ALD. 
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Figure 3-7 Expression of CLEVER-1 within hepatocellular carcinoma 
Representative images of sinsusoidal fields (A –D) and tumour-associated 
vessel (E,F) in hepatocellular carcinoma samples which were stained with an 
antibody against CLEVER-1 (A,C,E), or isotype matched control (B,D,F).  
Fields captured with a 20x objective. 
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3.2 CLEVER-1 expression in the liver by 
immunofluorescence 
3.2.1 Dual staining of CLEVER-1 with sinusoidal endothelial cell and 
kupffer cell markers.   
Although our initial immunohistochemical investigations clearly showed 
expression of CLEVER-1 within normal and diseased liver sinusoids, we 
could not conclusively identify the specific cell which expressed CLEVER-1 
using this technique (see section 3.1 ).  The two major cell populations within 
the hepatic sinusoids are the Kupffer cells and sinusoidal endothelial cells.  
Dual-colour immunofluorescence was therefore used to identify which of 
these two cell-types within the hepatic sinusoids was CLEVER-1 positive.  
CLEVER-1 colocalised with L-SIGN (a sinusoidal endothelial cell specific 
marker) confirming that CLEVER-1 was expressed by HSEC (Figure 3-8 A-
C).  Colocalisation was confirmed with confocal microscopy (Figure 3-8 D 
and E).  CLEVER-1 did not colocalise with CD68 (Kupffer cell marker) 
positive cells.  The absence of CLEVER-1 from Kupffer cells was noted in 
normal and diseased livers (Figure 3-9).   
3.2.2 Dual staining with vascular endothelial cell markers 
Our immunohistochemical studies demonstrated CLEVER-1 expression 
within fibrous septa of chronically inflamed livers (Figure 3-6).  The positive 
staining appeared to be present within the walls of inflammatory neovessels 
which are known to express the vascular endothelial marker CD34.  Dual 
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colour immunofluorescence was used to demonstrate colocalisation of 
CLEVER-1 with CD34 within the fibrous septa confirming the expression of 
CLEVER-1 on neo-vessels (Figure 3-10). 
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Figure 3-8 CLEVER-1 is expressed by HSEC 
Normal liver samples were stained using dual-colour immunofluorescence. 
Representative images are shown of a normal liver stained with  CLEVER-1 
antibody and texas red secondary (A), and  L-SIGN antibody with FITC 
secondary (B). Panel C demonstrates merged image of Panel A and B.  
Panel D demonstrates confocal imaging of a normal liver sample stained with 
CLEVER-1 antibody (Alexa Fluor 546 secondary) and L-SIGN antibody (FITC 
secondary. Colocalisation is seen as yellow. Panel E shows two colour 
intensity profile of line in Panel D (INT=Fluorescent intensity). Fields captured 
by 40x objective except Panel D which was captured by 63x objective.   
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Figure 3-9 CLEVER-1 is not expressed by Kupffer cells 
Liver samples were stained using dual-colour immunofluorescence.  
Representative images are shown from samples of normal liver (A) and from 
samples of explanted liver from a patient with primary biliary cirrhosis (B).  
Sections were stained with CLEVER-1 antibody (Texas red secondary) and 
CD68 antibody (FITC secondary).  Panel A is a field captured by 20x 
objective. Panel B is a field captured by 40x objective. 
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Figure 3-10 CLEVER-1 is expressed by neovessels 
Liver samples were stained using dual colour immunofluorescence. 
Representative images of  explant liver samples from a patient with alcoholic 
liver disease which were stained with CLEVER-1 antibody and Texas red 
secondary (A),  CD34 antibody and FITC secondary (B).  Images were then 
merged (C).  Fields were captured by 40x objective.  Representative confocal 
images were also taken of explanted liver sections which were stained with   
CLEVER-1 antibody and Alexafluor 546 secondary (D), CD34 antibody with 
FITC secondary (E).  Images were then merged (F). Fields were captured by 
63x objective.   
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3.2.3 The quantification of CLEVER-1 protein in liver tissue 
Semi-quantititative assessment of CLEVER-1 protein in normal liver tissue 
compared to diseased liver tissue was performed by western blotting.  
Protein lysates were obtained from normal liver and explanted livers from 
patients with a range of chronic inflammatory liver diseases.  Initial western 
blots using the 3-372 antibody to label CLEVER-1 were negative (not 
shown).  The assay was repeated without reducing the protein lysates with 
beta-mercaptoethanol.  Following this alteration to the assay, protein bands 
for CLEVER-1 were detected between molecular weight markers for 300kDa 
and 220kDa consistent with the known molecular weight of CLEVER-1 of 
270kDa. The results demonstrated the presence of protein in, and in contrast 
with immunohistochemical data we noted no obvious difference in intensity 
between normal liver and diseased livers (Figure 3-11).   
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Figure 3-11 CLEVER-1 Protein Expression in Normal and Diseased Liver 
Tissue 
The top row represents a western blot for CLEVER-1 of normal and diseased 
liver tissue.  A blot for β Actin was performed for the same samples to ensure 
equal protein loading.  NL- Normal liver, ALD-Alcoholic liver disease liver, 
AIH- Autoimmune hepatitis liver, CR- Chronic rejection, Primary Sclerosing 
Cholangitis. Data shows blots from two samples of each condition apart from 
PSC which is a single sample.   
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3.3 The expression of CLEVER-1 in primary human hepatic 
sinusoidal endothelial cells 
Several groups have studied the expression of CLEVER-1 on isolated human 
cells in vitro.  An early report studying human macrophages, confirmed basal 
expression of CLEVER-1 in these cells by immunoprecipitation and 
demonstrated a strong stimulatory effect of IL-4 and dexamethasone on 
protein expression (Goerdt et al., 1993).  Further studies confirmed the 
expression of CLEVER-1 in monocyte derived macrophages from humans 
and bone marrow derived macrophages from mice (Kzhyshkowska et al., 
2004; Politz et al., 2002; Schledzewski et al., 2006).  Studies by FACS and 
immunofluorescence with cultured endothelial cells from lymph node and skin 
lymphatics confirmed that these cells also expressed CLEVER-1 in vitro 
(Prevo et al., 2004; Salmi et al., 2004).  CLEVER-1 has also been shown to 
be expressed by primary human hepatic sinusoidal endothelial cells and pig 
and rabbit liver sinusoidal endothelial cells (Hansen et al., 2005a; Prevo et 
al., 2004).  Thus we wished to confirm and extend the available data for 
expression in human primary hepatic endothelial cells in the current study.  
To this end we confirmed the purity and phenotype of our cell populations 
and then we investigated  i)The expression of CLEVER-1 in the isolated 
HSEC from normal and diseased livers  by RT-PCR from normal and 
diseased livers and ii) the expression and distribution of CLEVER-1 on HSEC 
by immunofluorescence. 
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3.3.1 Purity and sinusoidal phenotype of isolated hepatic endothelial 
cells. 
HSEC were isolated from normal and diseased liver tissue as described in 
2.2.3.  Cultured HSEC displayed a characteristic morphology (Figure 3-12) 
and endothelial cell purity was assessed by CD31 expression using flow 
cytometry, shown to be 99%. (Figure 3-12).  LYVE-1 is expressed on 
sinusoidal endothelial cells and this marker was used to confirm the 
phenotype of the endothelial cells from HSEC isolates (Mouta et al., 2001).  
LYVE-1 expression was demonstrated by immunofluorescence and the 
presence of LYVE-1 messenger RNA was confirmed by reverse transcriptase 
PCR in HSEC isolates from normal and diseased livers (Figure 3-13 C).  
3.3.2 Expression of CLEVER-1 in isolated human hepatic sinusoidal 
endothelial cells 
Once we had confirmed the phenotypic identity of our cell isolates we studied 
CLEVER-1 expression by semiquantative RT-PCR in HSEC isolates from 
normal liver specimens.  Agarose gels demonstrated PCR products for 
CLEVER-1 at the expected size in both early and late passage samples 
(Error! Reference source not found.Panel A).  However as is evident in 
his figure, several non-specific bands were also amplified during the PCR 
reaction.  To increase the specificity of the PCR reaction a touchdown 
protocol was set up which commenced at a high annealing temperature and 
subsequently decreased the temperature with each cycle.  The touchdown 
protocol resulted in a clear specific band (Error! Reference source not 
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ound. panel B).  The touchdown method was therefore used in any further 
PCR reactions to detect CLEVER-1.   
During chronic liver injury HSEC are known to undergo significant 
morphological and phenotypical changes (Couvelard et al., 1993; Mori et al., 
1993).  Our staining results suggested that HSEC from diseased livers 
maintained their CLEVER-1 expression in vivo (see section 3.1.2).  To 
confirm these findings in vitro semiquantative RT-PCR for CLEVER-1 was 
performed in HSEC isolates from explanted livers from patients with alcoholic 
liver disease, primary biliary disease.  Figure 3-15  shows CLEVER-1 mRNA 
was detected in all these samples confirming that HSEC from diseased liver 
maintained CLEVER-1 expression.    
  
145 
 
 
Figure 3-12 Purity and morphology of isolated HSEC 
Panel A- Isolated human hepatic sinusoidal endothelial cells (HSEC) from 
liver samples were stained for CD31 and isotype matched control and 
analyzed by flow cytometry. Panel B – Photograph of isolated HSEC in 
culture.  
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Figure 3-13 Sinusoidal phenotype  of isolated HSEC from normal and 
diseased livers 
Representative images of isolated human hepatic sinusoidal cells (HSEC) 
stained for LYVE-1 (FITC secondary) (Panel A) and isotype matched control 
(Panel B).  Nucleii were stained with DAPI(Blue).  Representative agarose 
gel of HSEC isolates from normal liver (NL), alcoholic liver disease (ALD) and 
primary biliary cirrhosis (PBC). 
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Figure 3-14 Detection of CLEVER-1 m RNA in HSEC 
RT-PCR was performed by a standard protocol and a representative agarose 
gel of HSEC isolates is shown (Panel A). Lane 1) Ladder; Lane 2) Positive 
control; Lane 3) no sample; Lane 4) HSEC passage 3;Lane 5) HSEC 
passage 6.  RT-PCR was performed by a touchdown protocol and a  
representative agarose gel of a HSEC isolate is shown (Panel B). Lane 1) 
Ladder; Lane 2) HSEC passage 5; Lane 3) no sample. 
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Figure 3-15 Detection of CLEVER-1 mRNA in HSEC from normal and 
diseased livers 
A representative agarose gel of HSEC isolates from normal liver (NL), 
alcoholic liver disease (ALD), primary biliary cirrhosis (PBC). 
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Isolated  HSEC were cultured on coverslips as described in section2.4.2. 
Immunofluorescent staining confirmed the expression of CLEVER-1 protein 
in isolated HSEC.  As seen in Figure 3-16 CLEVER-1 protein was present in 
isolated HSEC.  CLEVER-1 expression in cultured HSEC was predominantly 
intracellular with a diffuse perinuclear localisation. 
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Figure 3-16 CLEVER-1 expression by immunofluorescnce in primary 
HSEC 
Representative images of isolated human hepatic sinusoidal cells (HSEC) 
stained for CLEVER-1 (FITC secondary) (Panel A) and isotype matched 
control (Panel B).  Nucleii were stained with DAPI (Blue).  Fields captured 
with x63 objective. 
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3.4 Summary of CLEVER-1 expression studies. 
The immunohistochemical studies in this chapter have detailed the 
expression of CLEVER-1 in normal and diseased human liver.  Within the 
normal liver CLEVER-1 was restricted to the hepatic sinusoids, specifically 
restricted to HSEC and absent from Kupffer cells.   To our knowledge studies 
of CLEVER-1 expression in chronic liver disease or hepatocellular 
carcinomas have not been published.  Examination of tissue sections from a 
variety of chronic liver diseases confirmed that CLEVER-1 expression was 
maintained on HSEC during disease with evidence that expression increased 
compared to normal liver.   CLEVER-1 was also found at other sites in the 
diseased liver.  Whereas CLEVER-1 was restricted to sinusoidal endothelium 
in normal liver tissue in diseased livers its expression was upregulated on 
neovessels within fibrous septa and vessels supplying portal associated 
lymphoid tissue.  Furthermore, studies of hepatocellular carcinoma samples 
demonstrated CLEVER-1 within tumour sinusoids and tumour associated 
vessels.  CLEVER-1 protein expression in liver tissue from normal and 
diseased livers was confirmed by western Blotting.  Finally, CLEVER-1 
expression in isolated HSEC was confirmed by immunofluorescence and RT-
PCR.  
The results of CLEVER-1 expression in normal human liver tissue are in 
keeping with previous studies (Martens et al., 2006).  Investigation of 
diseased liver samples demonstrated changes in CLEVER-1 expression in 
response to chronic inflammation which is associated with morphological 
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changes in HSEC.  During ongoing inflammation the hepatic sinusoidal 
vascular bed undergoes a phenomenon termed ‘capillarisation’.  Studies 
using animal models have demonstrated that capillarisation involves the loss 
of fenestrae from HSEC and the formation of a subendothelial basement 
membrane (Bhunchet and Fujieda, 1993; Ishak et al., 1991; Martinez-
Hernandez and Martinez, 1991; Mori et al., 1993).  There is evidence that 
this change in structure is also associated with a change in receptor 
expression, including increased expression of vascular markers such as 
CD31 and CD34 (Couvelard et al., 1993).  Examination of tissue sections 
from a variety of chronic liver diseases confirmed that CLEVER-1 expression 
was maintained on HSEC during disease and there was evidence that the 
distribution and intensity of staining actually increased compared to normal 
livers although this was not confirmed by western blotting.  A range of chronic 
liver diseases were studied and compared.   The changes in CLEVER-1 
expression in parenchymal and biliary diseases were very similar and this 
suggested that there were no disease specific differences (Figure 3-3 and 
Figure 3-4).  Other C-type lectins such as LYVE-1 have been shown to be 
down regulated in liver  disease (Arimoto et al., 2009).  This suggests that the 
regulation of CLEVER-1 expression on HSEC differs from other C-type 
Lectins.   
Vascular structures within the fibrous septa found in chronically inflamed 
livers were also CLEVER-1 positive (Figure 3-6). These neovessels are 
thought to be vascular in nature and they express markers such as CD34.  
They may also be sites of lymphocyte recruitment in chronic inflammation 
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(Freemont, 1988; Grant et al., 2001).  Another example of vascular 
endothelium is found in vessels which supply lymphoid follicles that develop 
in chronic inflammation.  These vessels are similar to high endothelial 
venules (HEVs) seen in lymph nodes.  These HEV-like vessels were also 
positive for CLEVER-1 (Figure 3-6). The fibrous septum and lymphoid 
follicles are thought to be important sites of lymphocyte recruitment and 
retention in chronic inflammation and therefore CLEVER-1 expression in 
these structures supports the hypothesis that CLEVER-1 plays a role in 
lymphocyte recruitment to the chronically inflamed liver.   
The progression of chronic inflammation to cirrhosis leads to an increased 
risk of tumour formation, specifically the development of hepatocellular 
carcinomas.  These tumours are dependent on angiogenic factors and 
develop on the background of dysplastic nodules (Kimura et al., 1998).  They 
can also contain sinusoidal channels as seen in normal tissue but the 
endothelium is more vascular in nature (Nascimento et al., 2009).  Our group 
and others have also demonstrated that these tumours are infiltrated by a 
mix of effector and regulatory T cells (Unitt et al., 2005; Yoong et al., 1999).  
The finding of CLEVER-1 within tumour sinusoids and tumour associated 
vessels suggests that CLEVER-1 may also play a role in lymphocyte 
recruitment to hepatocellular carcinomas.   
The increased expression of CLEVER-1 at sites of chronic inflammation 
suggests that inflammatory stimuli may contribute to the regulation of this 
receptor.  The presence in neovessels and hepatocellular carcinomas also 
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suggest that angiogenic factors may play a role in the induction of CLEVER-1 
expression.   
Western blotting allowed total protein quantification of CLEVER-1 in normal 
and diseased liver samples.  Whilst the immunohistochemistry results 
suggested increased CLEVER-1 expression within the sinusoids of diseased 
livers compared to normal liver, these differences were not demonstrated in 
the blotting studies in which no differences were seen in the total amounts of 
CLEVER-1 protein between normal and diseased livers, Figure 3-11.    A 
possible explanation is that the increased expression of CLEVER-1 in the 
sinusoids is balanced out by the changes in liver tissue during chronic 
inflammation such as architectural distortion and deposition of extracellular 
matrix. The immunohistochemistry studies combined with the western 
blotting data suggests that there is a change in the distribution of CLEVER-1 
expression rather than in the total protein levels. 
Confirmation of CLEVER-1 expression on isolated HSEC was successful by 
immunofluorescence and conventional PCR using both high and low 
passage cells and cells from normal and diseased liver tissue (Figure 3-15).  
But, whereas immunohistochemistry suggested stronger staining of 
CLEVER-1 in HSEC from diseased livers, this was not seen with mRNA 
expression (Figure 3-15).  Significant variation in CLEVER-1 expression 
between batches of isolated endothelial cells has been noted previously in 
the context of human lymphatic endothelial cells (Salmi et al., 2004). To our 
knowledge, the expression of CLEVER-1 in endothelial cells from normal and 
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diseased organs has not been compared previously.    A likely explanation 
for these contrasting results is that HSEC from normal and diseased livers 
revert to a common phenotype once they are isolated and cultured in vitro, as 
they no longer receive signals from the hepatic microenvironment.   
These studies have demonstrated the expression of CLEVER-1 in human 
hepatic tissue and isolated human HSEC but the signals which influence 
CLEVER-1 expression in vivo have not been identified.    In the next chapter 
we will try to identify these factors by investigating the regulation of CLEVER-
1 expression on HSEC.    
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CHAPTER 4  
THE REGULATION OF CLEVER-1 IN HUMAN 
HEPATIC SINUSOIDAL ENDOTHELIUM 
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4.1 Response to cytokine stimulation 
The regulatory factors which influence CLEVER-1 expression in sinusoidal 
endothelial cells in vitro are unclear.  Its expression on cultured macrophages  
is strongly induced by a combination of IL-4 and dexamethasone, while 
interferon γ has inhibitory effects (Goerdt et al., 1993).  Stimulation by IL-4 
and dexamathasone also led to alteration in CLEVER-1 localisation with an 
increase in cell surface expression (Kzhyshkowska et al., 2004).  However, 
CLEVER-1 expression in endothelial cells appears to be differently regulated; 
studies in human lymphatic endothelium showed no induction by IL-4 or 
dexamethasone whereas LPS led to a modest increase (Salmi et al., 2004).  
In addition, cytokine stimulation has not been shown to alter CLEVER-1 
localisation in lymphatic endothelial cells (Prevo et al., 2004). Since there is 
limited published data relating to the regulation of CLEVER-1 in hepatic 
sinusoidal endothelial cells, the aims in this chapter were to 
1. Study the protein expression of CLEVER-1 in HSEC by cell-based 
ELISA under basal conditions and in response to various stimuli. 
2. Study factors which may influence CLEVER-1 mRNA expression in 
HSEC by quantitative real time PCR. 
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4.2 Protein expression of CLEVER-1 in HSEC and its 
response to cytokine stimulation. 
Cell based ELISA was used to measure basal CLEVER-1 protein levels in 
HSEC and to determine response to cytokine stimulation.  We used cell 
based ELISA rather that flow cytometry because for the latter endothelial 
cells must be lifted off culture plates and analysed in suspension whereas 
cell based ELISA keeps them as an intact monolayer which is more 
physiological.  Initial pilot ELISA experiments with untreated or cytokine 
treated HSEC suggested that levels of CLEVER-1 expression were 
extremely low or that the protein was absent (Figure 4-1 Panel A).  However, 
later experiments were modified to include an additional goat serum blocking 
step and this led to consistent detection of CLEVER-1 (Figure 4-1 Panel B).  
This suggests that adequate blocking of non-specific antibody binding was 
necessary to allow discrimination of CLEVER-1 antibody binding above that 
of isotype control signals.   
Our group has previously shown that the classical endothelial adhesion 
molecules are upregulated on HSEC by inflammatory stimuli such as 
recombinant TNFα and IFNγ (Lalor et al., 2002a).  Experiments were 
performed to investigate if 24 hour stimulation with TNFα, LPS and IFNγ 
alone or in combination had similar effects on CLEVER-1 expression.  I used 
concentrations of the three cytokines that had been shown to induce optimal 
levels of ICAM-1 in previous studies from our group Figure 4-2 shows the 
results of these experiments demonstrating that these cytokines had no 
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significant effect on CLEVER-1 protein expression when compared to resting 
conditions.   
In view of these findings, alternative cytokine stimuli were studied: TGFβ 
which is known to have a significant profibrogenic role in chronic liver disease 
(discussed in section1.6); IL-10 which, as discussed in section 1.5, can be 
secreted by a variety of liver resident cells and IL-4 which has been shown to 
induce CLEVER-1 expression in macrophages (discussed in section 4.1).  
Interestingly these cytokines also had little effect on CLEVER-1 expression 
by HSEC as shown in, Figure 4-3. 
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Figure 4-1 Measurement of CLEVER-1 expression by ELISA in HSEC 
The figure demonstrates representative results of ELISAs for CLEVER-1 
detection in unstimulated and cytokine stimulated HSEC  without goat serum 
blocking step (Panel A) and with blocking step (Panel B).  The values 
represent the mean absorbance of three replicate wells minus the 
absorbance of an isotype matched control antibody.  Data are shown for one 
experiment.  Cells were stimulated with cytokines for 24 hours. 
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Figure 4-2 Measurement of CLEVER-1 expression by HSEC in response 
to Inflammatory Stimuli 
ELISA data comparing the levels of CLEVER-1 protein in unstimulated (white 
bars) and stimulated (black bars, 24hours) HSEC.  Data are the mean and 
SEM of three independent experiments and values are the mean absorbance 
of three replicate wells minus the absorbance of an isotype matched control 
antibody.   
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Figure 4-3 Measurement of CLEVER-1 expression by HSEC in response 
to cytokine stimulation 
ELISA data comparing the levels of CLEVER-1 protein in unstimulated (white 
bars) and stimulated (black bars, 24hours) HSEC.  Data are the mean and 
SEM of three independent experiments and values are the mean absorbance 
of three replicate wells minus the absorbance of an isotype matched control 
antibody.   
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4.3 Expression of CLEVER-1 in HSEC and its response to 
growth factor stimulation. 
The growth factors VEGF and HGF are known to be important in the 
crosstalk between sinusoidal endothelial cells and hepatocytes within the 
liver (LeCouter et al., 2003) and we use them to maintain the phenotype of 
HSEC in vitro.  Since these factors would be present in the in vivo 
environment in which HSEC reside we investigated whether they contribute 
to CLEVER-1 expression in vitro by ELISA.    Figure 4-4, demonstrates that 
treatment of HSEC for 24 hrs with 10ng/ml HGF significantly increased the 
expression of CLEVER-1.  Although VEGF on its own had no discernible 
effect the combination of HGF plus VEGF appeared more potent than HGF 
alone at upregulating CLEVER-1 expression. 
. 
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Figure 4-4 Hepatocyte growth factor Increases CLEVER-1 protein 
expression 
ELISA data comparing the levels of CLEVER-1 protein in unstimulated to 
hepatocyte growth factor (HGF) and vascular endothelial growth factor 
(VEGF) stimulated HSEC.  Data are the mean of three independent 
experiments and values are the mean absorbance of three replicate wells 
minus the absorbance of an isotype matched control antibody : **p<0.005 
(Student’s T test).  Cells were stimulated with 10ng/ml of growth factor for 24 
hrs.  
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4.4 Quantitative analysis of CLEVER-1 mRNA levels in 
HSEC. 
Having demonstrated CLEVER-1 protein expression in HSEC we next 
studied the regulation of CLEVER-1 at the messenger RNA level using 
quantitative real time PCR.   
4.4.1 Response to cytokine stimulation 
HSEC were stimulated with the same panel of cytokines for 24 hours TNFα, 
IFNγ, IL-4, LPS, and IL-10).  In support of our ELISA data, initial analysis of 
mRNA levels did not demonstrate any consistent responses to cytokine 
stimulation.   
However the HSEC used for these experiments had been isolated from two 
broad groups of liver tissue:  HSEC isolated from ‘normal livers’ (donor livers, 
resection margins) and HSEC isolated from explanted livers from patients 
with end-stage liver disease.  Upon analysis of these two groups separately it 
appeared that the cells responded differently to cytokine stimulation.  The 
trend in HSEC from ‘normal’ livers was for TNFα stimulation to increase 
CLEVER-1 expression, in contrast IFNγ treatment led to a downregulation in 
expression whereas the opposite responses were seen in HSEC from 
diseased livers (Figure 4-5).  A possible explanation for these differential 
responses could be that ‘diseased’ HSEC were primed to respond because 
of their exposure to inflammatory signals in vivo thus requiring shorter 
periods of stimulation.  I therefore compared 4 and 24 hour stimulations with 
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TNFα.   The response to cytokine stimulation showed the same pattern when 
4 hours was compared to 24 hour incubation (Figure 4-6), suggesting that the 
differences in ‘normal’ and ‘diseased’ HSEC were unlikely due to priming in 
vivo.  
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Figure 4-5 CLEVER-1 mRNA Expression in HSEC under cytokine 
stimulation 
Relative expression of CLEVER-1 mRNA in cytokine treated HSEC 
compared to unstimulated HSEC.  HSEC in these experiments were isolated 
from (A) Normal liver tissue or (B)  explanted livers from patients chronic liver 
disease.  The data are the mean of at three independent experiments.  : 
*p<0.05 (Students T test).  Cells were stimulated with cytokines for 24 hours. 
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Figure 4-6 Comparison of CLEVER-1 mRNA expression in HSEC from 
normal and diseased livers 
Representative experiments comparing CLEVER-1 expression in response to 
TNFα stimulation over time in HSEC from normal and diseased livers.  Data 
shown are results of one isolation from each condition. 
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4.4.2 Response to hypoxia, bile acids and growth factors. 
Our data so far suggested that unlike conventional adhesion molecules, 
CLEVER-1 expression was not increased by cytokine stimulation of HSEC.  
Therefore other factors which are characteristic of the hepatic 
microenvironment were studied for their influence on CLEVER-1 expression.  
These factors included the impact of hypoxia, since a significant proportion of 
hepatic blood supply arises from the portal vein and Zone 3 of the hepatic 
sinusoids is more ‘hypoxic’ than the portal areas where blood enters the 
sinusoids; and stimulation by bile acids.  
 We exposed cultures of HSEC from different livers to 0.1% oxygen for 24 
hours and saw no consistent changes in CLEVER-1 mRNA.  This is 
illustrated in Figure 4-7 where CLEVER-1 expression was downregulated in 
HSEC isolates from a normal resection and an autoimmune hepatitis liver but 
upregulated in HSEC isolates from primary bilary cirrhosis and primary 
sclerosing cholangitis.  It is possible that HSEC from biliary diseases show 
different responses to hypoxia compared with other aetiologies and given 
more time I would have explored this further. 
Similarly stimulation of HSEC with bile acids for 24 hours also had variable 
results on CLEVER-1 mRNA expression.  As seen with hypoxia, the 
responses in HSEC from biliary diseases were different with suppressed 
CLEVER-1 mRNA in response to bile stimulation (Figure 4-8).  Interestingly 
the cells isolated from a PBC liver showed complete downregulation of 
CLEVER-1 after treatment. 
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In contrast to hypoxia and bile acids however, growth factor stimulation had a 
consistent and reproducible effect on CLEVER-1 mRNA expression 
regardless of the origin of the HSEC.  As discussed in section 2.2.4 isolated 
HSEC are cultured in a combination of VEGF and HEGF.  Comparison was 
made of the expression of CLEVER-1 in HSEC cultured in media 
supplemented with growth factors and cells cultured for 24 hours in media 
without growth factors.  A consistent reduction of CLEVER-1 expression in 
HSEC from diseased and normal livers was detected in the absence of 
growth factors (Figure 4-9 A).  Further expression analysis of HSEC 
stimulated by HGF or VEGF demonstrated that, in agreement with our ELISA 
data, HGF had the dominant effect on CLEVER-1 expression (Figure 4-9 B). 
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Figure 4-7 CLEVER-1 expression in HSEC in response to Hypoxia 
Relative expression of CLEVER-1 mRNA in HSEC, in each experiment 
HSEC cultured in normoxic conditions were compared to HSEC cultured for 
24 hours in a hypoxic chamber.  Data shown are HSEC from one isolation 
from each condition.  PSC – Primary Sclerosing Cholangitis, PBC- Primary 
Biliary Cirrhosis 
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Figure 4-8 CLEVER-1 expression in HSEC in response to bile 
Relative expression of CLEVER-1 mRNA in HSEC, in each experiment 
HSEC were cultured in media were compared to HSEC cultured in media 
supplemented with Bile for 24 hours. Data shown are HSEC from one 
isolation from each condition PBC- Primary Biliary Cirrhosis 
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Figure 4-9 Hepatocyte growth factor upregulates CLEVER-1 mRNA 
expression 
A- Relative expression of CLEVER-1 mRNA in HSEC cultured in media with 
or without growth factor supplementation.  The mean and SEM of three 
independent experiments are shown:* p<0.05 (Student’s T test).  B- Relative 
expression of CLEVER-1 mRNA in HSEC cultured in media without growth 
factor supplementation or with either hepatocyte growth factor (HGF) or 
vascular epidermal growth factor (VEGF).  The mean and SEM of four 
experiments are shown :* p<0.05 (Student’s T test) Growth Factor (GF). 
Cells were stimulated with growth factors for 24 hours.  
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4.5 The trafficking of CLEVER-1 
Our preliminary data suggested that HSEC constitutively express CLEVER-1 
at protein and RNA level and that expression was regulated by growth factors 
(HGF), with no consistent response to cytokines. The nature of the response 
to cytokine stimulation appeared to vary dependent on the origin of the 
HSEC. We considered it possible that our results may be complicated by 
altered trafficking of CLEVER-1 in the cells and by the generation of soluble 
CLEVER-1.  Previous studies in sinusoidal endothelial cells have shown that 
the majority of intracellular CLEVER-1 is membrane anchored with no 
evidence of secretion of a soluble form.  The receptor appears to undergo 
constitutive recycling between the plasma membrane and early endosomes 
in cultured human sinusoidal endothelial cells (Prevo et al., 2004).    A further 
study investigated the role of CLEVER-1 and its close homologue, Stabilin-2, 
in rat liver sinusoidal endothelial cells.  Both receptors were found in early 
endosomes and their association with clathrin and adaptor protein 2 (AP-2) 
suggested a role in receptor mediated endocytosis (Hansen et al., 2005b). 
Thus we decided to use our cultured HSEC to study the intracellular 
localisation of CLEVER-1 in more detail in human cells. The aims of these 
studies were to determine the intracellular trafficking and localisation of 
CLEVER-1 in HSEC using agents that block receptor re-cycling.  
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4.6 The regulation of intracellular trafficking and surface 
expression of CLEVER-1. 
Localisation of CLEVER-1 was studied by immunofluoresence and confocal 
microscopy.  HSEC stimulated by inflammatory cytokines were studied for 
any alteration of CLEVER-1 distribution.  Our fluorescent micrographs 
suggest that CLEVER-1 resides in the cytoplasm of unstimulated cells and 
has a ‘granular’ distribution, and that stimulation with TNFα had no effect on 
this distribution pattern  (Figure 4-10).  Although our ELISA and Quantitative 
PCR had demonstrated that CLEVER-1 expression was upregulated by 
growth factors, growth factor stimulation did not appear to alter CLEVER-1 
distribution (Figure 4-10).    
In order to determine whether there is a rapid recycling of CLEVER-1 from 
the cell surface to the cytoplasm of HSEC, live cells were incubated with 
CLEVER-1 antibody followed by fixation and fluorescent staining.  The 
cytoplasmic pattern of staining observed suggests that CLEVER-1 bound to 
antibody was internalised from the cell surface and that this occurred within 
15 minutes (Figure 4-11). 
In order to further characterise the localisation of the cytoplasmic pool of 
CLEVER-1 we treated the cells with bafilomycin A1.  This is a macrolide 
which is a highly specific inhibitor of vacuolar type H+-ATPase and has been 
shown to block endocytic transport (Bayer et al., 1998).  Previous groups 
have colocalised CLEVER-1 with early endosomes (Hansen et al., 2005b).  
HSEC were treated with Bafilomycin A1 for 24 hours to asses if it altered 
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CLEVER-1 localisation and influenced surface expression.  After treatment 
the receptor remained predominantly intracellular (Figure 4-12) but was seen 
to aggregate in large vesicles.  There did not appear to be any increase in 
surface expression after treatment.  Dual colour immunofluoresence and 
confocal microscopy were then used to colocalise CLEVER-1 with subcellular 
organelles.  CLEVER-1 did not colocalise with early or late endosome 
markers (Figure 4-13) but further analysis demonstrated colocalisation with 
the Golgi Apparatus and the Trans Golgi Network of HSEC (Figure 4-14).    
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Figure 4-10 Stimulation of HSEC with cytokines or growth factors does 
not alter CLEVER-1 localisation 
These panels show representative confocal images of HSEC grown on 
coverslips and stained for the CLEVER-1 receptor under, resting conditions, 
TNFα stimulation for 2 and 24 hours and growth factor stimulation.  CLEVER-
1 is shown with a FITC secondary and the nucleii are stained with dapi (blue) 
Isotype matched controls were negative. Fields captured with 63x objective. 
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Figure 4-11 CLEVER-1 internalises antibody from HSEC cell surface 
within 15 minutes 
HSEC were incubated with CLEVER-1 antibody or isotype matched control 
for 15 or 30 minutes.  Following incubation HSEC were fixed, permeabilised 
and stained with fluorescent secondary (Alexafluor 546).  Confocal images 
taken of HSEC incubated with 3-372 for 15 minutes (Panel A), 3-372 for 30 
minutes (Panel B) and isotype matched control for 30 minutes (Panel C).  
Nucleii are stained with DAPI (blue).  Fields captured with 63xobjective.  
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Figure 4-12 Bafilomycin A1 treatment alters CLEVER-1 trafficking in 
HSEC 
Representative confocal images of HSEC stained for CLEVER-1.  Panel A 
shows untreated cells. Panel B shows cells treated with 10 nanomolar 
bafilomycin A1 for 24 hours.  Experiments were performed on three separate 
isolates.  CLEVER-1 is shown with a FITC secondary and the nucleii are 
stained with dapi (blue). Isotype matched controls were negative.  Fields 
captured with 63x objective. 
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Figure 4-13 CLEVER-1 does not colocalise with endosomes or 
lysosomes in Bafilomycin treated HSEC 
Representative confocal images of Bafilomycin A1 treated HSEC. Panel A 
shows dual colour immunofluorescence for CLEVER-1(red) and the early 
endosome marker Rab 5 (green).  Panel B shows dual colour 
immunofluorescence for CLEVER-1 (red) and late endosome marker LAMP-
1(green).  Nuclei are stained with dapi (grey).  Isotype matched controls were 
negative.  Fields captured with 63x objective. 
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Figure 4-14 CLEVER-1 colocalises with Golgi and Trans Golgi markers 
in Bafilomycin treated HSEC 
Representative confocal images of Bafilomycin A1 treated HSEC. Panel A 
shows dual colour immunofluorescence for CLEVER-1 (red) and Golgi lectin 
marker(green).  Panel B is a profile image of the red line in Panel A .  Panel 
C shows dual colour immunofluorescence for CLEVER-1(red) And Trans 
Golgi network marker TGN46 (green).  Panel D is a profile image of the red 
line in panel C. Isotype matched controls were negative. INT= Fluorescent 
intensity. Fields captured with 63x objective. 
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4.7 Summary of regulation studies 
These studies investigated the expression and trafficking of CLEVER-1 in 
response to cytokine stimulation.  It was not possible to increase CLEVER-1 
protein expression in HSEC by pro-inflammatory cytokines or by TGFβ, IL-10 
or IL-4.  Although I saw some intriguing responses in some disease groups to 
hypoxic conditions or exposure to bile acids these were not consistent and 
will require further investigation to either confirm or refute.   In contrast, we 
found a consistent upregulation of CLEVER-1 with HGF stimulation which, to 
our knowledge, has not been described previously.   Bafilomycin had a 
profound effect on CLEVER-1 intracellular localisation leading to aggregation 
of receptor in large vesicles that colocalised with the trans Golgi network and 
the Golgi Apparatus.  Previous studies in alternatively activated human 
macrophage populations studies have also detected CLEVER-1 in the trans 
Golgi network (Kzhyshkowska et al., 2004).  
I used cell based ELISA to study CLEVER-1 protein expression and in these 
assays the HSEC are permeabilised and the assays therefore measure total 
CLEVER-1 expression (ie membranous and intracellular).  We were able to 
confirm constitutive expression of CLEVER-1 in HSEC but we could not 
significantly upregulate this basal level of expression.  Thus CLEVER-1 does 
not behave like conventional adhesion molecules such as ICAM-1 or VCAM-
1 which are markedly upregulated by pro-inflammatory cytokines.    Previous 
studies in lymphatic endothelium have demonstrated modest increases with 
LPS treatment (Salmi et al., 2004), but we did not find this with HSEC.  This 
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may be due to the fact that HSEC in vivo are continuously exposed to LPS 
and therefore have a altered responsiveness to LPS challenge (Crispe, 
2009).   
IL-4, which is known to induce CLEVER-1 expression in macrophages 
(Goerdt et al., 1993) and increases the expression of other C-type lectins 
such as L-SIGN on HSEC, had no effect on CLEVER-1 (Lai et al., 2006). 
This is consistent with studies in lymphatic endothelium where IL-4 has no 
effect (Prevo et al., 2004).   This confirms that the pathways which lead to 
CLEVER-1 upregulation in macrophages do not operate in endothelial cells 
and in addition that its regulation differs from other C-type lectins. 
HSEC isolated from normal and diseased liver expressed similar levels of 
CLEVER-1 protein, but difference in response to cytokines were seen using 
quantitative PCR studies.  Whereas there was a trend for TNFα to increase 
CLEVER-1 mRNA in ‘normal’ HSEC, the opposite was seen in ‘diseased’ 
HSEC.  This could reflect the desensitisation of ‘diseased’ HSEC after 
prolonged exposure to inflammatory cytokines in vivo however the changes 
were small and were not associated with significant changes in protein 
casting doubt on their significance.   
ELISA studies and quantitative PCR both demonstrated that HGF 
supplementation led to an induction of CLEVER-1 expression in HSEC.  This 
was a consistent finding in HSEC isolates from normal and diseased livers.  
HGF was the growth factor which had the dominant effect on CLEVER-1 
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expression rather than VEGF.  HGF potentially contributes to the expression 
of CLEVER-1 in vivo, this is discussed in more detail in section 6.2.   
ELISA and PCR studies allow the assessment of total protein and mRNA 
expression respectively, but they give no information on the cellular 
localisation of receptors.  Confocal microscopy allowed detailed analysis of 
CLEVER-1 localisation in isolated HSEC.  These studies demonstrated that 
CLEVER-1 was predominantly intracellular in isolated HSEC.  A striking 
feature was the response to Bafilomycin A1 which led to CLEVER-1 densely 
aggregating in vesicles confirming that CLEVER-1 does have clear trafficking 
properties within HSEC.    
Despite attempted stimulation with various factors we could not increase the 
surface expression of CLEVER-1 on HSEC, other groups have also found it 
difficult to consistently upregulate CLEVER-1 on the surface of human 
lymphatic endothelial cells (Prevo et al., 2004; Salmi et al., 2004).  This low 
surface expression could be explained by CLEVER-1’s trafficking behaviour 
with CLEVER-1 rapidly moving from the plasma membrane back to 
intracellular organelles.    We demonstrated this by showing the rapid uptake 
of CLEVER-1 antibody by cultured HSEC. 
The studies in this chapter have attempted to understand the regulation of 
CLEVER-1 in human HSEC.  In the next chapter we attempt to investigate 
the functional properties of CLEVER-1 in the context of lymphocyte 
recruitment to HSEC.   
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CHAPTER 5   
THE FUNCTIONAL ROLE OF CLEVER-1 IN HUMAN 
HEPATIC SINUSOIDAL ENDOTHELIUM 
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My expression studies demonstrate that CLEVER-1 is expressed at 
important sites of lymphocyte recruitment in the normal and chronically 
inflamed human liver, especially the hepatic sinusoids, neovessels within the 
fibrous septum and the vessels within portal associated lymphoid tissue.  My 
regulation studies confirm that CLEVER-1 is a trafficking receptor within 
HSEC moving from the plasma membrane to intracellular compartments and 
within the cells to the trans golgi network, which is similar to the trafficking of 
CLEVER-1 reported in macrophages (Kzhyshkowska et al., 2004).  In terms 
of function, CLEVER-1 has been shown to mediate lymphocyte recruitment 
to lymphatic endothelium and lymphatic vessels in both in vitro and in vivo 
studies (Karikoski et al., 2009b; Salmi et al., 2004).  Since lymphatic 
endothelium shares several phenotypic features with hepatic sinusoidal 
endothelium, including the expression of CLEVER-1, we hypothesised that 
CLEVER-1 would mediate lymphocyte recruitment to the liver via hepatic 
sinusoidal endothelium. To study the role of this trafficking receptor in 
lymphocyte recruitment to the human liver I used static adhesion assays to 
assay binding to intact vessels in tissue sections and to elucidate its role in 
the adhesion cascade I used flow-based adhesion assays incorporating 
HSEC monolayers.  The aim of my functional assays were to: 
Determine whether CLEVER-1 supports lymphocyte adhesion to hepatic 
endothelium and if so to determine the lymphocyte subsets involved and the 
precise role of CLEVER-1 in the adhesion cascade. 
To do this I  
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1. Used modified Stamper Woodruff assays to study lymphocyte 
adhesion to CLEVER-1 in liver tissue. 
2. Used flow based adhesion assays to study the role of CLEVER-1 in 
peripheral blood lymphocyte recruitment to HSEC. 
3. Investigated if CLEVER-1 preferentially recruits subsets of 
lymphocytes by studying purified populations of CD4+, CD8+ and B 
lymphocytes under conditions of flow. 
5.1 Static adhesion assays 
My earlier expression studies had demonstrated CLEVER-1 expression in 
the sinusoids of normal liver and showed discreet areas of increased 
endothelial expression in both parenchymal and biliary liver disease.  I 
therefore performed static adhesion assays on chronically inflamed liver 
tissue and assessed lymphocyte binding to parenchymal regions.  Modified 
Stamper Woodruff assays were used incorporating tissue sections from 
explanted livers from patients with chronic liver disease (including alcoholic 
liver disease n=2, autoimmune liver disease n=1, primary sclerosing 
cholangitis n=4, primary biliary cirrhosis n=2).  These assays demonstrated a 
significant reduction in lymphocyte binding to hepatic tissue with CLEVER-1 
antibody blockade.  The number of adherent lymphocytes per high power 
field in control sections was 6.9 ± 2.5 cells compared to 4.6 cells ± 1.9 cells 
after CLEVER-1 blockade.   This translated to a 30% reduction of lymphocyte 
binding when CLEVER-1 blockade was compared to isotype matched control 
Figure 5-1.    
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5.2 Flow-Based Adhesion Assays 
The static adhesion assays described above allowed me to study the function 
of CLEVER-1 within liver tissue and confirm that it could support lymphocyte 
adhesion to endothelium within the liver parenchyma.  However these simple 
static adhesion assays do not clarify the specific role CLEVER-1 plays in the 
adhesion cascade.  Flow assays allow the study of lymphocyte endothelial 
interactions under conditions of physiological shear stress.  We recapitulate 
the hepatic sinusoids by culturing HSEC in glass capillaries and then 
lymphocytes are perfused over this monolayer of cells at a rate of flow 
calculated to reproduce the shear stress within hepatic sinusoids.  The shear 
stress is a stress that is applied parallel or tangential to a surface as opposed 
to normal stress which is perpendicular.  Any fluid that is moving along a 
boundary will exert a shear stress on that boundary.   Shear stress has been 
shown to be an essential component of lymphocyte transmigration across 
endothelium (Cinamon et al., 2001). The flow rate of the assays used for the 
experiments described here was set to generate a shear stress of 0.5 
dyne/cm2, to reflect the stress within the hepatic sinusoids.   
Initial flow assays were carried out with HSEC grown in microslides, these 
have been used by our group previously to study the role of ICAM-1 and 
VAP-1 in lymphocyte recruitment (Lalor et al., 2002a) .  Additionally, to 
perform multiple blocking assays HSEC were grown in Ibidi µ slide VI 
chamber slides where 6 parallel microchannels are mounted in one slide.  
This allowed assays on the same isolate of HSEC to be performed 
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consecutively with minimal handling and delay.  When I commenced my 
experiments Ibidi slides had not been routinely used in flow assays by our 
group and so an initial comparison was made with conventional microslides.  
Here HSEC were cultured in both types of slides and flow assays were 
performed using peripheral blood lymphocytes with either unstimulated 
HSEC or HSEC stimulated with TNFα and IFNγ for 24 hours.  These 
experiments confirmed that lymphocytes did not bind to unstimulated HSEC 
cultured in either slide type but underwent tethering, firm adhesion and 
transmigration across cytokine stimulated HSEC in both types of microslides.   
Essentially the adhesive behaviour was the same in either culture system, 
although we noted a reproducible but small reduction in the total number of 
adherent cells binding to HSEC in ibidi slides in comparison to conventional 
microslides (Figure 5-2)   
 
 
 
 
 
 
 
190 
 
 
 
Figure 5-1 CLEVER-1 mediates the adhesion of lymphocytes to liver 
tissue 
Peripheral blood lymphocytes (1 x106/ml) were adhered to liver sections 
under static conditions. Prior to adhesion sections were blocked with 
CLEVER-1 antibody (3-372 20µg/ml or isotype matched control (IMC).  A 
significant reduction in lymphocyte adhesion per high power field was seen 
with CLEVER-1 blockade compared to IMC.  Mean and SEM of 9 
experiments are shown : ** p<0.005 (Student’s T test). 
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Figure 5-2 Flow based adhesion assays in microslides and Ibidi 
chamberslides 
HSEC were cultured in microslides and Ibidi chamberslides and flow 
adhesion assays were performed with peripheral blood lymphocytes 
(1x106/ml) perfused at the same shear stress of 0.05 Pa.  The figure 
compares the adherence of lymphocytes to monolayers of untreated or 
cytokine stimulated HSEC in both types of slide. Data shown is for one assay 
for each condition. Cells were treated with interferon γ and TNFα  at 10ng/ml 
for 24 hours. 
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5.2.1 The role of CLEVER-1 in peripheral blood lymphocyte recruitment 
via HSEC  
Next, I carried out flow based adhesion assays on HSEC to elucidate the 
exact role CLEVER-1 played in the adhesion cascade.  Initial experiments 
used peripheral blood lymphocytes isolated from whole blood.  As before, 
HSEC under resting conditions did not support lymphocyte recruitment from 
flow and cytokine stimulation was required prior to lymphocyte perfusion 
(Lalor et al., 2002a) to allow adhesion. Therefore HSEC monolayers were 
stimulated with TNFα and interferonγ for 24 hours prior to assays.  We have 
previously shown that <10% of adherent lymphocytes persistently roll over 
stimulated HSEC in these assays, and the majority of adherent cells at any 
one time will be arrested on the endothelium with a proportion of these cells 
then undergoing transendothelial migration.  Interestingly, the presence of a 
blocking antibody against CLEVER-1 led to a significantly larger proportion of 
lymphocytes exhibiting persistent rolling across the HSEC monolayer (Figure 
5-3).  CLEVER-1 blockade did not alter the total adherence of lymphocytes to 
HSEC but it significantly reduced the proportion of adherent lymphocytes 
undergoing transendothelial migration compared to an isotype matched 
control (Figure 5-4).  Since our previous quantititative PCR experiments had 
demonstrated differential regulation of CLEVER-1 in HSEC from normal and 
diseased livers it was important to study CLEVER-1 function in HSEC from 
these two groups of livers.  However, flow assays using diseased and 
‘normal’ HSEC did not show a difference in the contribution of CLEVER-`1 to 
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transmigration, with approximately 25% of transmigration events being 
inhibited on both normal and diseased HSEC after blockade (Figure 5-5). 
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Figure 5-3 CLEVER-1 blockade increases the proportion of peripheral 
blood lymphocytes that roll across HSEC 
Peripheral blood lymphocytes (1x106/ml) were perfused across cytokine 
treated HSEC monolayers (24 hour stimulation) at a shear stress of 0.05Pa.  
HSEC monolayers were blocked with CLEVER-1 antibody (3-372 20µg/ml) or 
an isotype matched control prior to assay.  A larger proportion of adherent 
lymphocytes that were rolling in the presence of CLEVER-1 blockade 
compared to an isotype matched control.  Mean and SEM of 5 experiments 
are shown (Student’s T test).   
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Figure 5-4 CLEVER-1 mediates the transendothelial migration of 
peripheral blood lymphocytes across HSEC 
The number of adherent, shapechanged and transmigrated cells were 
enumerated after flow assays performed at a shear stress of 0.05 Pa.  Panel 
A demonstrates that CLEVER-1 blockade significantly reduced 
transmigration.  The results are expressed as a percentage of binding when 
compared to isotype matched control (IMC) and are a mean and SEM of six 
independent experiments: *p<0.05 (Student’s T test).  Panel B shows the 
percentage of adherent cells that transmigrated across HSEC in each 
experiment comparing CLEVER-1 to IMC. 
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Figure 5-5 Comparison of CLEVER-1 blockade in normal and diseased 
HSEC 
The proportion of adherent cells that underwent transmigration were 
enumerated after flow assays performed at a shear stress of 0.05 Pa.  
Comparison is made with flow assays performed with cytokine treated (24 
stimulation) normal HSEC and diseased HSEC.  The results are expressed 
as a percentage compared to isotype matched control and are a mean and 
SEM of four independent experiments: *p<0.05, **p<0.005(Student’s T test). 
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5.2.2 Comparison of CD4 and CD8 Subsets 
As discussed in section 1.4, the peripheral blood lymphocyte population is 
comprised of a range of subsets and there is evidence that these subsets 
can respond to different signals during recruitment to tissue.  To study 
whether CLEVER-1 preferentially recruited a specific subset I isolated the 
major subsets of lymphocytes from whole blood and then performed flow 
based adhesion experiments with each group. I began by purifying CD4+ 
lymphocytes, and CD8+ lymphocytes from whole blood using magnetic bead 
selection kits.  Typical isolations yielded cells with a purity for CD4+ and 
CD8+ cells of 95% and 94% respectively (Figure 5-6).  
Flow assays with these two subsets demonstrated similar levels of absolute 
binding: total adhesion of CD4 lymphocytes was 124 ± 32 cells/mm2/106; 
total adhesion of CD8 lymphocytes was 160 ± 15 cells/ mm2/106.   Blockade 
of CLEVER-1 in flow assays with purified CD4+ lymphocytes demonstrated  
no effect on the firm adhesion of these cells but led to a significant reduction 
in the proportion of adherent cells that underwent transendothelial migration 
(Figure 5-7).  In contrast, in flow assays with purified CD8+ lymphocytes  
CLEVER-1 blockade had no effect transendothelial migration (Figure 5-8), 
although we noted a modest but statistically insignificant increase in 
adhesion and the proportion of shape-changed cells after blockade. 
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Figure 5-6 Isolation of CD4 and CD8 lymphocytes from whole blood 
using negative selection Dynabeads ® kits 
Peripheral blood lymphocytes were purified for CD4 and CD8 lymphocyte 
fractions for use in flow adhesion assays.  Purity was assessed by flow 
cytometry. The CD4 lymphocyte fractions were 95% pure (Panel A) and CD8 
lymphocytes were 94% pure (Panel B). 
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Figure 5-7 CLEVER-1 mediates CD4 transmigration across HSEC under 
conditions of flow. 
The number of adherent, shapechanged and transmigrated cells were 
enumerated after flow assays.  Panel A demonstrates that CLEVER-1 
blockade using 20µg/ml of 3-372 mAb significantly reduced transmigration.  
The results are expressed as a percentage of binding when compared to an 
isotype matched control (IMC) and are a mean and SEM of four independent 
experiments: *p<0.05(Student’s T test).  Panel B shows the percentage of 
adherent cells that transmigrated across HSEC in each experiment 
comparing CLEVER-1 to IMC. (Shear stress 0.05 Pa).   
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Figure 5-8 CLEVER-1 does not mediate CD8 transmigration across 
HSEC under conditions of flow 
The number of adherent, shapechanged and transmigrated cells were 
enumerated after flow assays.  Panel A demonstrates that CLEVER-1 
blockade, 20µg/ml of mAb 3-372, had no effect on lymphocyte firm adhesion, 
shapechange/activation or transmigration.  Results expressed as a 
percentage of binding compared to isotype matched control (IMC) and are a 
mean and SEM of four independent experiments (Student’s T test).  Panel B 
shows the percentage of adherent cells that transmigrated across HSEC in 
each experiment comparing CLEVER-1 to IMC.  (Shear stress 0.05 Pa). 
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5.2.3 Regulatory T cells and Effector CD4 lymphocytes 
In view of the finding that CLEVER-1 preferentially recruited CD4 
lymphocytes I analysed CD4 lymphocyte subsets.  Section 1.4.2 discusses 
the separate CD4 subsets and their functions in details, but they can be 
broadly divided into two groups: the effector group and the suppressor group 
(T regulatory cells).  The effector group is characterised by low levels of cell 
surface IL-2 receptor (CD25) expression on their surface whereas the T 
regulatory (Treg) are known to express CD25.  These differences in receptor 
expression were used to isolate the two populations from whole blood using 
a magnetic bead selection kit.  The CD25 positive population expressed 
FOXP3 at high levels (Figure 5-9) confirming that this was the suppressor 
population.  I performed flow adhesion assays with these two populations 
and assessed the effect of CLEVER-1 blockade.  The two subpopulations 
demonstrated similar levels of absolute binding: total adhesion of CD4 
effector lymphocytes was 148 ± 38 cells/mm2/106; total adhesion of Tregs  
was 138 ± 13 cells/ mm2/106. CLEVER-1 blockade significantly reduced the 
proportion of Treg cells undergoing transendothelial migration (Figure 5-10).  
In contrast, CLEVER-1 blockade did not significantly reduce the proportion of 
CD4 effector cells undergoing transendothelial migration, an increase in the 
proportion of shapechanged cells was noted but this was not significant 
(Figure 5-11).   
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Figure 5-9 T regulatory cell isolation from whole blood with CD4+CD25+ 
Dynabead® kit 
Peripheral blood lymphocytes were purified for T regulatory cells.  The 
isolated lymphocytes were 95% pure for CD4+CD25+ cells (Panel A). Within 
the CD4+CD25+ population, 84% expressed FoxP3 and were negative for 
CD127 (Panel B).  In total, 87% CD4+CD25+ population expressed FoxP3. 
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Figure 5-10 The effect of CLEVER-1 blockade on Treg adhesion to HSEC 
under conditions of flow 
The number of adherent, shapechanged and transmigrated cells were 
enumerated after flow assays (shear stress 0.05 Pa).  Panel A demonstrates 
that CLEVER-1 blockade, 20µg/ml of 3-372, significantly reduced 
transmigration.  The results are expressed as a percentage of binding when 
compared to isotype matched control (IMC) and are a mean and SEM of 
three independent experiments: p<0.05 (Student’s T test).  Panel B shows 
the percentage of adherent cells that transmigrated across HSEC in each 
experiment comparing CLEVER-1 blockade to IMC.   
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Figure 5-11 The effect of CLEVER-1 blockade on CD4 effector cell 
adhesion to HSEC under conditions of flow 
The number of adherent, shapechanged and transmigrated cells were 
enumerated after flow assays (shear stress 0.05 Pa).  Panel A demonstrates 
that CLEVER-1 blockade, 20µg/ml 3-372, had no effect on lymphocyte firm 
adhesion or transmigration.  Results expressed as a percentage of binding 
when compared to isotype matched control (IMC) and are a mean and SEM 
of three independent experiments (Student’s T test).  Panel B shows the 
percentage of adherent cells that transmigrated across HSEC in each 
experiment comparing CLEVER-1 blockade to IMC.  
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5.2.4 The molecular mechanisms of T regulatory cell transmigration 
across HSEC 
The flow assays with CD4 subsets suggested that CLEVER-1 was involved 
in the transmigration of T regs across hepatic sinusoidal endothelium.  I then 
proceeded to study the molecular mechanisms of Treg transendothelial 
migration through hepatic sinusoidal endothelium in more detail and 
examined the interplay of CLEVER-1 with other molecules.  Our group has 
previously published that VAP-1, ICAM-1 and the chemokine receptor 
CXCR3 are all involved in lymphocyte transendoethelial migration across 
HSEC (Curbishley et al., 2005; Lalor et al., 2002a).  They have also reported 
roles for CCR4 and in some cells CCR10 in recruitment of Tregs beyond the 
endothelium into the liver (Eksteen et al., 2006; Oo et al., 2010).  In contrast 
there is limited information on the adhesion molecules specifically utilised by 
Tregs.  Thus I concentrated on the transmigration of Tregs and studied the 
effects of CLEVER-1 blockade in combination with ICAM-1 and VAP-1, two 
well known mediators of T cell transmigration across HSEC (Lalor et al., 
2002a).  It has been previously published that VCAM-1 predominantly 
mediates the capture and adhesion of Tregs on HSEC (Oo et al., 2010).  In 
support of this, my experiments involving blockade of ICAM-1, VAP-1 and 
CLEVER-1 showed that these receptors did not play a significant role in the 
capture and adhesion of the Tregs (Figure 5-12).  However, further analysis 
demonstrated that the blockade of each receptor led to a decrease in the 
proportion of adherent cells undergoing transendothelial migration and the 
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blockade of all three receptors in combination led to a cumulative effect 
(Figure 5-13).   
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Figure 5-12 ICAM-1, CLEVER-1 and VAP-1 do not mediate the adhesion 
of T regulatory cells to HSEC under conditions of flow 
The number of adherent cells on cytokine treated HSEC were enumerated 
from flow assays (shear stress of 0.05 Pa) after pretreatment with blocking 
antibodies to ICAM-1, CLEVER-1 and VAP-1 and the three receptors in 
combination.  Results were normalized to adherent cells per mm2 per 106 
cells.  Results were compared to an isotype matched control (IMC) and are 
the mean of three independent experiments and SEM.    
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Figure 5-13 ICAM-1, CLEVER-1 and VAP-1 mediate the transendothelial 
migration of T regulatory cells across HSEC under conditions of flow 
The transmigration of Tregs across cytokine treated HSEC under conditions 
of flow (shear stress of 0.05 Pa) is shown with prior blockade of ICAM-1, 
CLEVER-1, VAP-1 and all three receptors in combination.  Adherence is 
compared to an isotype matched control and data is expressed as the 
proportion of firmly adherent lymphocytes which underwent transmigration.  
Mean and SEM are shown of three independent experiments. *p<0.05 
(Student’s T test). 
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5.2.5 The recruitment of B cells 
We also investigated the role of CLEVER-1 in the recruitment of B 
lymphocytes.  B cells are implicated in the pathogenesis of liver disease 
(discussed in section1.7.3) but there is a paucity of literature regarding the 
recruitment of B cells to the liver via hepatic sinusoidal endothelium.  I used 
the flow assays to systematically determine the molecules involved in B cell 
adhesion to and migration across HSEC.    B cells were isolated from whole 
blood using magnetic bead selection with a purity of 98% (Figure 5-14).  
Experiments were carried out in which antibodies were used to block the 
conventional adhesion receptors VCAM-1 and ICAM-1 and the 
unconventional adhesion molecules VAP-1 and CLEVER-1 blockade.  The 
contribution of chemokines was assessed by using pertussis toxin treatment 
of B cells to inhibit G-protein coupled chemokine receptors.  Flow assays 
were performed under the conditions described above with TNFα and IFNγ 
treated HSEC and a shear stress of 0.05Pa.   
 In contrast to T cells, B cells did not undergo even a brief rolling/tethering  
step prior to firm adhesion on HSEC.  The primary mediator of B cell firm 
adhesion was VCAM-1, with no significant role for the other molecules 
(Figure 5-15).  Analysis of the transmigration step demonstrated that a 
smaller proportion of adherent B cells underwent this step in comparison to T 
cells (proportion of B cells undergoing transmigration 7.6± 0.5% vs CD4 cells 
25 ± 5%).  Additionally, transmigration of B cells was reduced by ICAM-1, 
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CLEVER-1, VAP-1 and pertussis blockade (Figure 5-16).  Interestingly, 
VCAM-1 did not play a role in the transmigration step for B cells.    
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Figure 5-14 Isolation of B lymphocyte population from whole blood 
using a CD19+ Dynabead ® kit 
Peripheral blood lymphocytes were purified for B cell fractions for use in flow 
adhesion assays.  Purity was assessed by flow cytometry and demonstrated 
a purity of 98%. 
 
 
 
 
 
212 
 
 
 
 
Figure 5-15 B cell adherence to HSEC under conditions of flow 
The number of adherent cells on cytokine treated HSEC were enumerated 
from flow assays (shear stress of 0.05 Pa) after pretreatment with various 
blocking antibodies.  Results were normalized to adherent cells per mm2 per 
106 cells.  Results were compared to an isotype matched control (IMC) and  
are the mean of three independent experiments and SEM: *p<0.05 (Students 
T test).    
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Figure 5-16 B cell transmigration across HSEC under conditions of flow 
The transmigration of B cells across cytokine treated HSEC under conditions 
of flow (shear stress of 0.05 Pa) is shown with prior blockade of various 
receptors.  Adherence is compared to an isotype matched control and data is 
expressed as the proportion of firmly adherent lymphocytes which underwent 
transmigration.  Mean and SEM are shown of three independent 
experiments: *p<0.05 (Student’s T test). 
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5.3 Comparison of B and T cell motility 
Flow adhesion assays had demonstrated differences in B cell recruitment 
when compared to T cells in terms of rolling behaviour, firm adhesion and 
transendothelial migration.  As described in section 1.9.3 the ‘typical’ 
adhesion cascade comprises an additional step of ‘crawling’, which occurs 
once leucocytes have undergone firm adhesion to the endothelial surface.  
Leucocytes can crawl across the apical surface of the endothelial monolayer 
and, if the necessary signals are present, migrate into the subcellular space.  
To investigate this phenomenon we compared the crawling of B cells and T 
cells by using Image J software to manually track each lymphocyte in a field 
of view over a set period of time.  A chemotaxis tool allowed this tracking to 
be plotted graphically.   B cell and T cell behaviour were markedly different: 
while T cells clearly demonstrated the ability to crawl across the endothelial 
surface, B cells demonstrated minimal motility under conditions of flow 
(Figure 5-17).  These data were concordant with the transendothelial 
migration data where T cells exhibited a greater propensity to migrate across 
the endothelial monolayer than B cells under conditions of flow. 
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Figure 5-17 The motility of T and B cells on cytokine treated HSEC under 
conditions of flow. 
B cells and T cells were perfused separately over monolayers of cytokine 
treated HSEC at a shear stress of 0.05 Pa .  Adherent cells within a single 
field were manually tracked over a period of 5minutes using Image J 
software.  Tracking data was analysed using a chemotaxis tool which plotted 
the movement of each T cell (Panel A) and each B cell  (Panel B) from a 
common point.  Each dot is an individual lymphocyte, black labelling 
demonstrates overall movement against the direction of flow and red labelling 
demonstrates overall movement in the direction of flow.    
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5.4 The transmigration of CD4 lymphocytes across HSEC 
Thus far my flow based adhesion assays had demonstrated for the first time 
that CLEVER-1 is involved in the transmigration step of lymphocyte 
recruitment through hepatic sinusoidal endothelium.  Moreover I show a 
marked subset preference for CD4 lymphocytes and B cells.  Transmigration 
is the least well understood step of lymphocyte diapedesis, and so to 
elucidate the role of CLEVER-1 in this process I decided to examine 
transmigration in more detail.   Assays with B cells had shown that only a 
small proportion of adherent cells underwent transendothelial migration.  I 
therefore decided to concentrate on CD4 lymphocyte transmigration across 
HSEC under conditions of flow as an experimental system to investigate 
transendothelial migration.  Initial experiments involved perfusing CD4 
lymphocytes over HSEC monolayers in ibidi chamber slides.  The cells were 
immediately fixed in paraformaldehyde followed by staining with a nuclear 
DAPI stain.  The ibidi slides with adherent cells in situ were then imaged with 
confocal microscopy.   Lymphocyte nuclei could be clearly distinguished from 
HSEC nuclei and there were several examples where lymphocyte nuclei 
were deforming HSEC nuclei suggesting that the attached lymphocytes were 
transmigrating through the endothelial cytoplasm rather than across cell 
junctions distal to the nuclei (Figure 5-18). 
To confirm that CD4 lymphocytes were transmigrating through a transcellular 
route flow assays were repeated using HSEC and CD4 lymphocytes which 
were fluorescently labelled prior to the experiment.  Following perfusion and 
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adhesion of lymphocytes a ‘cell mask’ membrane stain was applied and live 
cell imaging was carried out.  ‘Cell Mask’ probes specifically bind to plasma 
membranes.  They are comprised of amphipatic molecules which have a 
lipophilic moiety and a negatively charged hydrophilic dye.  These properties 
allow membrane loading and anchoring of the probes to the membrane with 
stability for up to 60 minutes.  These probes can be used with live cells and 
therefore were ideal for studying the integrity of cellular boundaries during 
transendothelial migration.   Imaging of these fluorescently labelled cells 
clearly demonstrated transcellular pores within the HSEC surrounding 
transmigrating lymphocytes (Figure 5-19).   
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Figure 5-18 CD4 lymphocyte interaction with HSEC under conditions of 
flow 
Representative confocal images of fixed cells after flow assays (shear stress 
0.05 Pa) performed with CD4 lymphocytes with HSEC monolayers in Ibidi 
chamber slides.  HSEC nucleii (*) can be seen being deformed by 
lymphocyte nucleii (arrows).  Cell nucleii stained with DAPI.  Fields captured 
with 63x objective 
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Figure 5-19 Transcellular migration of CD4 lymphocytes through HSEC 
Live cell imaging of CD4 lymphocytes adhering to HSEC monolayers after 
flow based adhesion assays (shear stress 0.05 Pa) in Ibidi chamberslides.  
Panel A and B demonstrate CD4 lymphocytes forming transcellular pores 
through HSEC monolayers . Panel C is a representative  orthogonal (z stack) 
image of a CD4 lymphocyte transmigrating through the HSEC monolayer.  
HSEC were stained with CFMDA (green), Lymphocytes were stained with 
cell tracker violet (blue) and plasma membranes were stained with cell mask 
(red). Fields captured with 63x objective. 
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5.4.1 Transcellular migration of CD4 lymphocytes and the role of 
ICAM-1 and VAP-1 
It was not possible to ascertain from these initial experiments the proportion 
of CD4 lymphocytes which were transmigrating via the transcellular route.  
To maximise the number of lymphocyte adhesion events to permit more 
detailed characterisation of transmigration we increased the duration of 
perfusion of lymphocytes in flow assays from 5 minutes to 10 minutes.  This 
led to increased numbers of adherent and therefore transmigrating cells.  It 
was possible to image more cells transmigrating and from these experiments 
(Figure 5-20).   We counted the number of CD4 cells undergoing  
transcellular migration and the number which were migrating at junctions in 
each field using z-stack imaging to confirm transendothelial migration.  The 
total numbers could then be expressed as the proportion of cells which took 
either the transcellular route or the paracellular route.  We found that 62% of 
cells (SEM ±6%) underwent transcellular migration and 42% (SEM± 6%) of 
cells underwent paracellular migration.   Data from n=27 fields.   
ICAM-1 is known to play a central role in leucocyte transmigration.  Our 
group has shown previously that ICAM-1 mediates lymphocyte 
transmigration across HSEC, and it has also been shown to mediate 
transcellular leucocyte migration in other endothelial cells (Carman et al., 
2007; Lalor et al., 2002a; Yang et al., 2005).  In view of these findings I 
proceeded to characterise the localisation of ICAM-1 expression in relation to 
the transcellular pores in HSEC.  Flow based assays were repeated with 
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CD4 lymphocytes and, following fixation, immunofluorecent staining for 
ICAM-1was performed as described in section 2.12.  These experiments 
demonstrated an enrichment of ICAM-1 which clearly demarcated the 
borders of the transcellular pores as the CD4 lymphocyte underwent 
transmigration (Figure 5-21).    
As discussed in section 1.10.5, studies have shown that VAP-1 mediates 
transmigration of lymphocytes across HSEC (Lalor et al., 2002a)  I therefore 
studied VAP-1 localisation during transcellular migration using the method 
described above.  These experiments demonstrated colocalisation of VAP-1 
with ICAM-1 during lymphocyte transcellular migration (Figure 5-22). 
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Figure 5-20 CD4 Lymphocytes transmigrate via the paracellular route 
and the transcellular route 
Representative confocal image of CD4 lymphocytes transmigrating across 
HSEC monolayers after flow adhesion assay.  Lymphocytes were perfused 
over a monolayer of HSEC at a shear stress of 0.05 Pa before fixation with 
paraformaldehyde. HSEC were pre-labelled with cell tracker green (Panel A), 
lymphocyte and HSEC nucleii were stained with DAPI (Panel B).  Merged 
image is shown in Panel C, white arrows denoting areas of CD4 transcellular 
migration and red arrows denoting areas of CD4 paracellular migration.    
Fields captured with a 63x objective.   
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Figure 5-21 ICAM-1 enriches around transmigrating CD4 lymphocytes 
Representative confocal image of CD4 lymphocytes transmigrating across 
HSEC monolayers after flow adhesion assay.  Lymphocytes were perfused 
over a monolayer of HSEC at a shear stress of 0.05 Pa before fixation with 
paraformaldehyde.   HSEC were pre-labelled with cell tracker green (Panel 
A).  Following fixation cells were stained with ICAM-1 (Panel B) and nucleii 
were stained with DAPI (Panel C).  Merged image is shown in Panel D. 
Fields captured with 63x objective.   
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Figure 5-22 ICAM-1 and VAP-1 colocalise around transmigrating CD4 
lymphocytes. 
Representative confocal image of CD4 lymphocytes transmigrating across 
HSEC monolayers after flow adhesion assay.  Lymphocytes were perfused 
over a monolayer of HSEC at a shear stress of 0.05 Pa before fixation with 
paraformaldehyde.   Following fixation cells were stained with ICAM-1 (Panel 
A), VAP-1 (Panel B) and nucleii were stained with DAPI (Panel C).  Merged 
image is shown in Panel D. Fields captured with 63x objective.   
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5.5 Transcellular migration of T regulatory cells and the role 
of CLEVER-1 
Our functional assays confirmed that CLEVER-1 preferentially mediated the 
recruitment of the Treg subset of CD4 lymphocytes (see 5.2.3), but we 
wanted to determine whether Tregs followed the transcellular or paracellular 
pathway of migration, and if CLEVER-1 was involved in either process.  Flow 
based adhesion assays were repeated with T regulatory cells isolated from 
whole blood and after fixation and permeabilisation a FOXP3 
immunofluorescent stain was used to confirm the T regulatory cell phenotype 
of adherent cells (see section 2.12).  Subsequent confocal imaging 
suggested that T regulatory cells transmigrated using the transcellular route 
(Figure 5-23).   
Following our observation of T reg transcellular migration, the next step was 
to study the distribution of CLEVER-1 in HSEC during T reg extravasation.  
This was done using the same immunofluorescent staining described for 
ICAM-1 detection (see 2.12).  Our experiments confirmed that CLEVER-1 
was visible on HSEC as T regs underwent diapedesis (Figure 5-24) and z-
stack image analysis confirmed the enrichment of CLEVER-1 around 
transmigrating T regs (Figure 5-24).   
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Figure 5-23 Tregs transmigrate via the transcellular route 
Representative confocal image of T reg transmigrating across HSEC 
monolayers after flow adhesion assay. T regs were perfused over a 
monolayer of HSEC at a shear stress of 0.05 Pa before fixation.   HSEC were 
pre-labelled with cell tracker green (Panel A).  Following fixation cells were 
stained for FoxP3 (Panel B) and nucleii were stained with DAPI (Panel C).  
Merged image is shown in Panel D.  Z stack image is shown in Panel E. 
Fields captured with 63x objective. 
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Figure 5-24 CLEVER-1 colocalises with T regulatory cells during 
transmigration 
Representative confocal image of T reg transmigrating across HSEC 
monolayers after flow adhesion assay. T regs were perfused over a 
monolayer of HSEC at a shear stress of 0.05 Pa before fixation.   HSEC were 
pre-labelled with cell tracker green (Panel A).  Following fixation cells were 
stained for FoxP3 (Panel B) and CLEVER-1 (Panel C).  Merged image is 
shown in Panel D.  Z stack image is shown in Panel E. Fields captured with 
63x objective. 
 
C 
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5.6 Summary of Functional Assays 
A combination of static and adhesion assays were used to study the role of 
CLEVER-1 in lymphocyte trafficking to the liver.  Static adhesion assays 
confirmed that CLEVER-1 mediated the binding of lymphocytes to liver 
tissue.  Flow adhesion assays were then used to assess the role of CLEVER-
1 in lymphocyte recruitment across HSEC.  Initial assays with peripheral 
blood lymphocytes demonstrated that CLEVER-1 blockade led to a 
significant reduction in the proportion of lymphocytes undergoing 
transendothelial migration.   
Lymphocyte subsets were isolated from whole blood to assess if CLEVER-1 
preferentially recruited a particular subset.  Assays with CD4 and CD8 
lymphocytes confirmed that CLEVER-1 mediated the transmigration of CD4 
lymphocytes but had no effect on CD8 lymphocytes.  More detailed analysis 
of CD4 subsets demonstrated a preferential activity for T regulatory cells.   
The adhesion of B cells to HSEC was also studied under conditions of flow.  
B cells were captured from flow and underwent firm adhesionmediated by 
VCAM-1.  Only a small proportion of B cells underwent transmigration but 
this process involved a combination of ICAM-1, VAP-1 and CLEVER-1. 
The use of Ibidi chamberslides allowed me to use confocal microscopy to 
image lymphocytes adhering to HSEC and undergoing transmigration.  CD4 
lymphocytes were visualised transmigrating through HSEC via the 
transcellular route as well as the paracellular route.  Transmigration took 
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place through transcellular pores which were surrounded by a ring of ICAM-1 
and included VAP-1.  Further studies showed that the Treg subpopulation of 
CD4 lymphocytes also followed the transcellular route during transmigration.  
Confocal imaging demonstrated that CLEVER-1 colocalised with T regs 
during their transmigration, confirming the role of this receptor during the 
extravasation step of T reg recruitment. 
I initially used the modified Stamper Woodruff assay to study the role of 
CLEVER-1 in lymphocyte recruitment.  It was important to start with this 
assay because it allowed me to study CLEVER-1 in the context of whole 
human liver tissue.  The primary drawback of this assay is that it is a static 
assay and therefore only assesses the adhesive properties of CLEVER-1 but 
does not give an indication if CLEVER-1 plays a specific role in the adhesion 
cascade.   
It is not possible to study the leucocyte adhesion cascade within the human 
liver using an in vivo technique.  Intravital microscopy with animal models 
could be used but important differences between human and animal cells 
make human in vitro studies essential.   The in vitro flow based adhesion 
assays used in this chapter have the advantage of incorporating primary 
human hepatic sinusoidal endothelial cells.  I have already confirmed that 
these cells express CLEVER-1 in culture and we performed these assays 
under physiological shear stress relevant to the hepatic sinusoids.  Our group 
has previously used this model to study adhesion molecules such as ICAM-1, 
VCAM-1 and VAP-1 (Lalor et al., 2002a).  The steps of the adhesion cascade 
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which are demonstrated by these in vitro flow assays have been reproduced 
in hepatic in vivo assays using animals (Wong et al., 1997).  Importantly, the 
major molecular mechanisms mediating these steps in vitro have also been 
confirmed in vivo (Bonder et al., 2005; Wong et al., 1997).     
A further potential confounding factor is the use of lymphocytes that have 
been isolated from blood and cultured in vitro during which time their 
molecular expression may be altered in comparison to in vivo human 
peripheral blood lymphocytes.  We minimised these changes by using freshly 
isolated lymphocytes without culturing them prior to adhesion assays.   We 
studied highly pure subsets of lymphocytes to determine whether CLEVER-1 
had preferential activity for particular subsets.   I was careful to use magnetic 
bead kits and negative immunomagnetic selection to minimise affects of 
beads or antibody binding on the subsets of CD4, CD8 and B cells.   This 
was not possible with the T regulatory cells as these isolation kits required 
positive selection using CD25, the benefit of this positive Treg isolation was 
that it allowed the comparison between a highly pure population of Foxp3 
positive CD4 population against an effector population.   
The flow assays demonstrated that CLEVER-1 contributed to the 
transmigration step of lymphocyte recruitment.  Blockade of CLEVER-1 could 
not abolish total lymphocyte transmigration.  This led us to investigate 
whether CLEVER-1 had a preferential effect on a particular subset of 
lymphocytes.  We found CLEVER-1 mediated CD4 and B cell 
transendothelial migration with preferential activity for T regulatory cells.  
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Even when subsets were used CLEVER-1 blockade only partially inhibited 
transendothelial migration suggesting that these processes involve multiple 
receptors during the transmigration step.   Previous studies support the idea 
that paracellular migration requires sequential molecular interactions (Lou et 
al., 2007; Schenkel et al., 2002)  Our findings suggest that transmigration 
through HSEC also requires multiple interactions and in the case of B cell 
and Treg migration these involve a combination of ICAM-1, VAP-1 and 
CLEVER-1.  Blocking all three of these receptors abolished most but not all 
of the transmigration.   Our in vitro findings will have to be confirmed by in 
vivo experiments.   There is in vivo evidence that CLEVER- 1mediates 
lymphocyte recruitment to the lymphatic system but a subset specific activity 
has yet to be shown (Karikoski et al., 2009a).    
Once we had confirmed the role of CLEVER-1 in transmigration we 
attempted to study the mechanism by which CLEVER-1 mediated this 
process.  By prelabelling our cells with fluorescent dyes prior to flow assays 
we were able to visualise the transmigration step using a confocal 
microscope.  To our surprise we visualised lymphocytes transmigrating 
through transcellular pores within endothelial cells without disruption of 
endothelial junctions.   This phenomenon was visualised in live cells and 
therefore it was not an artefact of fixation.  Furthermore, we were able to 
show that ICAM-1 is enriched around these transcellular pores.  This is 
important since ICAM-1 is a major mediator of lymphocyte transmigration and 
has been shown in transcellular pores in other types of endothelial cell 
(Millan et al., 2006).    
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This technique also allowed us to demonstrate that T regulatory cells could 
transmigrate via the transcellular route and there was an enrichment of 
CLEVER-1 around these cells by cross sectional imaging using the z-stack 
function.   Similar techniques have been used previously to demonstrate the 
role of ICAM-1, CD31 and CD99 in leucocyte transmigration in other systems 
(Carman & Springer, 2004a; Lou et al., 2007). To our knowledge this is the 
first demonstration that transcellular migration is implicated in the liver and 
that Tregulatory cells undergo transcellular migration.   
 
 
 
 
 
 
 
 
 
 
233 
 
 
 
 
 
 
 
CHAPTER 6  
                          DISCUSSION 
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6.1 CLEVER-1 expression in the human liver 
Endothelial cells line all blood vessels and lymphatics in the human body but 
the structure and function of these endothelial cells can differ markedly 
between vascular beds (Aird, 2007a).  The endothelial cells of the hepatic 
sinusoid highlight this heterogeneity by displaying a unique morphology and 
phenotype (Aird, 2007b).  These characteristics could potentially be used to 
identify liver-specific therapeutic targets.   
The aim of this work was to study the scavenger receptor CLEVER-1, a 
receptor which is restricted to sinusoidal vascular beds (Goerdt et al., 1991), 
and elucidate if it plays a role in lymphocyte trafficking and thereby identify a 
potential organ specific target for lymphocyte recruitment.  
There are several published studies describing the expression of the 
CLEVER-1 receptor in normal liver tissue and hepatic sinusoidal endothelial 
cells.  To our knowledge these studies have not gone on to study CLEVER-1 
expression in the context of either inflammatory liver diseases or malignant 
liver disease.  Using  surgical samples from normal and diseased livers it was 
possible to compare CLEVER-1 expression in normal and disease states.  
Chronic inflammatory liver diseases can be broadly divided into parenchymal 
or biliary liver diseases depending on the site of lymphocyte infiltration and 
both these groups were studied.  In the normal human liver CLEVER-1 was 
restricted to the sinusoidal vascular bed.  On the background of chronic 
inflammation CLEVER-1 expression changed markedly.  The uniform 
expression of CLEVER-1 was lost with a more patchy expression across the 
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sinusoids.  The intensity of CLEVER-1 staining at these sites was much 
stronger in comparison to normal liver tissue.  Sections of diseased liver also 
demonstrated the presence of CLEVER-1 in other vascular locations such as 
neovessels of the fibrous septum and vessels supplying portal lymphoid 
tissue which are characterised by a ‘continuous’ vascular phenotype.  There 
were no disease specific differences in CLEVER-1 expression.  As discussed 
in section 1.6 most liver diseases follow a common pathway.  The expression 
of CLEVER-1 is probably driven by tissue injury and chronic inflammation 
irrespective of aetiology, making it a possible therapeutic target for a wide 
range of liver diseases. 
It was clear that CLEVER-1 expression on vascular endothelial cells and 
sinusoidal endothelial cells is differentially regulated.  CLEVER-1 is 
constitutively expressed on HSEC in vivo.  Vessels of ‘continuous’ vascular 
origin that develop in response to chronic injury and inflammation are also 
CLEVER-1 positive.  Interestingly, these locations are all potential sites of 
lymphocyte recruitment or retention.   
The presence of CLEVER-1 was also noted in primary liver tumours 
(hepatocellular carcinomas), within tumour sinusoids and tumour associated 
vessels both potential sites of lymphocyte trafficking within tumours. Studies 
by our group and others have demonstrated that lymphocyte infiltration is an 
important component of tumour development (Fu et al., 2007; Yoong et al., 
1999).  These findings suggest that the tumour microenvironment influences 
CLEVER-1 expression at sites of lymphocyte recruitment.  CLEVER-1 may 
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therefore have an important role in tumour development as well as chronic 
inflammation. 
In view of these findings it was important define the factors which were 
driving CLEVER-1 expression.  Chronic inflammation is a common theme in 
the liver diseases studied suggesting that pro-inflammatory cytokines could 
be inducers of CLEVER-1 expression.  Hepatocellular carcinomas develop 
on the background of liver cirrhosis and therefore cytokines may influence 
CLEVER-1 expression within these tumours.  Hepatocellular carcinomas are 
also highly  vascularised tumours (Bruix et al., 2001), a consequence of the 
shift in the secretion of antiangiogenic factors to pro-angiogenic factors 
(Semela and Dufour, 2004).  This shift is another possible factor that drives 
the expression of CLEVER-1 in tumour sinusoids and tumour vessels.  
Angiogenesis has also been described as a response to chronic 
inflammatory liver disease. Thus either a proinflammatory or a 
proangiogeneic environment could explain the increased expression of 
CLEVER-1 in tumour vessels and neo-vessels of the fibrous septum and 
vessels supplying tertiary lymphoid follicles (Medina et al., 2004).  Previous 
studies with FEEL-1/CLEVER-1 have suggested a link with angiogenesis, 
where blockade of the receptor reduced angiogenesis (Adachi & Tsujimoto, 
2002).  
6.2 The regulation of CLEVER-1 in HSEC 
Using a method developed by our group to isolate hepatic sinusoidal 
endothelial cells I demonstrated that these cells maintained their expression 
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of CLEVER-1 in vitro.  This allowed me to study the changes in CLEVER-1 
expression in response to various stimuli.  Conventional endothelial adhesion 
molecules such as ICAM-1 and VCAM-1 are upregulated by proinflammatory 
cytokines but I was unable to consistently increase the expression of 
CLEVER-1 with proinflammatory cytokines, suggesting that its regulation was 
more complex.  The response of CLEVER-1 expression to factors such as 
hypoxia or bile acids was extremely variable and the only consistent effect I 
observed was detected with hepatocyte growth factor which led to increased 
CLEVER-1 expression.   
Hepatocyte growth factor (HGF) could influence the expression of CLEVER-1 
in normal and diseased liver tissue.  It is a cytokine that is described as a 
motogen, mitogen and morphogen and which has been implicated in liver 
development, growth, regeneration chronic inflammation and carcinogenesis 
(Jiang et al., 2005).  It was initially identified as a potent mitogen of rat 
hepatocytes (Michalopoulos et al., 1984).  HGF was also separately identified 
and named scatter factor because of its ability to promote epithelial cell 
dissociation and increase cell motility (Weidner et al., 1991).  In the liver its 
main source is stellate cells (Hu et al., 1993).  The induction of CLEVER-1 
expression may relate to its ability to promote angiogenesis in vitro and in 
vivo  (Bussolino et al., 1992; Grant et al., 1993) and lymphangiogenesis 
(Martin and Jiang, 2010) Abnormalities in HGF signalling have also been 
implicated in carcinogenesis including the development of HCCs, although 
the exact mechanism is not clear (Comoglio et al., 2008; Villanueva et al., 
2007). HGF may therefore contribute to the maintenance of CLEVER-1 
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expression on sinusoidal endothelium and its induction on neovessels and 
vessels supplying lymphoid follicles in chronically inflamed tissue as well as 
tumour associated vessels in HCCs.   
Having investigated levels of CLEVER-1 protein and mRNA I went on to 
study its intracellular and surface localisation in HSEC as CLEVER-1 is 
known to undergo intracellular trafficking in other cell types.  CLEVER-1 was 
predominantly intracellular, this finding was consistent with previous studies 
in lymphatic endothelium and alternatively activated macrophages 
(Kzhyshkowska et al., 2004; Prevo et al., 2004).  Stimulation with growth 
factors and cytokines had no effect on the cellular localisation of CLEVER-1.  
The trafficking properties were confirmed by treatment with Bafilomycin A1, 
this led to accumulation of CLEVER-1 in large vesicles.  These vesicles were 
not early endosomes but were found to colocalise with the trans-Golgi 
network and Golgi apparatus.   This supports previous findings that CLEVER-
1 is involved in two pathways 1) trafficking from the plasma membrane to 
early endosomes and 2) intracellular sorting pathway involving trafficking 
between the endosomal compartment and the biosynthetic compartment 
(trans Golgi network)(Kzhyshkowska et al., 2004).    
It is clear from these regulation studies that CLEVER-1 does not behave as a 
conventional adhesion molecule.  Its mRNA expression and surface 
expression are unaltered by inflammatory cytokines and it does not localise 
to inter-cellular junctions.  Other features are consistent with a scavenger 
receptor profile: primarily its trafficking behaviour from the plasma membrane 
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to intracellular compartments.   The regulation of CLEVER-1 is probably a 
complex process in vivo with hepatocyte growth factor contributing to an 
increase of CLEVER-1 expression in sinusoidal endothelial cells and an 
induction in vascular endothelial cells that develop in response to chronic 
inflammation.  
6.3 The role of CLEVER-1 in lymphocyte trafficking to the 
Liver 
I used modified Stamper-Woodruff assays to confirm that CLEVER-1 on 
hepatic sinusoidal endothelium in ex vivo tissues supports lymphocyte 
adhesion.  This assay allows the study of CLEVER-1 in the context of whole 
liver tissue but does not clarify the exact role of CLEVER-1 within the 
adhesion cascade.   
This was studied using flow based adhesion assays which recapitulate the 
hepatic sinusoids, the channels where lymphocyte recruitment takes place in 
vivo.  There is evidence that the hepatic sinusoids are a unique environment 
for lymphocyte recruitment: 1) Recruitment occurs in a low shear 
environment, 2) The endothelial cells that line the hepatic sinusoids have a 
unique phenotype, 3) Conventional adhesion molecules, such as selectins 
are absent from this vascular bed, 4) Unconventional adhesion molecules 
such as VAP-1 play a role in the recruitment of lymphocytes in this vascular 
bed. 
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Lymphocyte recruitment involves a multistep adhesion process which is 
mediated by several receptors.  Flow based adhesion assays have been 
used to elucidate the exact role of several receptors in the adhesion cascade.  
Our group has previously used flow based adhesion assays to study the role 
of conventional adhesion molecules (ICAM-1 and VCAM-1) and 
unconventional adhesion molecules (VAP-1) in lymphocyte recruitment to 
HSEC.   
By pre-blocking HSEC monolayers with an antibody to CLEVER-1 it was 
clear that CLEVER-1 played a role in the transmigration of peripheral blood 
lymphocytes.  These findings were similar to those detected in lymphatic 
endothelium (Salmi et al., 2004).  There was also an increase in the rolling of 
lymphocytes across the endothelial layer, but the overall proportion of 
lymphocytes rolling in our model is small (<10%) which reflects the low shear 
environment.  Blockade of CLEVER-1 had no effect on firm adhesion or 
activation of lymphocytes.   
The transmigration step of leucocyte extravasation is a complex process and 
appears to involve several receptors depending on both the leucocyte and 
endothelial type involved (Vestweber, 2007).  Neutrophils, monocytes and 
lymphocytes use different receptors and appear to follow different routes 
during this process.  We hypothesised that lymphocyte subsets may also use 
different receptors during extravasation across endothelium.  .  Two of the 
major populations of lymphocytes, CD4 and CD8 lymphocytes, were studied.  
Flow assays with these two subsets demonstrated that CLEVER-1 played a 
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specific role in CD4 lymphocyte transmigration across HSEC rather than CD8 
lymphocytes.  Further analysis of CD4 subsets demonstrated that CLEVER-1 
promoted the transmigration of FoxP3 positive T regulatory cells.    
Another subset which is recruited to the liver and contributes to liver 
immunopathology are B cells.  B cells have been shown to be present within 
normal and diseased liver tissue and must therefore migrate from the 
peripheral circulation across the endothelial barrier.  Despite this, there is 
little understanding of B cell recruitment to tissue and so I proceeded to study 
their behaviour in flow assays.  There were clear differences in B cell 
recruitment compared with T cells.  B cells were captured from flow and 
underwent firm adhesion similar to other subsets but there was no prior 
tethering step.  VCAM-1 was the primary capture receptor for B cells but only 
small proportion underwent transmigration.  It was clear from the flow assays 
that B cells did not have the same level of motility seen in T cells.  This lack 
of motility probably explains the reduced efficiency in transmigration.  As in 
other leucocytes, B cell transmigration was a multistep process with ICAM-1, 
VAP-1 and CLEVER-1 all contributing to diapedesis.  
These functional assays suggest that CLEVER-1 is a recruitment signal for T 
regulatory cells and B cells by promoting the transmigration of these subsets.  
It was important to try and understand the mechanism by which CLEVER-1 
promoted transmigration.  As discussed in section 1.9.3 there have been two 
pathways described for transmigration: between endothelial junctions 
(paracellular); and directly through endothelial cells (transcellular).  The 
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pathway chosen is dependent on the type of endothelium, as well as the 
leucocyte subset. (Carman et al., 2007; Vestweber, 2007).  To our 
knowledge, the route taken by transmigrating lymphocytes has not been 
studied in the context of HSEC.  Using confocal imaging it was clear that a 
large proportion of CD4 lymphocytes transmigrated across HSEC using the 
transcellular route.  This supports the finding that CLEVER-1 mediates 
transmigration across HSEC.  Receptors that support paracellular migration 
are found on the endothelial cell surface and are enriched at intercellular 
junctions.  Transcellular migration is less well understood but probably 
requires a combination of receptors that are surface expressed (ICAM-1) and 
intracellular receptors (CLEVER-1).  I confirmed this by demonstrating ICAM-
1 enriched around transcellular pores as well as CLEVER-1 enriching close 
to transmigrating T regulatory cells.   
These studies identify CLEVER-1 as a potential target for therapy of liver 
disease.  CLEVER-1 is a non-conventional adhesion molecule which in 
normal conditions is restricted to sinusoidal endothelium.  In inflammatory 
liver diseases it is also induced on inflammatory neo vessels and tumour 
vasculature.  This restricted expression profile makes CLEVER-1 an 
attractive target for therapy in comparison to conventional adhesion 
molecules which are more widely expressed on vascular endothelium.   
The preferential recruitment of Tregulatory cells by CLEVER-1 is a possible 
tissue-based response to chronic inflammation, to prevent excessive tissue 
damage.  Induction of CLEVER-1 expression may therefore be beneficial in 
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controlling immune-mediated liver diseases (eg autoimmune liver disease, 
primary biliary cirrhosis) to enhance T regulatory cell recruitment.  This may 
suppress inflammation and inhibit self reactive T cells.  Alternatively, 
CLEVER-1 blockade may be beneficial in other liver diseases such as 
chronic viral hepatitis.  In these conditions Tregulatory cells may prevent 
virus-specific immune responses and blocking their recruitment may enhance 
viral eradication.  Similarly, blocking CLEVER-1 in the context of 
hepatocellular carcinomas may prevent T reg infiltration and thereby promote 
tumour specific cytotoxicity.   
CLEVER-1 also appears to be a recruitment signal for B cells.  There is 
gathering interest in the contribution of B cells to liver disease.  They have 
been implicated in the development of liver fibrosis and the transmission of 
viruses such as Hepatitis C.  Therefore CLEVER-1 blockade may influence 
the development of fibrosis in chronic hepatitis as well as viral infection of the 
liver. 
The ligand on Tregulatory cells and B cells which binds to CLEVER-1 is 
unknown.  As discussed in 1.13.1 CLEVER-1 has been shown to bind to 
phosphatidylserine (PS).  PS is a molecule which is expressed on the 
cytosolic side of cell membranes and becomes exposed on the surface of the 
cell during apoptosis.  During early apoptosis the exposure of PS on the 
surface allows phagocytosis by macrophages (Verhoven et al., 1995).  
CLEVER-1 has been shown to recognise phosphatidylserine via its 
epidermal growth factor repeats (Park et al., 2009).  Interestingly, there are 
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studies which show that PS is not only exposed on the cell surface during 
apoptosis.  It has been detected on the surface of viable B cells as well as a 
subset of CD4+ memory T cells (Dillon et al., 2000; Elliott et al., 2005).  In 
view of these findings PS is a candidate for the CLEVER-1 ligand on 
lymphocytes.   
In conclusion, these studies have identified CLEVER-1 as a new lymphocyte 
adhesion molecule within the hepatic sinusoids.  It does not play a role in the 
capture or activation of lymphocytes but mediates the downstream step of 
lymphocyte diapedesis via the transcellular route.  Moreover, CLEVER-1 
appears to be a subset specific adhesion molecule which mediates the 
recruitment of regulatory T cells and B cells.    
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Within the human liver, CLEVER-1 is expressed constitutively by sinusoidal 
endothelium but only on vascular endothelium that develops in response to 
inflammation and malignancy.  Further work is required to understand why 
CLEVER-1 is differentially regulated on these two types of endothelium.  
CLEVER-1 expression may be influenced by other hepatic resident cells.  
Therefore co-culture experiments with stellate cells, kupffer cells and 
hepatocytes would be an important step to gain further understanding of 
CLEVER-1 regulation. 
In functional assays CLEVER-1 was found to promote CD4 lymphocytes and 
B cell transmigration.  These studies concentrated on lymphocyte 
populations but CLEVER-1 may mediate the recruitment of other leucocyte 
populations.  Future flow assays with neutrophils and monocytes would 
answer these questions, as well as studies with NK and NKT cells.   
CLEVER-1 appears to play a role in transcellular migration across HSEC.  I 
and others (Karikoski et al., 2009a) have hypothesised that 
phosphatidylserine could be a possible ligand on transmigrating lymphocytes 
but this requires confirmation  
To my knowledge this is the first demonstration of transcellular migration 
across HSEC.  Further work is required to understand this process and the 
contribution of ultrastructural components of HSEC such as fenestrae, actin 
cytoskeleton and microtubules.  Other scavenger receptors, the mannose 
receptor and stabilin 2, may also contribute to this phenomenon.  .    
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As discussed earlier, in vivo studies have demonstrated a role for CLEVER-1 
in lymphocyte recruitment via lymphatics. Animal models would be an 
important step in further understanding the importance of CLEVER-1 in liver 
injury.  Function blocking antibodies or CLEVER-1 knockout models could be 
used to investigate the role of CLEVER-1 in the development of fibrosis and 
cirrhosis.   
These studies have concentrated on the role of CLEVER-1 in lymphocyte 
recruitment.  There is evidence that tumour cells metastasise using 
mechanisms similar to lymphocyte trafficking.  Furthermore, scavenger 
receptors such as CLEVER-1 and mannose receptor have been implicated in 
tumour cell adhesion to endothelium (Irjala et al., 2003a).  In vitro flow assays 
with tumour cells may elucidate the mechanism by which tumours, such as 
colonic carcinomas, metastasise to the liver and may implicate CLEVER-1 in 
this process.   
The findings of CLEVER-1 on neo vessels, up regulation by HGF and studies 
by other groups suggest that CLEVER-1 may also have a role in 
angiogenesis.  Other transmigration molecules such as VAP-1 and JAM-C 
have also been implicated in angiogenesis (Marttila-Ichihara et al., 2009; 
Rabquer et al., 2010).  Studying the angiogenic properties of CLEVER-1 in 
HSEC may uncover a further contribution of CLEVER-1 to the pathogenesis 
of chronic liver disease and hepatocellular carcinomas.    
This thesis has described the presence of the CLEVER-1 receptor at sites of 
lymphocyte homing to the inflamed human liver and demonstrated a role for 
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this receptor in transcellular migration of lymphocytes.   Further in vivo and in 
vitro studies are required to see if CLEVER-1 is a potential therapeutic target 
for inflammatory liver diseases 
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